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1. Introduction 
Cardiovascular disease (CVD) accounts for almost half of the morbidity and mortality world-
wide and develops mostly from atherosclerosis and subsequent obstruction or thrombosis of 
large arteries1. The World Health Organisation2 estimates 17.3 million people died from CVD 
in 2008, representing 30% of all global death. Of this death, an estimated 7.3 million were 
due to coronary heart disease and 6.2 million were due to stroke. By 2030, almost 25 million 
people will die from CVD, mainly from heart disease and stroke. These are projected to 
remain the single leading cause of death2. In this context, CVD can be considered to be a 
civilization disease, because the indigenous people were largely unaffected by this disease 
and its consequences. The risk factors of CVD mostly include tobacco use, unhealthy diet 
and obesity, physical inactivity, raised blood pressure, diabetes and raised lipids2. The 
pathogenesis of CVD arises from atherosclerosis and gives rise to cerebrovascular disease 
and coronary artery disease (CAD) through a slowly progressive lesion formation and luminal 
narrowing of arteries. Upon plaque rupture and thrombosis, these most common forms of 
CVD manifest as acute coronary syndrome (ACS), myocardial infarction (MI) and stroke3. 
The following introduction provides an overview about the development and pathogenesis of 
atherosclerosis which gives rise to the subsequent MI, and highlights the importance of 
chemokines and their receptors, to prevent the development of atherosclerosis and the 
therapy of the heart after MI. 
1.1. Atherosclerosis 
In the last decades the knowledge regarding the pathology of atherosclerosis increased 
enormously and research on this field is one of the timeliest topics in the area of medicine. In 
1829 Jean Lobstein implemented the term "arteriosclerosis", in his unfinished Traité 
d’Anatomie Pathologique, a four-volume treatise on pathological anatomy, based upon his 
lifelong personal experience, that is defined as a form of CVD affecting the arteries and 
arterioles4, 5. In contrast the term “atherosclerosis” is a specific form of “arteriosclerosis” 
developed by the formation of fatty streaks which is an accumulation of lipid-loaded 
macrophages in the intima of the artery6. Virchow7 proposed that the lesion of 
atherosclerosis results from injury of the arterial wall. Further he hypothesized that 
atherogenesis involved in combination of inflammatory and proliferative responses within the 
arterial wall preceding the degenerative changes that have been recognized in the advanced 
lesions of atherosclerosis. Duguid8 modified this hypothesis that mural thrombi become 
incorporated into the lesion of atherosclerosis and provide a part of cellular response in 
lesion formation. This hypothesis was modified by Frech9, Mustard and Packham10, 
Wissler11, Thomas et. al.12 and Ross et. al.13, and increased the emphasis to one of the 
principle alterations in atherosclerosis, the intimal accumulation of smooth muscle cells. The 
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response-to-injury hypothesis by Ross implies that the lesion of atherosclerosis results as a 
response to some form of injury to arterial endothelial cells (EC) that result in their 
desquamation13. This hypothesis was further developed by Steinberg who suggested that 
altered lipoproteins may account for the initiation of atherosclerosis formation14-16. But to date 
the knowledge in the area of atherosclerosis grew and it is known that hyperlipidemia is the 
main risk of atherosclerosis6. Studies in animal and humans have shown that 
hypercholesterolemia causes focal activation of endothelium in large and medium size 
arteries17. The development of an atherosclerotic lesion (atheroma) is initiated by the 
activation and dysfunction of ECs6. The platelet is the first blood cell to arrive at the scene of 
endothelial activation17, 18. The platelet glycoproteins (GP) Ib and IIb/IIIa engage surface 
molecules on the EC, which may contribute to endothelial activation17. The Leucocyte is the 
second cell which contributes to the scenario of the activated ECs. The activated ECs 
express several types of leukocyte adhesion molecules, which cause blood cells rolling along 
the vascular surface to adhere at the site of activation17. Once the blood cells have attached 
it comes to an increase in the permeability of blood vessels for lipid components in the 
plasma such as low density lipoprotein (LDL)6, 17. Monocytes migrate into the intima and 
subintima of the endothelium where they become loaded with cell-activating oxidized LDL 
(oxLDL) and other lipids and transform into macrophages. OxLDL and other lipids are taken 
up by scavenger receptors of macrophages which accumulate to the evolving lesion and 
transform to the foam cell to form early “fatty streaks” (plaques) in the intima6, 17. OxLDL also 
triggers the secretion of chemokines by ECs which drives the intimal immune cell infiltration3. 
The intima then becomes thicker as a result of a pathophysiological response to changes in 
fluid dynamics at atherosclerosis-prone areas of the arterial tree, such as artery branching 
points6. Early “fatty streaks” lesions consist of T-cells and monocyte-derived macrophage-like 
foam cells loaded with lipids followed by the accumulation of apoptotic cells, debris and 
cholesterol crystals which form the necrotic core3. The advanced atherosclerotic plaque 
consists of necrotic cores, calcified regions, accumulated modified lipids, inflamed smooth 
muscle cells (SMCs), ECs, leukocytes and foam cells19. The progression of plaques that 
leads to narrowing of the arterial lumen is further initiated by the release of cytokines, growth 
factors and the deposition of extracellular matrix components (EMCs). The secretion of 
matrix-degrading proteases and cytokines by plaque cells can cause a thinning of the fibrous 
cap, which prevents contact between the blood and the pro-thrombotic material in the 
plaque6. Activated, infiltrated immune cells of the plaque produce further numerous 
inflammatory molecules and proteolytic enzymes which can disintegrate the cap and activate 
cells in the core, transforming the stable plaque into a vulnerable unstable plaque that can 
rupture and induce a thrombus, which can block the artery and result in coronary syndromes, 
MI and stroke6, 17 (Figure 1). 
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Figure 1: Development of atherosclerosis. 
Modified from Weber et. al.6. 
A. Endothelial-cell dysfunction and activation under 
pro-inflammatory conditions of hyperlipidemia leads 
to early platelet and leukocyte adhesion and 
increased permeability of the endothelium. 
 
 
B. Monocytes that are recruited to the intima and 
subintima accumulate lipids and transform into 
macrophages or foam cells, which make up fatty 
streaks. Continued mononuclear-cell influx, 
deposition of matrix components and recruitment of 
smooth muscle cells give rise to fibroproliferative 
progression of the plaques.  
 
 
C. Apoptosis of macrophages and other plaque cells 
creates a necrotic core, and a fibrous cap that 
consist of matrix and smooth-muscle-cell layer 
forms. Neovascularisation can occur within the 
plaque and from the adventitia, and leakage of 
fragile vessels can lead to plaque haemorrhage.  
 
 
 
 
D. Thinning and erosion of the fibrous cap in 
unstable plaques, for example owing to matrix 
degradation by proteases, ultimately results in 
plaque rupture, with release of debris, activation of 
the coagulation system and plaque thrombus artery. 
This leads to arterial occlusion and MI or stroke.  
 
 
 
 
 
B. 
C. 
A. 
D. 
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1.2. Myocardial infarction (MI) 
The heart is built of long chains of striated muscle and exhibits a high content of 
mitochondria to sustain resistance to fatigue and maintain all vital functions of the 
organism20. MI is the leading cause of morbidity and mortality in the developed nations3 and 
is associated with persistent muscle damage, scar formation and reduced cardiac 
performance21. MI generally arises as a consequence of coronary artery occlusion which 
results either from atherosclerotic or inflammatory processes causing lumen narrowing 
(stenosis) or thrombus formation, which leads to limited oxygen supply (ischemia), 
irreversible muscle damage and cardiomyocyte death22. The most common complication is 
the occurrence of left ventricular (LV) dysfunction and heart failure23. Ischemia in the heart 
subsequently initiates a remodeling process that involves modifications of the cellular 
metabolism in surviving myocytes and changes of the LV structure leading to cardiac 
hypertrophy, fibrosis and enlarged chambers21. These changes lead to a loss of the heart 
function, which results in the progression of cardiac recompensation and heart failure24. 
Patients with MI benefit from early myocardial reperfusion, which is the most effective 
strategy to improve clinical outcome25-27. Despite the success of reperfusion, mortality and 
morbidity after MI remains substantial, with 5% to 6% of patients having a subsequent 
cardiovascular event in the next 30 days25-27. After ischemia, different cellular and molecular 
events are involved to achieve the healing of the myocardium, such as inflammatory phase, 
proliferative phase and healing phase.  
During the inflammatory phase, it comes to a release of reactive oxygen species (ROS) from 
ECs and cardiomyocytes but also to an increased expression of cytokines and adhesion 
molecules23. Other participants such as superoxide anion contributes to MI extent by 
including cellular changes such as mitochondrial permeability, enzyme denaturation and 
DNA damage, but also triggering neutrophil infiltration23, 28, 29. The CXCR2-binding 
chemokines CXCL8, CXCL2, CXCL1, CXCL6, as well as CCL3 and CCL5 are involved in the 
recruitment of neutrophils into the inflamed myocardium30-32. Within the first hours, 
neutrophils are recruited from the blood stream into the inflamed tissue and contribute to 
further cardiac damage by releasing ROS, inflammatory mediators and proteases28, 29. In a 
CCR2-dependent manner, the extravasation of inflammatory monocytes but not of resident 
monocytes, is sustained by neutrophils33. In addition and beside to cellular external help, the 
inflammatory response has also a fundamental role in preparing the surrounding unaffected 
cardiomyocytes for the stress conditions20. Not only infarcted tissue but also unaffected 
surrounded tissue synthesizes chemokines and cytokines to trigger the initiation of the 
defense mechanism, like activation of hypoxia inducible factor-1α (HIF-1α)34 and place 
cardiomyocytes in a “pre-conditioning” state, increasing resistance to a new hypoxic event20. 
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HIF-1α has the ability to mediate an increase of stromal cell-derived factor-1 (SDF-
1/CXCL12) and macrophage migration inhibitory factor (MIF), which lead to targeting the 
CXCR4 expressing cells to the infracted area35 (Figure 2). 
During the proliferation phase the heart wall is cleaned of dead cardiomyocytes and matrix 
debris without having build new supporting structures yet and will ineluctably break under 
high blood pressure and high mechanical force20. After removing necrotic cells and matrix 
debris, an inhibition of inflammation by transforming growth factor beta (TGF-β) and 
interleukin 10 (IL-10) follows in order to achieve an optimal healing of the infarcted area of 
the myocardium. For the initiation of the healing, the inflammatory cells are replaced by 
resident or recruited Gr1low monocytes, lymphocytes and mast cells20. The chemokine 
receptor CX3CR136, 37 and CCR537 are required for rapid tissue invasion at the site of 
inflammation by resident monocyte population, which initiate an early immune response and 
differentiate into macrophages. Resident monocytes patrol between the cardiomyocytes 
using CX3CR1 receptors33 and maintain the homeostasis of the normal tissue20. For an 
optimal blood supply and to regenerate the heart and its function angiogenesis is 
necessary20. For angiogenesis to occur, stem cells (SCs) are important to be recruited to the 
injured tissue. The CXCL12/CXCR4 axis plays a crucial role in controlling and modulation of 
the recruitment of SCs and the formation of new blood vessels38 (Figure 2). 
The healing phase is the last stage after MI, forming a mature scar which contains a dense 
collagen-based extracellular matrix, myofibroblasts, SCs and newly formed vessels20. During 
scar maturation, lysyl-oxidase is upregulated and induces collagen cross-linking. The 
formation of a stable cross-linked extracellular matrix may shield the myofibroblasts from 
mechanical tension promoting quiescence that promotes apoptosis of infarct 
myofibroblasts39. A prolonged presence of myofibroblasts in the infarcted myocardium may 
promote adverse remodeling39. In the past the mature infarction scar was considered as inert 
and disabled of biological function, but during the last years different studies30, 40 showed that 
increased collagen content supports contractility and sustains heart function. The healing of 
the infarcted heart results in massive changes of the ventricular architecture and geometry, 
and is also referred as “ventricular remodeling”32. These molecular and cellular changes 
affect both the cardiomyocytes and interstitial cells and result in an increased ventricular 
size, altered shape of the ventricle and worsened cardiac function32. The remodeling of the 
heart after MI is associated with poor prognosis, ventricular dilation and adverse cardiac 
events, including the development of heart failure and ventricular arrhythmias.31 
To develop new therapeutic strategies after MI it is essential to understand the cellular and 
molecular mechanisms to reduce injury and promote repair to improve LV remodeling and 
the function of the heart. 
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Figure 2: Cellular and molecular events after MI. Modified after Liehn et. al.20.The healing after MI 
involves 3 overlapping phases: the inflammatory, proliferative, and healing phase. Each is 
characterized by specific events (red), implicating different cells, controlled by specific chemokines 
(orange). Extracellular matrix (ECM) evolves the mature scar (dark blue), which ensures the stability 
and the function of the heart. (HIF = hypoxic inducible factor; IL = interleukin; MCP = monocyte 
chemotactic protein; MI = myocardial infarction; MIF = macrophage inhibitory factor; MSC = 
mesenchymal SC; NF-κB = nuclear factor kappa B; CXCL12 = stromal cell-derived factor 1 (SDF-1); 
TGF = transforming growth factor; TNF = tumor necrosis factor.)  
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1.3. Chemokine receptors 
Chemokine receptors are large proteins binding different chemokines and chemokines 
themselves are able to bind several different receptors. This interaction is the most complex 
processes in chemokine physiology. The recognition of chemokine-encoded messengers is 
mediated by specific cell surface G-protein-coupled receptors (GPCRs) with seven 
transmembrane domains41. All chemokine receptors share common structural features which 
include: (1) an extracellular amino-terminus (N-terminus); (2) a polypeptide which loops 
across the plasma membrane seven times to form three intracellular and three extracellular 
loops; (3) a disulfide bond linking cysteine residue in the first and second extracellular loops; 
(4) an intracellular carboxyl-terminus (C-terminus)42. Compared with other members of the 
GPCR family, the chemokine receptors are relatively small, consisting of approximately 350 
amino acid residues. There is at least approximately 20% homology between all chemokine 
receptors. The characteristic of the N-terminus of the receptors is rarely acidic, and the C-
terminus is relatively short42. The GPCR family is one of the most diverse classes of cell 
surface receptors which perceive signals from ligands, such as hormones, biogenic, amines, 
pheromones, neurotransmitters, classical chemoattractants, lipid mediators, sweet, bitter, 
and umami tasting molecules, odorants, and light photons41. 
When a chemokine binds to its receptor, a conformational change is induced which results in 
a receptor activation. This activated receptor catalyzes exchange of GDP for GTP which 
maintains the Gi protein activation by dissociation of the α-subunit, which then induces 
phospholipase C activity. The active enzyme catalyzes the hydrolysis of phosphatidylinositol-
4,5-biphosphate (PIP2) to generate second messengers, i.e. diacylglycerol (DAG) and 
inositol-1,4,5-triphosphate (IP3). IP3 diffuses into the cytoplasm and binds to an IP3 receptor 
on the membrane of a particulate calcium store. This binding results in the release of calcium 
ions, contributing to the large increase in cytoplasmic Ca2+ 42. This process describes in 
general the G-protein-coupled signal transduction pathway. 
Chemokine receptors contain three fundamental functions of the chemokine-induced “cellular 
reflex” which are not independent. These functions are message acquisition, message 
decoding, and initiation of cell responses41. Chemokines “are comparable with the human 
language” where word perception, interpretation of meaning, and induction of a response can 
be separated41. For example message acquisition means, a chemokine binds to a particular 
receptor and this binding is determined by receptor affinity, which varies greatly between 
ligands and does not necessarily translate into functional potency41, 43, 44. The importance of 
chemokines is influenced by the agonist-antagonist affinity to a particular receptor. This 
particular receptor can be shifted into its “productive” signaling conformation using a very 
good binding agonist or preventing such a shift by an antagonist41, 45, 46. The chemokine 
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relevance is dependent on the degree of potency response (efficacy) and the capability to 
initiate different regulatory and signal transduction pathways, which dictate the current 
response. The potency of a response but also its quality are dependent of the chemokine 
induced shift in the receptor configuration45. The receptor potency is variable for each 
receptor ligand46. 
To understand the molecular interactions responsible for matching of approximately 50 
human chemokines47 and 19 human chemokine receptors41 will take some time, because 
these interactions can vary for each receptor and ligand48. The determination of agonist and 
antagonist is variable for each chemokine and its receptor, but also many signaling 
pathways49 and cell responses show huge variances. Chemotaxis is the only response that is 
elicited by almost all chemokines in almost all receptor-bearing cells41. During the last years, 
the understanding of the mode of action of GPCRs increased, especially in the area of 
classical chemoattractants and its molecular events which lead from chemokine GPCRs to 
cell locomotion. 
Chemokine receptors are primarily expressed in hematopoietic cells (HCs), including 
neutrophils, monocytes, lymphocytes, myeloid progenitor cell lines, eosinophils, basophils 
and erythrocytes42. Chemokines are implicated in the directional cues for the movement of 
leukocytes in development of homeostasis, and inflammation. Extravasation of leucocytes 
from the blood into the tissue is adjusted by a multistep process sequencing a series of 
concerted interactions between leukocytes and ECs50. Chemokines provide the signals for 
the movement that leads to extravasation of leukocytes and control their homeostatic 
circulation through the tissue. Lymphocytes continuously circulate through the blood, tissue 
and lymphatics in an organized manner and brings naive lymphocytes into the lymph nodes, 
where they encounter antigens and are transformed into memory lymphocytes that migrate 
into the tissue to ensure immunity50. For example, the dramatic increase of CCL5 during 
inflammation results in the selective recruitment of lymphocytes in the inflamed tissue51. 
Monocytes/macrophages, eosinophils, and mast cells are produced in the bone marrow 
(BM), adjudge primary in other tissue and also migrate via chemotaxis into tissue where an 
increased chemoattractant is present50. For example, monocytes/macrophages respond to 
CX3CL1 chemokine via the CX3CR1 receptor and require cell chemotaxis52. The CXCL12 
chemokine was demonstrated to drive chemotaxis of HCs from BM through the CXCR4 and 
CXCR7 receptors, but it is also responsible for the retention of HCs in the bone marrow53-55. 
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1.4. Chemokines 
Chemokines belong to a superfamily of small chemotactic cytokines with a molecular weight 
ranging from 8 kDa to10 kDa, containing 60 to 100 amino acids and 20% to 90% sequence 
homology among each other at the protein level48. Chemokines are a small group of 
signaling proteins which have a central role in the migration of immune cells into the tissue 
and in the transmigration from the blood. Some chemokines have an activating effect on 
immune cells, while others are involved in the development of organs and angiogenesis. The 
approximately 50 different chemokines 47 are produced by immune cells and many other 
tissue cells. They develop their function after binding to chemokine receptors, which are 
widely distributed in the immune system. Chemokines operate as a communication medium 
with their own language that carry encrypted messages to cells that have the means to 
decode. Diverse stimuli of many different cell types are able to prompt the chemokine 
dispatches. Perceived and decoded, these messages can influence the most profound 
aspects of a cell’s life, including not only eponymous chemotaxis and adhesion but also 
proliferation, maturation, differentiation, apoptosis, malignant transformation, and 
dissemination41. Without the chemokines, which can effect each cell and the whole immune 
system, the body could not function. Chemokines regulate various functions such as the 
immune survival, development, hematopoiesis, wound healing, inflammation, viral infections, 
or metastases56. Independent of the chemokine function, chemokines are defined based on 
their amino acid composition, specifically on the presence of a conserved tetra-cysteine 
motif41. The chemokines are classified into four major subclasses, the CXC-, CC-, C- and 
CX3C-chemokines, based on the relative position of the first consensus cysteins on N-
terminal part of the protein. The first two cysteins of CXC-chemokines, also called α-
chemokines are separated by a non-conserved amino acid (cystein – X amino acid - 
cystein)48. This chemokine family attract neutrophils, T-lymphocytes, B- lymphocytes and 
natural killer (NK) cells. The α-chemokines are further subdivided into those containing the 
sequence glutamic acid-leucine-arginine (ELR) near the N-terminus and those that do not50. 
The first two cysteins of CC-chemokines are next to each other and are called β-
chemokines48. This family can attract monocytes, macrophages, basophils, eosinophils and 
T-lymphocytes, but have little to no effect on neutrophils. Structurally, the β-chemokines can 
be subdivided into two families, the monocyte-chemoattractant proteins and eotaxin, which 
are approximately 65% identical to each other, and all other β-chemokines50. The C-
chemokine subfamily, also known as γ-chemokines are structurally different from the other 
chemokine families, in that they contain only two of the four conserved cysteins. The only 
members of this family are the lymphotactin a and b (also called XCL1 and XCL2), which are 
known as chemoattractant for T-lymphocytes. These chemokines are specific ligands for the 
XCR1 receptor48. So far, only one member of CX3C-chemokine has been identified, which is 
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called fractalkine (CX3CL1). This chemokine subfamily is also known as δ-chemokine and 
has been characterized by the presence of three amino acids between the first two cysteine-
residues, and includes a transmembrane and mucin-like domain48 (Figure 3). All four 
chemokine families have very similar tertiary structure which is composed of a three-
stranded anti-parallel β-sheet, and preceded by a disordered amino terminus and covered on 
one side by a C-terminal α-helix57. Upstream of the β-sheet is the N-terminal region, which 
consists of more or less disordered and extended region of 6-10 residues, followed by a long 
loop (N-loop) and a short helix. The overall structure is stabilized by disulfide bonds involving 
N-terminal and core domain cysteins56. It has become more and more clear that biological 
information required to run the chemokine system is not only stored in the sequence of the 
chemokines involved, but also in a structure of a class of polysaccharide called 
glycosaminoglycans (GAGs), which are bound to most chemokines through ionic 
interactions58 (Figure 3). 
GAGs are covalently attached to core proteins, present on all cell surfaces and in the 
intracellular matrix58, 59. Chemokines display a high affinity to GAGs, which led to the 
presumption, without such an immobilization mechanism, chemokine gradients would be 
disrupted by diffusion60. GAGs are divided into four different groups: hyaluronic acid (HA), 
chondroitin/dermatan sulfate (CS/DS), heparan sulfate/heparin (HS/HP), and keratin sulfate 
(KS). GAGs are polysaccharides consisting of a repeated disaccharide unit, composed of a 
hexosamine and hexose or hexuronic acid, either or both, which may be sulfated at different 
positions56. HS is the class which most chemokines bind primarily through ionic 
interactions61. HS is composed of hexosamine, which is a glucosamine, and the hexuronic 
acid, which is either a glucuronate or its C5 epimer, an iduronate56. HS molecules are not 
only recognized by chemokines, they are also recognized as ubiquitous protein ligands of 
cytokines, growth factors, morphogenetic proteins, adhesion molecules, enzymes, plasma 
proteins, proteins from the extracellular matrix and apolipoproteins58. HS influences different 
functions of a ligand, like the local concentration, compartmentalization, stability, structure 
and its activity. It plays also a role in cell proliferation, cell adhesion, matrix assembly, 
chemoattraction, immune response, development, lipid metabolism, angiogenesis, wound 
healing or pathogen attachment. GAGs influence chemokines in this manner, they enhance 
their immobilization and form haptotactic gradients along cell surfaces, which can affect their 
transport, clearance, degradation and oligomerization56. Chemokines are characterized to 
include a receptor and a GAG binding domain and both of them are crucial for an accurate 
function56. In detail, mutated chemokines which show a GAG binding deficiency are unable to 
induce cell migration in vivo62. The localization of the receptor binding site of a chemokine is 
highly conserved, whereas the GAG binding site is localized on four different areas of the 
chemokine surface. Depending on the positions, the GAG binding cluster, may overlap the 
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receptor binding domain. This depends on the concerned localization of the two binding 
domains, suggesting that GAGs could potentially control receptor selectivity. Distinctions 
between a wild type and a GAG deficient binding chemokine concerning their activity was 
observed, which could be either due to the lack of GAG binding or to changes in receptor 
affinity or selectivity56. So far, the exact role of GAG in chemokine activity is not clearly 
defined, for this reason it is difficult to describe the exact effect of the GAG binding site, and 
the chemokine function. On the other hand, the various functions of GAGs may influence 
chemokines, depending through which receptor the signal transduction proceeds. 
In the pathogenesis of atherosclerosis and after MI a number of chemokines play very 
important roles. In both cases, an inflammatory reaction occurs, followed by chemokine 
release, which plays a crucial role in the immune response. For this study the CCL5 and 
CXCL12 chemokines were investigated in the context of MI and CX3CL1 in the context of 
atherosclerosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Overview of the secondary structure of chemokines and the corresponding 
chemokine receptors. Chemokines are subdivided into four families based on the relative position of 
the cysteine residues on the protein level. In CXC-chemokines, one amino acid separates the first two 
cysteine residues. In CC-chemokines, the first two cysteine residues are adjacent to each other. The 
C-chemokine subfamily is distinguished structurally as containing only two of the four conserved 
cysteine residues that are found in the other families. The CX3C-chemokine subfamily, is 
characterized by the presence of three amino acids between the first two cysteine residues, as well as 
a transmembrane and mucin-like domain48. 
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1.4.1. CCL5 (RANTES, Regulated on Activation, Normal T-Cell Expressed 
and Secreted) 
The CCL5 chemokine is a low molecular mass protein with 7.8 kDa, which participates in 
chronic inflammation by the recruitment of inflammatory cells63, 64. CCL5 is secreted by 
different cell types including ECs, SMCs, macrophages, platelets and activated T-cells65. 
CCL5 is the ligand for CCR1, CCR3 and CCR5 receptors64, 66 and is chemotactic for T-cells, 
eosinophils, basophils, and leukocytes. Furthermore CCL5 plays a critical role as neutrophil 
and macrophage activator in inflammation, atherosclerosis and MI67. During inflammation 
CCL5 attracts immune cells via haptotaxis, which underlies the multistep process of immune 
cell extravasation from the blood vessel into tissue68 (Figure 4).  
A model of sponge-induced inflammatory angiogenesis found a dynamic expression of the 
chemokine CCL5 to correlate with neovascularization and inflammatory cell accumulation69. 
Interestingly, in the early stage of the process the exogenous CCL5 was observed to prevent 
angiogenesis. CCR5 and CCR3 are the main receptors for CCL5, consequently a deletion of 
CCR5 alone will still allow CCL5 to bind to CCR165, 66. It has been shown that exogenous 
CCL5 no longer modified angiogenesis in CCR5(-/-) mice, accordingly CCL5 signals mainly 
through CCR5 in this model. Therefore, the activation of CCR5 by exogenous CCL5 may 
initiate a cascade of events leading to inhibition of sponge-induced angiogenesis70.  
The treatment with anti-CCL5 mAb significantly reduced both infarct size and post infarction 
heart failure in mouse model of chronic cardiac ischemia and the cardioprotective effects 
were associated with the reduction of leukocyte recruitment within the infarcted hearts67. It 
was already shown that functional impairment and structural remodeling after MI is reduced 
in the genetic absence of CCR1 due to an abrogated early inflammatory recruitment of 
neutrophils and improved tissue healing30. 
Braunersreuther et. al.71 showed that the injection of chemokine CCL5 antagonist 
[(44)AANA(47)]-CCL5 in an in vivo mouse model of ischemia/reperfusion (I/R) reduce infarct 
size in ApoE(-/-) mice after ligature of the left coronary artery71. The inhibition of CCL5 exerts 
cardioprotective effects during early myocardial reperfusion, which is associated with 
reduced leukocyte infiltration into the reperfused myocardium71. Nevertheless, deficient mice 
for the CCL5 receptor CCR5 did not exhibit myocardium salvage in our model of I/R71. 
Furthermore, [(44)AANA(47)]-CCL5 did not mediate cardioprotection in these ApoE(-/-) 
CCR5(-/-) deficient mice, probably due to enhanced expression of compensatory 
chemokines71. The inhibition of CCL5 shows cardioprotective effects during early myocardial 
reperfusion, through its anti-inflammatory properties71.  
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The CCL5 antagonist, Met-CCL572-74, which antagonizes the CCR5 receptor and its function 
in response to its natural ligand in vitro, was described. Met-CCL5 reduces the homing of 
early-outgrowth cells (EOCs), a step that is essential to endothelium building and the 
induction of neo-angiogenesis cells65, 72. Furthermore, Met-CCL5 is able to reduce 
inflammation in models of induced inflammatory and autoimmune diseases, in vivo. Indeed, 
Met-CCL5 is capable of partial agonist activity regarding receptor signaling and 
internalization and it does not function as a conventional receptor antagonist74. As receptor 
trafficking impacts on cell surface expression and the ability of the receptor to respond to 
other ligands, this information may indicate an alternative regulation of CCR5 by Met-CCL5 
that allows the modified ligand to reduce inflammation74. These facts indicate that Met-CCL5 
influences the progression of atherosclerosis and inhibits the recruitment of inflammatory 
cells. The blocking of chemokine receptor/ligand interactions might become a novel 
therapeutic strategy to reduce reperfusion injuries in patients during acute coronary 
syndromes. 
 
 
 
 
 
 
 
 
 
Figure 4: Role of CCL5 in inflammation. Figure modified from Krensky et. al.68. CCL5 (red ovals) 
attracts immune cells from the peripheral blood to sites of inflammation. Leukocytes ‘roll’ along the 
vascular endothelium via interactions with selectins. Chemokines, such as CCL5, attract immune cells 
via haptotaxis, inducing firm adhesion and diapedesis. CCL5 induces expression of integrins (e.g. 
CD11a/CD18 [lymphocyte function-associated antigen-1]) involved in adhesion, and 
metalloproteinases involved in movement through the vascular wall basement membranes and 
tissues. The immune cells follow the chemotactic gradient to the site of inflammation. T-cells, once 
activated by specific antigen, express CCL5 within 3–5 days, amplifying the immune response in time 
and space.68. 
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1.4.2. CXCL12 (SDF-1, Stromal Cell-derived Factor 1) 
The CXCL12 chemokine is also known as pre-B cell growth-stimulating factor (PBSF), which 
is a member of the CXC chemokine subfamily and was initially isolated from murine bone 
stromal cells75. The CXCL12 is constitutively and inducible expressed in several tissues such 
as BM, heart, liver, kidney, thymus, spleen, skeletal muscle and brain76, 77. This chemokine is 
highly conserved among mammalian species and is a key regulator of oriented cell 
migration58. It is able to orchestrate a huge array of functions during development but also in 
adult life and is importantly involved in a number of pathogenic mechanisms58. Indeed, 
knockout mice deficient in CXCL12 are not viable and die perinatally78. These mice show 
severely affected hematopoiesis with deficiencies in B-cell development, reduced 
myelopoiesis, and HC colonization of the BM75, 79, 80. In addition, CXCL12(-/-) mice show a 
cardiac ventricular septal defect and defective formation of the large vessels supplying the 
gastrointestinal tract78. Predominantly, the physiological effect of CXCL12 is mediated by the 
CXCR4 receptor, where the chemokine binds and triggers the signaling81, 82. This receptor 
was first identified in 1996 by two independent groups as the orphan receptor LESTR/Fusion, 
which was subsequently renamed CXCR481, 82. The CXCL12 binds to the CXCR4 and 
induces dimerisation of the receptor and activation of inhibitory Gi proteins. Different signal 
transduction pathways downstream of CXCR4 were identified, including activation of tyrosine 
kinases, focal adhesion kinase, paxillin, extracellular-signal-regulated kinases, protein kinase 
C (PKC), phospholipase C-γ, and phosphoinositol 3-kinase. Furthermore, the CXCL12 
binding to CXCR4 can also induce Janus kinases, the JAK/STAT transcription pathway and 
NF-κB78. The internalization of the CXCR4 receptor and its lysosomal degradation are 
important mechanisms causing desensitization towards CXCL12 signals, and 
phosphorylation of CXCR4 by PKC and G protein receptor kinases has been shown to 
increase its endocytosis owing to β-arrestin binding the C-terminus83. In addition, CXCL12 
was shown to bind with high affinity to a second orphan receptor CXCR7/RDC1, which was 
originally cloned on the basis of its homology with conserved domains of GPCRs84, 85. This 
receptor might activate MAPK, PI3K and JAK/STAT pathways thereby regulating progenitor 
cell migration86. The CXCL12 attracts HCs from the circulating blood and induces 
angiogenesis through CXCR4 and CXCR753. 
The structure of CXCL12 shows a typical chemokine fold stabilized by two disulfide bonds, 
which consists of a poorly structured N-terminus of 10 residues, followed by a long loop, a 
310 helix, a three β-sheet and a C-terminal helix58. Different CXCL12 isoforms, arising by 
alternative splicing of the same gene are known. Until now six different isoforms (α, β, γ, δ, ε, 
ϕ) of the CXCL12 were shown in rodents87 and humans88, respectively58. All the isoforms 
share the same three first exons corresponding to the α-isoform (residue 1-68), but differ in 
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their fourth exon, which give rise to a specific C-terminal domain for each of them58. The 
most prominent isoform, is the α-isoform, which encodes for a 68 amino acids peptide, while 
the β-isoform contains four additional amino acids at the C-terminus. Gleichmann et. al.87 
identified the splicing variant of the γ-isoform in the adult rat brain, heart and lung with the 
strongest expression observed in the heart, which contains 30 additional amino acids in 
comparison to the α-isoform at the C-terminus. However, the γ-isoform expression remains 
unaltered upon MI, while the predominant α-isoform, was shown to be significantly induced 
suggesting an important role of this isoform in the pathophysiology of MI21, 89. Functional 
studies revealed differences of this isoforms in their ability to stimulate cell migration39. The 
most studied isoforms are the α- and β-isoforms, but the γ-isoform became also more 
prominent over time. However, further investigations are required to understand the 
functional diversity of these CXCL12 variants39. 
The CXCL12 possesses the unique ability of adhesion, migration and homing of circulating 
CXCR4+ progenitor cells to ischemic tissue35. In contrast to other chemokines, CXCL12 
selectively immobilized HCs90. For this reason, the already well-characterized CXCL12 
chemokine is a promising candidate for promoting tissue regeneration53. Under low oxygen 
supply during ischemia the transcription factor, HIF-1α was shown to regulate various 
downstream target genes such as CXCL12, which might further control the migration of 
progenitor and ECs towards the ischemic zone35. HIF-1α not only induces the expression of 
CXCL12 during ischemic injury, but also induces the expression of CXCR4 receptor on 
progenitor cells which might help to guide these cells towards CXCL12 gradients in ischemic 
tissue35. The involvement of CXCL12 in tissue repair after MI, was proven. For example, the 
CXCL12-mediated mobilization of BM-derived HCs to the ischemic heart was shown to result 
in angiogenesis and improved myocardial function (Figure 5)21. The interaction between 
CXCL12 and CXCR4 which has a significant role in regulating the homing and proliferation of 
SCs in the BM under homeostatic conditions has been discussed21. If the disruption of BM 
CXCL12/CXCR4 signaling under stress-induced conditions occurs, it is necessary to induce 
the mobilization of SCs into the circulation91. In parallel, the local elevation of CXCL12 levels 
in the inflamed or injured organ is capable of recruiting the mobilized cells to the site of injury 
where they can support tissue repair and regeneration (Figure 5)21. 
The effect of CXCL12 in the ischemic heart is limited by proteases that regulate the activity of 
many chemokines, which can increase or decrease their activity after N-terminal cleavage92. 
For example matrix metalloproteinase (MMP)-2 cleaves the CXCL12 chemokine at the N-
terminus, resulting in a tetrapeptide93, and a neurotoxic remnant94 which decreases its 
activity92. CXCL12 is also cleaved by Dipeptidyl Peptidase IV (DPPIV/CD26), a serine 
exopeptidase that releases Xaa-Pro dipeptides from the N-terminus of the polypeptide53, 95. 
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DPPIV is a transmembrane protein in ECs and leukocytes53, 96. Until now the physiological 
role of this cleavage is unknown, but CXCL12 inactivation by MMPs and DPPIV could cause 
immobilization of HCs from the BM53. In a previous study53, it was shown that a protease-
resistant CXCL12 (S4V) chemokine is resistant to MMP-2 and DPPVI/CD26 cleavage and 
retain receptor specificity of native CXCL12. Furthermore, the local delivery of the protease-
resistant CXCL12 (S4V) may improve cardiac function after MI by driving chemotaxis53, and it 
is a promising candidate for the therapy of MI to improve cardiac function. 
 
Figure 5: Potential role of CXCL12 in MI. Figure modified from Ghadge et. al.21. (1.) MI initiates the 
upregulation of the hypoxic signal HIF-1α, which then induces cell mobilization signals such as 
CXCL12 and VEGF and their release in the peripheral blood. (2.) These signals reach the bone 
marrow (BM). (3.) This leads to alterations in the BM microenvironment (e.g. MMP2/9, DPPIV, 
elastase, cathepsin G) resulting in proliferation and increased in CXCR4 receptor expression of 
progenitor cells as well as CXCL12 degradation. (4.) The changes in the BM CXCL12 gradient lead to 
the translocation of stem and progenitor cells into the peripheral blood and their homing towards the 
local CXCL12 gradient initiated in the myocardium. BM and progenitor cells selectively home to the 
ischemic myocardium where they are involved in myocardial repair through cardioprotective functions 
and induction of angiogenesis21. 
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1.4.3. CX3CL1 (Fractalkine) 
The CX3CL1 is the only chemokine known until now, which belongs to the CX3C chemokine 
subfamily. The CX3CL1 is a large protein of 373 amino acids containing multiple domains 
and is structurally distinct from other chemokines97. Structurally, CX3CL1 consists of an N-
terminal chemokine domain which contains 76 amino acids with the unique 3-residue 
insertion between cysteins, which represents the extracellular domain. Connected to the 
extracellular domain, a mucin-like stalk follows, containing 241 amino acids with a predicted 
O-glycosylated serine and threonine. The transmembrane domain contains 19 amino acids, 
and is connected to an intracellular domain with a 37 amino acid residue97. CX3CL1 exists in 
two different forms, i.e. a membrane-bound or soluble form after shedding from the cell 
surface97. Inflammatory cytokines such as IL-1, and interferon (IFN)-γ can induce the 
expression of membrane-bound CX3CL1 on primary ECs98. The soluble CX3CL1 is released 
by proteolysis at a membrane-proximal region by TNF-α–converting enzyme (TACE 
[ADAM17]) and ADAM1099, 100. The transmembrane protein supports integrin-independent 
leukocyte adhesion, whereas the soluble form of CX3CL1 has a potent chemoattractant 
activity90. The soluble form exhibits its efficient chemotactic activity for 
monocytes/macrophages, NK cells and T-cells, whereas the membrane-bound form captures 
and enhances the subsequent migration of these cells in response to secondary stimulation 
with other chemokines.98. Furthermore, stimulation through membrane bound CX3CL1 
activates NK cells, leading to increased cytotoxicity and IFN-production. The endothelium is 
the first obstacle to leukocyte transmigration, the properties and functions of CX3CL1 on ECs 
support its role as a gateway controlling leukocyte extravasation at sites of inflammation97. 
The CX3CL1 chemokine domain is presented at the top of a cell-bound extended mucin-like 
stalk98, 101, which functions as an adhesion molecule102 thereby obviating the need for both 
the association with proteoglycans and other adhesion molecules97. Under static and 
physiological flow conditions CX3CR1-expressing cells bind rapidly and with high affinity to 
immobilized CX3CL1 or CX3CL1-expressing cells102-104. It was shown with the help of video 
microscopy that CX3CR1-expressing cells adhere more rapidly to immobilized CX3CL1 than 
to vascular cell adhesion molecule (VCAM)-1 without cell tethering and dislodging under flow 
conditions97, 105. Thus, CX3CL1 may facilitate the extravasation of circulating leukocytes by 
mediating cell adhesion through the initial tethering and the final transmigration 
steps87(Figure 6). 
Both leukocyte adhesion and chemoattractant activity of CX3CL1 are mediated through the 
CX3CR1 receptor, which is also involved in atherogenic monocyte recruitment97, 106. CX3CL1 
is upregulated on activated SMCs via NF-κB and triggers monocyte adhesion to SMCs in 
vitro90, 107, 108. In an endothelial denudation injury model, it was shown that the expression of 
Introduction 
18 
CX3CL1 is delayed predominantly in ECs and neointimal SMCs109. After mechanical injury 
the reendothelialization is incomplete, so the CX3CL1-expressing neointimal SMCs exposed 
to the blood stream may enhance chronic monocyte recruitment110. Indeed, CX3CR1 
deficiency protects animals from developing intimal hyperplasia as a result of decreased 
monocyte trafficking to the lesion. CX3CR1 deficiency decreases VSMC proliferation and 
intimal accumulation either directly or indirectly as a result of defective monocyte 
infiltration109. It was already demonstrated, that TNF-α induces expression of CX3CL1 and 
CX3CR1 in rat aortic SMCs and this induction is mediated by NF-κB activation. Furthermore, 
CX3CL1 induces its own expression, which is mediated by the PI 3-kinase/ PDK1/ Akt/ NIK/ 
IKK/ NF-κB signaling pathway. In addition, CX3CL1 increases cell-cell adhesion and aortic 
SMC proliferation, indicating a role in initiation and progression of atherosclerotic and 
vascular disease108. Other studies confirm this assumption, by demonstrating high levels of 
CX3CL1 mRNA expression, as well as mRNA encoding of other 16q13-chromosome–linked 
chemokines, CCL17 (thymus and activation-regulated chemokine [TARC]), and CCL22 
(macrophage-derived chemokine [MDC]), have been observed in some, but not all, human 
arteries with advanced atherosclerotic lesions111. The distinctive staining patterns in native 
atherosclerosis and diabetes mellitus with atherosclerosis indicate that the expression of 
CX3CL1 and CX3CR1 may be important in the pathogenesis of these diseases112. 
Chemokines are the key regulators in monocyte migration from the blood to the vessel wall 
and the monocytes are the precursors of macrophages and foam cells during the 
progression of a atherosclerotic lesion6. Furthermore, it has been reported that CX3CL1 
expression is upregulated in atherosclerotic lesions of ApoE(-/-) mice and that crossing 
CX3CR1(-/-) into the ApoE(-/-) background results in decreased atherosclerotic lesion 
formation with reduced macrophage accumulation113, 114. Recently, it was observed that the 
reduction in atherosclerotic plaque size in hyperlipidemic mice upon aspirin administration 
was associated with a reduced lesional expression of CX3CL1, a NF-κB target gene 
important in atherosclerosis115, 116. Although the macrophage accumulation in the lesions was 
not measured in this study, previous data suggests reduced CX3CL1 expression to lower 
foam cell content in the plaques116. Another study shows that platelets in hyperlipidemic mice 
display increased CX3CR1-expression and assemble with circulating monocytes. The 
formation of platelet-monocyte-complexes (PMC) and the detection of platelet-bound 
CX3CL1 on inflamed SMCs suggest a significant involvement of the CX3CR1–CX3CL1 axis in 
platelet accumulation and monocyte recruitment at sites of arterial injury in atherosclerosis117. 
For influencing the CX3CR1–CX3CL1 axis, a CX3CR1 antagonist called F1-CX3CR1 with a 
modified N-terminus showing anti-inflammatory activity, was described27. The CX3CR1 
antagonist F1-CX3CL1 strongly decreases the migration of the CX3CR1-positive monocytic 
population, this study suggests that antagonists such as F1-CX3CL1 might be useful in a 
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thorough analysis of inflammation pathways and in a therapeutic setting, in the ultimate 
prevention of the side effects of broad-spectrum inhibitors27. Another study showed that 
platelet-CX3CR1 appears to play a notable role in PMC assembly, as preincubation of 
platelets with the CX3CR1-antagonist F1-CX3CL1 significantly decreased PMC formation. 
Similar observations could be made in mouse blood, since PMC formation during 
hyperlipidemia was dependent on CX3CR1117. The F1-CX3CL1 molecule could be used as a 
lead compound for the development of a novel class of anti-inflammatory substances that act 
by inhibiting CX3CR127. 
 
 
 
 
 
 
Figure 6: Schematic model of a CX3CL1-mediated pathway in the adhesion cascade. Figure 
modified from Umehara et. al.97. CX3CL1-mediated pathway. CX3CL1 is expressed on ECs as the 
membrane-bound form and captures leukocytes in a selectin- and integrinindependent manner. 
Interaction between CX3CL1 and CX3CR1 can also increase integrin avidity, resulting in firmer 
adhesion. Leukocytes then extravasate through the vascular wall and into the tissue towards a 
chemokine gradient. CX3CL1 may facilitate extravasation of circulating leukocytes by mediating cell 
adhesion through the initial tethering and final transmigration steps97. 
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1.5. Biocompatible and Degradable Hydrogels 
In recent years, the knowledge in the field of drug delivery grew and now it offers a suitable 
option of site-specific and/or time-controlled delivery of small or large molecular weight drugs 
and other bioactive agents118. To date several therapeutically active agents were formulated 
in biocompatible forms. These systems show many advantages in the area of drug delivery 
over conventional approaches. In terms of safety and efficacy, these systems are 
advantageous with regard to improved targeted delivery of drugs, improved bioavailability, 
extension of drug or gene effect in target tissue, and improved stability of therapeutic agents 
against chemical/enzymatic degradation119.  
In 1960, Wichterle and Lim120 introduced a novel type of hydrophilic gel for biological use. 
Until now, a huge sum of efforts and studies has been devoted to advancing and extending 
the potentials attributed to hydrogels118. Growing of hydrogel technology led to substantial 
advances in the pharmaceutical and biomedical field118. Hydrogel particles are hydrophilic 
crosslinked polymeric particles with submicrometer size121. The important characteristics of 
hydrogels are biocompatibility, high-water content as well as tunable chemical and 
mechanical properties with the features of these particles such as high-surface area and 
overall sizes in the range of cellular compartments121. While the water content of a hydrogel 
determines its unique physicochemical characteristics, these structures have some common 
physical properties resembling that of the living tissues, than any other class of synthetic 
biomaterials, which is attributed to their highwater content, their soft and rubbery 
consistency, and low interfacial tension with water or biological fluids118. Despite their high 
water absorbing affinity, hydrogels shows swelling behavior instead of being dissolved in the 
aqueous surrounding environment as a consequence of the critical crosslinks present in the 
hydrogel structure118. These networks can be classified into two main categories according to 
the types of cross-linking. The network cross-linked by covalent bonds is the so-called 
chemical gel, while the formation of physical gel takes place via physical association 
between polymeric chains and particles122. In some cases, chemical and physical gelling 
might coexist in one hydrogel122. These properties make them intriguing candidates for 
entrapment of hydrophilic bioactive molecules such as DNA or proteins to provide a 
hydrophilic environment and protect them from degradation118, 121.  
In general, hydrogels can be classified based on a variety of characteristics, including the 
nature of side groups (neutral or ionic), mechanical and structural features (affine or 
phantom), method of preparation (homo- or co-polymer), physical structure (amorphous, 
semicrystalline, hydrogen bonded, supermolecular, and hydrocollodial), and responsiveness 
to physiologic environment stimuli (pH, ionic strength, temperature, electromagnetic 
radiation, etc.)118. Hydrogels may absorb between 10-20% and up to thousands of times of 
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their dry weight in water, but they are chemically stable or they may degrade and eventually 
disintegrate and dissolve123. They are called ‘reversible’, or ‘physical’ gels when the networks 
are held together by molecular entanglements, and/or secondary forces including ionic, H-
bonding or hydrophobic forces123-125. Physical hydrogels are not homogeneous, since 
clusters of molecular entanglements, or hydrophobically- or ionically-associated domains, 
can create inhomogeneities. Free chain ends or chain loops also represent transient network 
defects in physical gels123. Chemical hydrogels may be generated by crosslinking of water-
soluble polymers, or by conversion of hydrophobic polymers to hydrophilic polymers plus 
crosslinking to form a network123. Hydrophilic hydrogels with high amounts of water in their 
structures show distinctive properties compared to hydrophobic polymeric networks118. Gel 
formation usually proceeds at ambient temperature and organic solvents are rarely required. 
In-situ gelation with cell and drug encapsulation capabilities further distinguishes hydrogels 
from the other hydrophobic polymers126. Hydrogels, particularly those intended for 
applications in drug delivery and biomedical purposes, are required to have acceptable 
biodegradability and biocompatibility which necessitates the development of novel synthesis 
and crosslinking methods to design the desired products118. An ideal injectable medical 
hydrogel should meet the following requirements: 1) In order to guarantee the injectability, 
the system should be, as usual, in a sol state before administration. "A sol is a colloidal 
suspension of solid particles (1-500 nanometres in size) in a liquid. The sol is desired to be of 
sufficiently low viscosity and thus allow a smaller pinhead in injection to alleviate the pain of a 
patient. 2) Gelation via either chemical crosslinking or physical association starts to happen 
or is completed after injection. 3) The gels should be biodegradable or gradually dissolvable, 
and the products should be bioresorbable. 4) The polymer itself and its degradable products 
as well as some necessary additives such as crosslinking agents in the case of in situ 
chemical gelling should be biocompatible. 5) Some specific requirements should be met, for 
instance, a sustained release profile for a drug delivery system, or cell-adhesive capability for 
tissue engineering122. 
For this study a biocompatible and degradable hydrogel carrier composed of thiol-
functionalized polymers based on star-shaped poly(ethylene oxide-stat-propylene oxide) 
(sP(EO-stat-PO)) and linear poly(glycidol) (PG) has been used. Hydrogel particles are 
prepared by crosslinking of the polymers in inverse mini emulsion via oxidation of thiol 
groups to disulfide bonds121. In vitro and in vivo studies have revealed that these 
thermogelling copolymers are of good biocompatibility and mechanical property122. Hydrogels 
were rapidly formed once injected and no significant immune response were observed in the 
surrounding of the injection sites127, 128. These hydrogels could be also potentially used as a 
drug delivery system, for a controlled release of other proteins, siRNA, and DNA. 
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1.6. Myocardial infarction (MI) therapies 
To obtain the restoration of the normal coronary blood flow and the regeneration of the 
myocardium after MI, different long-term therapies are actual. Very important for prevention 
of the disease is the prophylaxis of patients with suspicion for potential development of MI, 
even before the diagnosis is confirmed. Currently, various therapeutic approaches are being 
applied, for example antiplatelet agents, anticoagulants, GP IIb/IIIa antagonists, 
thrombolysis, beta blockers, nitrates, selective aldosterone blockers, as well as analgesia for 
reducing pain and anxiety. Angiotensin-converting enzyme (ACE) inhibitors or statins are 
also often prescribed shortly after MI129. Antiplatelet therapy prevents thrombus formation in 
the vast majority of patients presenting with an MI. The most prominent drug that is used as 
antiplatelet therapy is aspirin. Not only the anti-coagulant, but also the anti-inflammatory 
properties of aspirin influence positively the patient. In some cases, aspirin is 
contraindicated, due to hypersensitivity or gastrointestinal complications. Then clopidogrel is 
a good alternative. Clopidogrel is a thienopyridine derivative that exerts an irreversible 
antiplatelet effect by antagonizing adenosine phosphate. The combination of aspirin and 
clopidogrel provides additional antiplatelet activity129. The usage of heparin as an 
anticoagulant, which is an indirect thrombin inhibitor which complexes with antithrombin III 
and converts this circulating cofactor from a slow to a rapid inactivator of thrombin, factor Xa, 
and to a lesser extent, factors XIIa, XIa, and IXa, may be used in the clinic130. The 
development of the GP IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the 
potential to considerably enhance the treatment of acute myocardial infarction (AMI) patients. 
A number of recent studies have highlighted the potential incremental benefits with 
adjunctive IIb/IIIa-targeted therapy131. To reduce the infarct size and to improve the survival 
of the patients, the restoration of the perfusion to the ischemic area by lysis the clot is 
necessary. This may be obtained by thrombolytics, such as streptokinase and tissue 
plasminogen activator129. Beta-blocker application is a further therapeutic approach to 
treatment MI129. There are different effects on the myocardium applying beta-blockers, such 
as initial diminishing of myocardial oxygen demand by reducing heart rate, systemic arterial 
pressure, and myocardial contractility and the prolongation of diastole may augment 
perfusion to injured myocardium. Beta-blockade is now established as a highly effective 
therapy that reduces morbidity and mortality in patients with heart failure associated with 
reduced systolic function132. Furthermore the intravenous application of nitrates may be 
useful during the acute phase in patients with hypertension or heart failure, provided that 
there is no hypotension, right ventricular infarction or use of phosphodiesterase type 5 
inhibitors in the previous 48 h. In the acute and stable phase, nitrates remain valuable agents 
to control anginal symptoms129. The effects of ACE inhibitors are dilation of blood vessels 
and decrease resistant by lowering levels of angiotensin II, for an easier flow of blood 
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through the blood vessel. Clinical studies using the treatment of ACE inhibitors demonstrate 
an improvement in hemodynamics, LV remodeling, and mortality. The effect of ACE 
inhibitors during the acute phase of AMI was less clear, although there was evidence of 
protection from ischemic damage, possibly mediated by an increase in collateral coronary 
blood flow133. For the therapy of MI, statins may be also used to lower LDL cholesterol, raise 
high-density lipoprotein (HDL) cholesterol and lower triglyceride levels. The benefits of 
statins in prevention have been unequivocally demonstrated134, and specific trials have 
demonstrated the benefit of early and intensive statin therapy135, 136. Recent meta-analysis of 
trials compared more- vs. less-intensive LDL-cholesterol lowering with statins. The obtained 
data indicate that more-intensive statin therapy produced reductions in the risks of 
cardiovascular death, non-fatal MI, ischemic stroke and coronary revascularization129. Taken 
together, this major cause of death can not be cured completely with the present therapeutic 
approaches. For this reason, new therapeutic approaches are explored. 
Current strategies have been proposed the progenitor cell therapy, which was considered as 
a promising therapeutic approach to provide an alternative way to regenerate the heart 
structure after MI. Pioneering studies in animals have shown that transplantation of adult 
stem cells after acute MI improves neovascularization and reduces fibrosis, preserving the 
left ventricular heart function137, 138. Unfortunately, these promising results were less 
pronounced in clinical studies in patients139, probably due to incorrect translation of the 
knowledge from the animal to the human system. New data suggest that the main 
mechanism of improving the heart function by cell therapy is in fact due to the inflammation 
and its consecutive effects140. These findings are of notable significance, since it is known to 
be able to selectively control and manipulate the inflammatory reaction through 
chemokines20. 
Despite extensive research, the current knowledge regarding the control of molecular and 
cellular events after MI is still limited. Therefore, to be able to create efficient therapies, it is 
important to understand how all these processes are modulated and controlled. Chemokines 
and chemokine receptors have the most precise functions in leukocyte trafficking, 
angiogenesis, collagen synthesis, and cardiac repairing20. Manipulating this processes, by 
interfering with receptor–ligand interaction, chemokine–GAG interaction, heteromerization, or 
signaling pathways induced upon receptor activation141, should enable to control and modify 
molecular and cellular events20. 
A novel therapeutic approach showed the injection of an antagonist blocking the chemokine 
CCL5, which reduce myocardial leukocyte infiltration in a mouse model of induced 
myocarditis. The treatment with Met- CCL5 clearly diminished the infiltration of T-cells and 
fibronectin deposition, critical aspects of cardiomyopathy, in the heart of the mice142. 
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However, additional studies are required to clarify the role of CCL5 in post-ischemic cardiac 
repair. 
One potentially promising strategy for repairing damaged cardiac tissue following MI involves 
the use of CXCL12 to prevent or reverse heart failure143. Different scientists have shown that 
the cells can be mobilized and home to areas of injury, in part in response to the 
CXCL12/CXCR4 interaction143, 144. The essential role of CXCL12 in BM homing and 
recruitment was already demonstrated several times145, 146. This promising chemokine has 
been tested in gene therapy as a recruiter of BM-derived cells to the myocardium, in a 
murine infarct model38, 147, 148. The CXCL12 acts through CXCR4 and indeed recruit BM-
derived cells to the injured tissue, supporting the notion that this chemokine might have 
therapeutic potential143. Different clinical trials in this area have been recently completed or 
are still ongoing. For example, a phase 1 trial that is currently tested, is examining the effects 
of CXCL12 on infarcted hearts, where the ligand is injected directly into the heart and then 
monitoring homing of bone marrow cells (BMCs) into the myocardium of patients with 
ischemic heart disease. Also noteworthy is an open-label dose-escalation study to evaluate 
the safety of a single escalating dose of CXCL12, administered by endomyocardial injection 
to cohorts of adults with ischemic heart failure, which is currently enrolling patients, here 
naked DNA that encodes CXCL12 is being injected directly into the myocardium as a single 
dose at multiple sites through a percutaneous, left ventricular approach, using a needle 
injection catheter (ClinicalTrials.gov identifier: NCT01082094). These trials will demonstrate 
the safety and efficacy of using chemokines e.g. CXCL12 to treat heart failure in subjects 
with ischemic cardiomyopathy143. 
 
Aim of the study 
25 
2. Aim of the study 
Chemotactic cytokines and their receptors exert a fundamental role in the development of 
atherosclerosis and in the process of ischemic tissue revitalization through angiogenesis. 
The first part of this work was aimed to express and purify different modified chemokines 
and/or chemokine antagonists to study their role in cardiovascular diseases (CVDs). These 
chemokines and/or chemokine antagonists are Met-CCL5, protease-resistant CXCL12 
(S4V), CXCL12 (S2G4V) and F1-CX3CL1, which were expressed in E. coli as “inclusion 
bodies” in the cytoplasm and were purified by different sequential steps with 
chromatographic methods using FPLC and HPLC.  
The major goal of this study was to design a novel therapeutic strategy with Met-CCL5 and 
the protease-resistant CXCL12 (S4V) variant. Met-CCL5 is a chemokine receptor antagonist 
which retains the initial neutrophil infiltration during inflammation after MI. The protease-
resistant CXCL12 (S4V) variant is resistant to MMP-2 and exopeptidase cleavage, but 
retains its chemotactic bioactivity for the recruitment of circulating hematopoietic cells and 
promotes neovascularization after MI. For a proper time-controlled local release of the Met-
CCL5 and protease-resistant CXCL12 (S4V), two different biodegradable hydrogels were 
implemented. A fast degradable hydrogel (FDH) for delivering Met-CCL5 over 24 h and a 
slow degradable hydrogel (SDH) for a gradual release of CXCL12 (S4V) over 4 weeks. Both 
chemokines in biodegradable hydrogels were injected locally into the mouse heart after 
induction of MI. The major question of the second part of this work was: 
 Is the combined therapy with Met-CCL5 in FDH and protease-resistant CXCL12 in 
SDH a successful therapeutic strategy for the therapy after MI? 
The chemokine receptor CX3CR1 is an inflammatory mediator in vascular disease. On 
platelets, its ligation with CX3CL1 induces platelet activation followed by leukocyte 
recruitment to activated endothelium. Here, the role of platelet-CX3CR1 during the 
development of atherosclerosis was explored. The third goal of this work was to find the 
importance of the platelet-CX3CR1 and CX3CL1 for the formation of platelet monocyte 
complexes (PMC). The question of this part of the work was: 
 Does platelet F1-CX3CL1 antagonist play a role in PMC formation? 
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3. Materials 
All protocols were adapted from standard protocols unless otherwise described. The 
solutions are prepared with double distilled water (Heraeus Destamat, Heraeus, Germany) or 
Millipore water (Milli-Q Plus ultrapure purification, Millipore, MA). Reagents were purchased 
from Fluka (Buchs, Switzerland), Sigma (Deisenhofen, Germany), or Roth (Karlsruhe, 
Germany) unless otherwise specified. All animal studies were approved by local authorities 
and complied with German animal protection law. 
3.1. Instruments 
Equipment Manufacturer 
Autoclave Systec 2540EL (Systec, Wettenberg, 
Germany) 
Balance Analytical Plus, (Ohaus, Pine Brook, USA) 
Blotting System iBlot® 7-Minute Blotting System (Invitrogen, 
San Diego, USA) 
Centrifuges Eppendorf 5417C (Eppendorf, Hamburg, 
Germany), Heraeus Labofuge 400 and 
Heraeus Multifuge 3 S-R (Heraeus, 
Osterode, Germany), Beckman Avanti® J 30 
I (Beckman Coulter, Krefeld, Germany) 
Dialysis membrane (MWCO (molecular 
weight cut off) = 3500Dalton (Da)) 
Spectrum Laboratories, Inc (DG Breda, 
Netherlands) 
Diskus Software Carl H. Hilgers (Königswinter, Germany) 
Echocardiograph Vevo 770® (Visual Sonics, Toronto, Canada) 
Electroporator Gene Pulser® II (Bio-Rad, Hercules, USA), 
Nucleofector® Device (Amaxa®, Cologne, 
Germany) 
Fermenter/bioreactor  LAMBDA laboratory instruments (Baar, 
Switzeland) 
Flow cytometers FACS Canto  II (BD Biosciences, San Jose, 
CA, USA) 
Fluorescence Microplate reader SpectraFluor Plus (Tecan, 
Crailsheim, Germany), LS 55 Fluorescence 
Spectrometer (PerkinElmer, USA) 
FPLC system Äkta™ FPLC ( Amersham/GE Healthcare, 
Uppsala, Sweden) 
Gel electrophoresis Mini-sub Cell® GT (Bio-Rad, Hercules, USA) 
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Equipment Manufacturer 
Heparin sepharose™ 6 fast flow  GE Healthcare (Uppsala, Sweden) 
HPLC system Spectra System SCM (Thermo Electron 
Corp., Thermo Scientific®, Waltham, USA), 
Varion Prostar HPLC System (Varian Inc., 
Palo Alto,USA), Waters Delta Prep 3000 
HPLC System (Waters Corp., Milford, USA) 
HisTrap™ HP GE Healthcare (Uppsala, Sweden) 
Image reader LAS 3000 (Fujifilm, Düsseldorf, Germany) 
Incubator Innova 4230 (New Brunswick Scientific, 
USA) 
Laminar flow cabinet Herasafe (Heraeus, Osterode, Germany) 
Lyophilisator Alpha 2-4 LD plus (Christ, Osterode, 
Germany) 
Microscopes Olympus IX71, IX50, IX81 (Olympus Optical, 
Hamburg, Germany) 
Microplate reader GENios (Tecan, Männedorf, Switzerland) 
Microtome Cut 6062 (SLEE, Mainz, Germany) 
Ni-NTATM Column GE Healthcare (Uppsala, Sweden) 
PCR thermocyclers MyCycler (Bio-Rad, Hercules,USA) 
pH-meter InoLab level 1 (WTW, Weilheim, Germany) 
Resource S GE Healthcare (Uppsala, Sweden) 
Rodent respirator Harvard Apparatus (March Hugstetten, 
Germany) 
Sonicator Branson S-250 D Digital Sonifier (Branson, 
Danbury, USA) 
SP Sepharose FF™ column GE Healthcare (Uppsala, Sweden) 
Spectrophotometer GeneQuantTM 1300 (Amersham/GE 
Healthcare, Uppsala, Sweden), NanoDrop 
1000 (PeqLab, Erlangen, Germany) 
Tricon Mono STM 5/50GL GE Healthcare (Uppsala, Sweden) 
Vydac® column C8 250x10mm, 5µm Grace (Deerfield, USA) 
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3.2. Reagents and general materials 
Reagents Manufacturer 
Acrylamide (30%)/bisacrylamide (0,8%) Roth (Karlsruhe, Germany) 
Adenosin-5’triphosphate (ATP) Sigma (Taufkirchen, Germany) 
Agarose, ultra pure Roth (Karlsruhe, Germany) 
Ampicillin Sigma (Taufkirchen, Germany) 
Ammonium persulfate (APS) Roth (Karlsruhe, Germany) 
Aqua ad injectabilia Braun (Melsungen, Germany) 
Bacto-agar Roth (Karlsruhe, Germany) 
Benzonase® nuclease Novagen/Merck Bioscience (Darmstadt, 
Germany) 
β-mercapthoethanol Sigma (Taufkirchen, Germany) 
Bicoll Biochrom AG (Berlin Germany) 
Bouin´s solution Sigma (Taufkirchen, Germany) 
Bovine serum albumin (BSA) Sigma (Taufkirchen, Germany) 
Bromphenolblue Sigma (Taufkirchen, Germany) 
BugBuster® Protein Extraction Reagent Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Calcein Invitrogen (San Diego, USA) 
Calciumchloride (CaCl2) Sigma (Taufkirchen, Germany) 
Carbenicillin Roth (Karlsruhe, Germany) 
complete Mini, EDTA-free tablets Roche (Penzberg, Germany) 
Coomassie brilliant-blue G-250 Roth (Karlsruhe, Germany) 
Cysteamine (2-mercaptoethylamine)  Biochemica (Eastern, USA) 
Cysteine Fluka (Buchs, Switzerland) 
Cystine Fluka (Buchs, Switzerland) 
DAPI Vector (Burlingame, CA, USA) 
Deuterium oxide 99.9% Deutero (Kastelbraun, Germany) 
Dichloromethane (HPLC grade) Sigma (Taufkirchen, Germany) 
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Reagents Manufacturer 
Dimethyl sulfoxide (DMSO) Fluka (Neu-Ulm, Deutschland) 
5,5’-dithio-bis-(2-nitrobenzoic acid) (DTNB) Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Dithiothreitol (DTT) Roth (Karlsruhe, Germany) 
3,3’-dithiodipropionic acid  Sigma (Taufkirchen, Germany) 
4 DMAP (99+%)  Sigma (Taufkirchen, Germany) 
100 bp DNA ladder New England Biolabs (Ipswich, USA) 
1 kb DNA ladder Sigma (Taufkirchen, Germany) 
Enterokinase Novagen®/Merck Bioscience (Darmstadt, 
Germany) 
Ethanol Roth (Karlsruhe, Germany) 
Ethidiumbromide Sigma (Taufkirchen, Germany) 
Ethylenediaminetetraacetic acid (EDTA) Calbiochem (Schwalbach, Germany) 
Ethylene oxide-stat-propylene oxide (sP(EO-
stat-PO) 
Dow Chemicals (Terneuzen, Netherlands) 
Fetal calf serum (FCS) PAA (Pasching, Austria) 
Fibronectin Biochrom (Berlin, Germany) 
Formalin Roth (Karlsruhe, Germany) 
Glycerol Sigma (Taufkirchen, Germany) 
Glycine Roth (Karlsruhe, Germany) 
Gomori’s 1-step trichrome stain Sigma (Taufkirchen, Germany) 
Guanidine-HCl Roth (Karlsruhe, Germany) 
Hirudin Bayer Healthcare (Leverkusen, Germany) 
Hydrochloride (HCl) Roth (Karlsruhe, Germany) 
hydrogen peroxide  VWR (Darmstadt, Germany) 
HEPES Roth (Karlsruhe, Germany) 
iBlot® gel transfer stacks nitrocellulose, 
regular 
Invitrogen (San Diego, USA) 
Imidazole Roth (Karlsruhe, Germany) 
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Reagents Manufacturer 
Isopropyl alcohol Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) 
Roth (Karlsruhe, Germany) 
Kanamycine Roth (Karlsruhe, Germany) 
Ketamin CEVA CEVA (Düsseldorf, Germany) 
L-Glutathione oxidized Roth (Karlsruhe, Germany) 
L-Glutathione reduced Roth (Karlsruhe, Germany) 
Lysozyme Roth (Karlsruhe, Germany) 
Magnesium chloride (MgCl2) Roth (Karlsruhe, Germany) 
Mayer´s hemalum solution Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Mayer's hematoxylin solution Applichem (Darmstadt, Germany) 
MES Roth (Karlsruhe, Germany) 
Methanol Promochem (Wesel, Germany) 
Monopotassium phosphate Roth (Karlsruhe, Germany) 
Naphthol AS-D Chloroacetate Kit Sigma (Taufkirchen, Germany) 
N,N’-dicyclohexyl-carbodiimide (DCC), 
(99%)  
Acros (Geel, Belgium) 
Nucleoside triphosphate master mix (dNTP) Eurogentec (Seraing, Belgium) 
PageBlue™ Protein Staining Solution Fermentas (Ontario, Canada) 
Paraformaldehyde Sigma (Taufkirchen, Germany) 
Penicillin PAA (Pasching, Austria) 
Phosphate buffered saline (PBS) PAA (Cölbe, Germany) 
3.0 µm/ 8.0 µm  pore polycarbonate 
membrane insert 
Costar (MA, USA) 
Polyethylene glycol (PEG) 8000 Promega (Madison, USA) 
Poly(ethyleneglycol) diacrylate (PEG-DA) Sigma (Taufkirchen, Germany) 
PolymorphprepTM AXIS-SHIELD (Oslo, Norway) 
Ponceau S Sigma (Taufkirchen, Germany) 
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Reagents Manufacturer 
Potassium chloride (KCl) Sigma (Taufkirchen, Germany) 
Potassium hydrogen phosphate (KH2PO4) Sigma (Taufkirchen, Germany) 
Rhodamine 6G Sigma (Taufkirchen, Germany) 
Roti®-Block Roth (Karlsruhe, Germany) 
Silver nitrate Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Sodium carbonate Roth (Karlsruhe, Germany) 
Sodium chloride Prolabo (Montreal, Canada) 
Sodium deoxycholate Sigma (Taufkirchen, Germany) 
Sodium phosphate Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Sodium dodecyl sulfate (SDS) Roth (Karlsruhe, Germany) 
Sodium hydroxide (NaOH) Sigma (Taufkirchen, Germany) 
Sodium thiosulfate Roth (Karlsruhe, Germany) 
Streptavidin PAA (Pasching, Austria) 
Sulfuric acid (H2SO4) Sigma (Taufkirchen, Germany) 
Taurine Sigma (Taufkirchen, Germany) 
N,N,N',N'-Tetramethylethylendiamin 
(TEMED) 
Roth (Karlsruhe, Germany) 
Trifluoroacetic acid (TFA) Sigma (Taufkirchen, Germany) 
Tris (2-carboxyethyl) phosphine (TCEP) 
(99%)  
Sigma (Taufkirchen, Germany) 
Tris-(hydroxymethyl)-aminomethane (tris) 
(TAE) 
Roth (Karlsruhe, Germany) 
Tris-HCl Roth (Karlsruhe, Germany) 
Triton™ X-100 Sigma (Taufkirchen, Germany) 
Tween®-20 Roth (Karlsruhe, Germany) 
Tryptone/peptone from casein Roth (Karlsruhe, Germany) 
Urea Roth (Karlsruhe, Germany) 
Vitro Clud® R. Langenbrinck Labor und Medizintechnik 
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Reagents Manufacturer 
(Emmendingen, Germany) 
Xylol Honeywell (Offenbach, Germany) 
Yeast extract Roth (Karlsruhe, Germany) 
3.3. Cell culture materials 
Name Manufacturer 
Accutase™ PAA (Pasching, Austria) 
Collagen G Biochrom 
Gentamycin Gibco® (Darmstadt, Germany) 
HBSS Gibco® (Darmstadt, Germany) 
Human albumin  Baxter (Deerfield, IL, USA) 
Human serum PAA (Pasching, Austria) 
L-Glutamine PAA (Pasching, Austria) 
Trypanblue Sigma (Taufkirchen, Germany) 
Trypsin PAA (Pasching, Austria) 
 
3.4. Enzymes 
Name Manufacturer 
BglII Fermentas (St. Leon-Rot, Germany) 
DNAse I Sigma (Taufkirchen, Germany) 
DpnI Stratagene (La Jolla, USA) 
GoTaq® DNA Polymerase Promega (Madison, USA) 
KpnI Fermentas (St. Leon-Rot, Germany) 
NotI Fermentas (St. Leon-Rot, Germany) 
PfuUltra High Fidelity DNA Polymerase Stratagene (La Jolla, USA) 
Reverse transcriptase Invitrogen (San Diego, USA) 
T4 DNA Ligase Promega (Madison, USA) 
XhoI Fermentas (St. Leon-Rot, Germany) 
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Name Manufacturer 
XbalI Fermentas (St. Leon-Rot, Germany) 
3.5. Cytokines and recombinant proteins 
Name Manufacturer 
mCXCL12/SDF-1 PeproTech (Hamburg, Germany) 
CCL5/RANTES PeproTech (Hamburg, Germany) 
CXCL8/IL-8 PeproTech (Hamburg, Germany) 
CX3CL1/Fractalkine PeproTech (Hamburg, Germany) 
 
3.6. Antibodies 
3.6.1. Primary Antibodies 
Name mAb/Clone Manufacturer 
CD3 Rat anti-mouse/ KT3 Serotec (Düsseldorf, Germany) 
CD31 Goat anti-mouse/M-20 Santa Cruz (Santa Cruz, USA) 
Alpha-smooth muscle actin 
(α-SMA) 
Mouse anti-human/1A4 DAKO (Hamburg, Germany) 
F4/80 Rat anti-mouse/Cl:A31 Serotec (Düsseldorf, Germany) 
Human/mouse 
CXCL12/SDF-1 
E. coli derived recombinant 
human CXCL12/SDF1α 
Lys 22Lys89 /79018 
R&D Systems (Minneapolis, 
USA) 
Human CCL5/RANTES E. coli derived recombinant 
human CCL5/RANTES 
/16411 
R&D Systems (Minneapolis, 
USA) 
Anti-human 
CX3CL1/Fractalkine 
NS0-derived 
rhCX3CL1/51637 
R&D Systems (Minneapolis, 
USA) 
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3.6.2. Secondary Antibodies 
Name mAb Manufacturer 
Goat IgG, Cy3-conjugated Rabbit anti-
goat-IgG 
Jackson Immuno Research (Hamburg, 
Germany) 
Goat IgG, FITC-conjugated Goat anti-rat-
IgG 
Jackson Immuno Research (Hamburg, 
Germany) 
Goat IgG, FITC-conjugated Goat anti-
mouse-IgG 
Jackson Immuno Research (Hamburg, 
Germany) 
Rat IgG, Cy3-conjugated Donkey anti-
rat-IgG 
Jackson Immuno Research (Hamburg, 
Germany) 
Goat anti-rabbit IgG-HRP Goat anti-
rabbit IgG 
Santa Cruz (Santa Cruz, USA) 
Streptavidin-Biotinylated 
Horseradish Peroxidase 
Complex 
- Amersham/GE Healthcare, Uppsala, 
Sweden 
 
3.6.3. Isotype controls 
Name mAb Manufacturer 
IgG2A Rat R&D Systems (Minneapolis, USA) 
IgG1 Rat Serotec (Düsseldorf, Germany) 
Normal IgG Mouse Santa Cruz (Santa Cruz, USA) 
 
3.7. Kits 
Name Manufacturer 
BrdU Proliferation Assay Novagen/Merck Bioscience (Darmstadt, 
Germany) 
CellTiter-Blue® cell viability assay  Promega (Mannheim, Germany) 
DC Protein Assay BioRad (Hercules, USA) 
ECL Western blotting detection reagents Amersham/GE Healthcare (Uppsala, 
Sweden) 
GoTaq® Flexi DNA polymerase kit Promega (Madison, USA) 
Human CCL5/RANTES DuoSet Elisa R&D Systems (Minneapolis, USA) 
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Name Manufacturer 
Mouse CCL5/RANTES DuoSet Elisa R&D Systems (Minneapolis, USA) 
Mouse CXL12/SDF-1 DuoSet Elisa R&D Systems (Minneapolis, USA) 
QIAprep Spin Mini Kit Qiagen (Hilden, Germany) 
QIAquick gel extraction kit Qiagen (Hilden, Germany) 
QuikChange® II Site-Directed Mutagenesis 
Kit 
Stratagene (La Jolla, USA) 
QIAGEN Plasmid Midi Kit™ Qiagen (Hilden, Germany) 
QIAGEN Plasmid Maxi Kit™ Qiagen (Hilden, Germany) 
 
3.8. Plasmids 
Name Description 
pET-32a(+)  expression vector containing a Thioredoxin 
(Trx) Tag fused with the recombinant protein 
(Novagen/Merck, Darmstadt, Germany) 
pET-32a(+)/mCXCL12 (S4V and S2G4V) CCL5 expression vector, this study  
pET-26b(+)  expression vector containing pelB signal 
sequence for secretion of the recombinant 
protein into periplasma (Novagen/Merck 
Bioscience, Darmstadt, Germany)  
pET-26b(+)/Met-CCL5 Met-RANTES expression vector, this study  
pET-26b(+)/F1-His-anta  F1-His-anta expression vector, this study  
 
3.9. Primers 
3.9.1. Site directed mutagenesis primers 
Primer/Sequence 
SDF1a_neu_s: 
5´- GGC TGA CTG GTT TGG ACT TGT CGT CGT CGT CG -3` 
SDF1a_neu_as: 
5´- CGA CGA CGA CGA CAA GTC CAA ACC AGT CAG CC -3` 
SDF1a_S4V_s: 
5´- AGGGGCATCGGTAGCTCAGGACGACTGGTTTGGACTTGTC -3 
SDF1a_S4V_as: 
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Primer/Sequence 
5´- GACAAGTCCAAACCAGTCGTCCTGAGCTACCGATGCCCCT -3` 
SDF1a_S2G_s: 
5´- GGT AGC TCA GAA CGA CTC CTT TGC TCT TGT CGT CGT CG -3` 
SDF1a_S2G_as: 
5´- CGA CGA CGA CAA GAG CAA AGG AGT CGT TCT GAG CTA CC -3` 
SDF1a_S2G_2_s: 
5´- GGT AGC TCA GAA CGA CTC CTT TGC TCT TGT CGT CGT CAT CGG TAC CC -3` 
SDF1a_S2G_2_as: 
5´- GG GTA CCG ATG ACG ACG ACA AGA GCA AAG GAG TCG TTC TGA GCT ACC -3` 
et32_as: 
5´- TGG CAT CCG TGG TAT CCC GAC T -3` 
Met-CCL5_s: 
5´- ATC ATA TGT CCC CAT CCT CGG ACA CCA C -3´ 
Met-CCL5_as: 
5´- ACG GAT CCT AGC TCA TCT CCA AAG AGT TG -3´ 
 
3.9.2. Sequencing primers 
Primer/Sequence 
T7: 
5´- TAA TAC GAC TCA CTA TAG GG -3` 
T7 term: 
5´- CTA GTT ATT GCT CAG CGG T -3` 
pUC57s: 
5´- GTA AAA CGA CGG CCA GTA -3` 
 
3.9.3. Reverse transcriptase primer 
Primer/Sequence 
Oligo dT: 
5´- TTT TTT TTT TTT TTT  -3´ 
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3.10. Bacterial strains and cell lines 
Name Manufacturer 
BL21 (DE3) pLysS Stratagene (La Jolla, USA) 
DH5α™ Invitrogen (San Diego, USA) 
XL1-Blue Stratagene (La Jolla, USA) 
Rosetta™ (DE3) pLysS Novagen/Merck Bioscience (Darmstadt, 
Germany) 
Human Umbilical Vein Endothelial Cells 
(HUVEC) 
PromoCell (Heidelberg, Germany) 
Human Aortic Smooth Muscle Cells 
(HAoSMCs) 
PromoCell (Heidelberg, Germany) 
Jurkat T-cells Leibniz-Institute DSMZ-German Collection of 
Microorganisms and Cell Culture 
(Braunschweig, Germany) 
 
3.11. Bacterial and cell culture media 
Name Components 
LB (Luria-Bertani) medium 0.5% (w/v) yeast extract 
1% (w/v) peptone 
1% (w/v) NaCl 
LB agar medium LB medium with 1.4% (w/v) agar  
SOB (Super Optimal Broth) medium 0.5% (w/v) yeast extract 
 2% (w/v) peptone 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl 
10 mM MgSO4 
SOC medium SOB with 20 mM glucose 
TB medium 1.2% (w/v) peptone 
2.4% (w/v) yeast extract 
0.4% (v/v) glycerol 
EOC Medium Endothelial Cell Growth Medium MV2 
(PromoCell, Heidelberg, Germany) 
 Endothelial Cell Growth MV2 Supplement 
(PromoCell, Heidelberg, Germany) 
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Name Components 
HUVEC Medium Endothelial Cell Growth Medium (PromoCell, 
Heidelberg, Germany) 
 Endothelial Cell Growth Supplement 
(PromoCell, Heidelberg, Germany) 
HAoSMC Medium Smooth Muscle Cell Medium (PromoCell, 
Heidelberg, Germany) 
 Smooth Muscle Cell Medium Supplement 
(PromoCell, Heidelberg, Germany) 
Jurkat T-cell Medium RPMI 1640 (PAA, Pasching, Austria) 
10% FBS + 2 mM L-Glutamine 
 
3.12. Solutions 
Name Components 
Antibody buffer 0.13% EDTA 
0.15% bovine serum albumin (BSA) 
In phosphate-buffered saline (PBS) 
Blocking buffer (western blot) 5% (w/v) of nonfat dry milk in TBST 
Destaining solution 
(Coomassie blue staining) 
12.5% (v/v) isopropanol 
30% (v/v) EtOH 
DNA loading buffer (6x) 30% (v/v) glycerol 
6 mM EDTA 
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylenecyanol 
Electrophoresis buffer (SDS-PAGE) 250 mM Tris base 
1.92 M glycine 
1% (w/v) SDS 
Mini/Midiprep and maxiprep buffer I 50 mM glucose 
25 mM Tris-HCl, pH 8.0 
10 mM EDTA, pH 8.0 
Mini/Midiprep and maxiprep buffer II 200 mM NaOH 
1% (w/v) SDS 
Mini/Midiprep and maxiprep buffer III 3 M potassium acetate, pH 5.5  
TSS buffer 10% (w/v) Polyethylene glycol 
5% (v/v) DMSO 
20 mM MgCl2 
in 1x LB medium (1.3.13) 
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Name Components 
TAE electrophoresis buffer (1x) 40 mM Tris-acetate 
1 mM EDTA 
TBS (1x) (western blot) 25 mM Tris-HCl, pH 7.4 
2.7 mM KCl 
137 mM NaCl 
 
3.13. Mice 
Wild type C57BL/6J mice were purchased at Charles River, England. 
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4. Methods 
4.1. Cell culture 
4.1.1. Bacterial culture 
Plasmid transformed E. coli were cultured on LB plates with ampicillin (100 μg/ml) or 
kanamycine (35 μg/ml) or chloramphenicol (40 μg/ml) and grown for 24 h at 37°C. To 
achieve a single colony growth, a single bacteria colony was picked and inoculated in a mini 
culture LB medium with appropriate antibiotics and shaken overnight at 37°C. To achieve a 
desired amount of expressing bacteria, the bacterial mini culture was inoculated in 1L of LB 
medium and cultured over night at 37°C with vigorous shaking. The culture was then used for 
preparing frozen glycerol cultures, plasmid DNA or fusion protein purification. For long-term 
storage of bacteria, a glycerol stock culture was prepared by growing bacteria in culture 
medium over night with the appropriate antibiotics. 500 μL of the bacterial culture was added 
to 80% glycerol and then mixed thoroughly in a small 1.5 mL tube. The stock solution was 
subsequently frozen in nitrogen and stored at -80°C. For repeated overnight culture, bacteria 
were held at room temperature (RT) until the surface was thawed. A small amount of cells 
was picked and LB plates were inoculated and grown over night at 37°C. The frozen stock 
was immediately returned to storage at -80°C. 
4.1.2. Preparation of competent cells 
From a single colony on a petri dish, the preculture was started in 5 mL LB media and 
incubated overnight at 37°C with vigorous shaking. The next day, 750 µL of the preculture 
was inoculated in 100 mL LB media and cultured 1 to 2 h until a OD600 of approximately 0.4 
reach. Subsequently, the culture was cooled down on ice and than centrifuged for 10 min, 
3000 g and 4°C. The bacterial pellet was resuspended in 10 mL ice-cold TSS buffer. The 
suspension was aliquoted in 500 µL, frozen in liquid nitrogen and stored at -80°C. 
4.1.3. Heat-shock transformation of competent cells 
The competent E. coli were thawed on ice. 100 µL of competent E. coli were mixed with 1-
10 ng of plasmid DNA in a cold 1.5 mL microfuge tube and incubated for 30 min on ice. The 
bacteria were heat-shocked at 42°C for 90 sec, and then incubated for 2 min on ice. 500 µL 
antibiotic-free LB medium was added and the bacteria were incubated for 1 h at 37°C with 
gently shaking. Transformed bacteria were selected by plating 100 μL of the bacterial 
suspension on the antibiotic-containing agar plates. Only bacteria containing the desired 
plasmids, which contain the antibiotic resistance cassette, are able to grow on the agar 
antibiotic plates. One or more colonies were picked and expanded in LB medium and used 
for DNA preparation. 
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4.1.4. Maintaining of mammalian cell culture 
The cell culture was performed in a laminar flow cabinet under sterile conditions. All reagents 
were purchased sterile or have been sterilized through a 0.2 μm filter. The cells were 
incubated in a CO2 incubator at 37°C with 5% CO2. For all adherent cells, the cell culture 
flask was coated with Collagen G (4 mg/mL) using a 1:1000 dilution with PBS and incubated 
for 30 min at 37°C. The supernatant was discarded and the flask was washed with PBS. The 
cells were cultured until they reached 90% confluence and were then split in reasonable 
quantities to obtain an adequate density. To detach the adherent cells, accutase was used 
and incubated for 5 min at 37°C in the CO2 incubator. For inactivating the accutase additional 
medium was used. The cells were than centrifuged for 5 min at 200 g. Human umbilical vein 
endothelial cells (HUVECs) were cultured in endothelial cell growth medium and human 
aortic smooth muscle cells (HAoSMCs) were cultured in smooth muscle cell medium with the 
corresponding supplement and containing 50 μg/mL gentamicin to avoid contamination with 
bacteria. For growing cells in a suspension the maximum density of the culture was allowed 
to be 105-106 cells/mL. The cell suspension was centrifuged for 5 min at 200 g. 
For freezing the cells, the cells were resuspended at a concentration of 106-107 cells/mL in 
fresh media containing 13% (v/v) DMSO and aliquoted in cryovials. The aliquots were stored 
into a styropore box and left to freeze gradually in the -80°C freezer overnight and 
transferred to liquid nitrogen for long-term storage. To thaw the cells for further cultivation, 
cryovials were immediately put in a 37°C water bath for 2-3 min. Directly, after the cell 
suspension is thawed, cells were slowly added to 4 mL warm fresh media. The cells were 
centrifuged and resuspended in the corresponding fresh media. 
4.2. DNA techniques 
4.2.1. Electrophoresis of DNA on agarose gel 
The separation of double stranded DNA fragments with lengths between 0.1 kb and 10 kb 
was done according to their lengths on agarose gels. Agarose was dissolved in 1x TAE 
buffer to obtain a final concentration between of 0.75-2% (w/v) of the agarose gel. After 
complete solubilisation of the agarose in the microwave and cooled down to 50°C, 0.5 mg/L 
ethidium bromide was added and poured into the gel apparatus. The DNA was diluted with 
loading buffer and separated on the gel at 110 V performed in 1x TAE buffer containing 
0.1 μg/mL ethidium bromide. The DNA fragments were visualized on a UV light 
transilluminator and photographed for documentation. 
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4.2.2. Isolation of plasmid DNA from Agarose (QIAquick gel extraction kit) 
To isolate the digested DNA fragments with a specifically defined size from the agarose gel, 
the QIAquick gel extraction kit was used. The excised gel slice with the selective target 
fragment was initially depolymerized by heating at 50°C. The DNA contained in the 
depolymerized excised gel slice (>100 bp) binds at pH <7.5 and with a high salt 
concentration selectively to the membrane of the silicate ion exchanger column. The 
dissolved agarose and other contaminants are not bound to the column and removed by 
washing step. The purified DNA was then eluted from the membrane under basic pH and low 
salt concentrations. 
4.2.3. Purification of plasmid DNA (QIAprep spin mini kit) 
For the isolation of plasmid DNA, the QIAprep Spin Mini Kit was used. For the preparation 
and purification of plasmid DNA from E. coli, the appropriate protocols and systems from 
Qiagen were used. The method is based on the alkaline lysis of bacteria with extraction of 
DNA and the binding to a silica membrane under conditions of high salt concentrations and 
low pH (<7.5). Under basic pH and low salt concentrations, the bound and washed DNA can 
be eluted. The method is based on the principle of anion exchange chromatography. 
4.2.4. Ligation of DNA fragments 
For ligation of DNA fragments, the insert and linearized plasmid vector were added in a ratio 
of about 1:5 to a reaction tube in the presence of T4 DNA ligase and the corresponding 
10x ligation buffer, filled with water up to a volume of 10 or 20 μL and incubated overnight at 
4°C. 
4.2.5. Oligonucleotide primers 
All oligonucleotide primers for this study were synthesized from Eurofins MWG Operon 
(Ebersberg, Germany) and delivered in lyophilised form. The oligonucleotides were dissolved 
in sterile water to obtain a 100 µM stock solution. Primer solutions with desired concentration 
for the PCR reaction were prepared from these stocks. The sequencing primers usually have 
a length of 18-20 bases and a melting point of 55-65°C. The primers for mutagenesis PCR 
and/or the primers for conventional PCR have a length of up to 47 bases, having a melting 
point of about 72°C or higher. The GC content was chosen to be 40-60%, if possible. 
4.2.6. Polymerase chain reaction (PCR) 
The PCR was described by Saiki et. al.149. The PCR was used for in vitro amplification of 
DNA fragments. The GoTaq Flexi DNA polymerase kit and two primers were used, which 
flanked the amplified DNA. As a template the plasmid DNA was used which contain the 
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coding region of CXCL12 or CCL5. For denaturation of the DNA a temperature of 95°C was 
used. The annealing temperature for the primers was calculated with the following formula:  
T Annealing = 2°C (for AT-pair) + 4°C (for GC-pair) - 4°C150 
The polymerization of the DNA was performed at 72°C, wherein the elongation time depends 
on the length of the amplified DNA fragment. The Taq polymerase is able to amplify 
1000 bases per minute, so the polymerization time was calculated by multiplying the length 
of the expected fragment (in kb). Unless otherwise specified, 30 cycles were performed. The 
PCR was prepared on ice; following components were used for one reaction: 
Amount Reagents 
10 μL 5x Green GoTaq Flexi buffer 
1 μL template (1 μg) 
8 μL 25 mM MgCl2 
1 μL 10 mM PCR nukleotide 
1 μL 10 μM forward primer 
1 μL 10 μM reverse primer 
27.75 μL ddH2O 
0.25 μL GoTaq DNA Polymerase (5 U/μL) 
After the PCR reaction 10 μL of the PCR reaction was used to analyze the amplified template 
on agarose gel electrophoresis. 
4.2.7. DNA Site directed mutagenesis 
The QuikChange II Site-Directed Mutagenesis Kit allows site-specific mutation in virtually any 
double-stranded plasmid, thus eliminating the need for subcloning and for ssDNA rescue. 
The mutagenesis is carried out by the DNA synthesis starting with two mutagenesis primer 
(forward and reverse). Here, the reaction is catalyzed by a thermostable DNA polymerase 
(Pfu polymerase). The Pfu polymerase has a 3' - 5' exonuclease activity that detects 
improperly installed deoxynucleotides during synthesis and removes it (proofreading). The 
amplification of this enzyme has a 10x time lower error rate than Taq polymerase. The Pfu 
polymerase does not contain the adenosine at the 3'-end of the DNA strand and the resulting 
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products feature smooth ends, in contrast to other polymerases. The following components 
were used for one reaction: 
Amount Reagents 
5 μL 10x reaction buffer 
2 μL 10 ng dsDNA template 
1.25 μL 125 ng forward primer 
1.25 μL 125 ng reverse primer 
1 μL dNTP mix 
38.5 μL ddH2O 
1 μL PfuUltra HF DNA Polymerase (2.5 U/μL) 
Parameters for the thermocycler: 
cycle temperature time 
1 95°C 30 sec 
95°C 30 sec 
55°C 1 min 18 
68°C 1 min/kb of plasmid length 
After PCR reaction, the PCR product was digested with 1 µL DpnI for 1 h at 37°C. Only 
methylated DNA is recognized and digested by the restriction enzyme DpnI. The plasmid 
used for the PCR reaction was isolated from a dam+ E. coli strain, therefore the sequence of 
the plasmid 5' – Gm – ATC - 3' is methylated from bacteria. The amplified DNA sequence 
containing the mutation is not methylated and can not be digested by restriction enzyme. 
1 µL of the digestion was transformed into XL-1 Blue super competent cells, Stratagene and 
plated on agar plates containing the appropriate antibiotic. 
4.2.8. Mini-preparation of plasmid DNA 
E. coli overnight culture was grown in LB media at 37°C with the corresponding antibiotics. 
The bacteria cells were centrifuged at 14.000 rpm for 1 min, the supernatant was removed 
and the pellet was resuspended in 100 µL buffer I. 200 µL of buffer II (lysis buffer) was 
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added, gently mixed and incubated for 5 min at RT. The suspension was neutralized by 
adding of 200 μL ice-cold buffer III, mixing by inverting the tubes for 4-6 times and incubated 
on ice for 5 min. The suspension was centrifuged by 15.000 rpm for 3 min, the supernatant 
was transferred to a fresh microcentrifuge tube and 900 μL of pre-cooled 100% ethanol was 
added for precipitation at -70°C for 10 min. The suspension was centrifuged at 15.000 rpm 
for 10 min, the supernatant was removed and the pellet was washed with 200 μL 70% 
ethanol and air-dried for a few minutes, then resuspended in 30-50 μL 10 mM Tris-HCl, 
pH 7.8. 
4.2.9. Maxi-preparation of plasmid DNA 
The large-scale purification of plasmid DNA from E. coli was performed using the Qiagen 
Plasmid Midi or Maxi Kit according to the manufacturer’s instructions. 
4.2.10. Restriction digest 
For analytical approaches 1 µg of DNA, restriction endonucleases and the respective 
manufacturer's recommended reaction buffer in test tubes filled to 10 μL with distilled water 
was used. After an incubation period of 1-2 h at 37°C, the resulting DNA fragments were 
separated by gel electrophoresis and analyzed. The desired pattern of bands were excised 
from the gel and used for subsequent gel elution. 
4.2.11. Measurement of DNA concentration 
The concentration of DNA was determined by using the NanoDrop ND-1000 UV-photometer. 
The absorbance was measured at a wavelength of 260 nm. Absorption of 1.0 at 260 nm 
corresponds to a concentration of 50 μg/mL double stranded DNA. The purity of the DNA 
was determined by 260/280 ratio and should be over 1.8. 
4.2.12. DNA Sequencing 
The sequencing reaction of the plasmid DNA was performed by Eurofins MWG Operon. The 
sequencing results were monitored by using the program Gene Runner version 3.05 
(http://www.generunner.com). In addition, database comparisons were done to search for 
DNA and protein sequences with similarity to the edited sequences for this work using the 
programs BLASTX, BLASTN and BLASTP151, the National Center for Biotechnology 
Information (NCBI, Washington, USA) and related databases (http://www.ncbi.nlm.nih.gov). 
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4.3. Protein analyses 
4.3.1. Protein concentration assay 
The DC Bio-Rad protein assay is a colorimetric assay for the determination of the protein 
concentration. This reaction method is modified after the well known Lowry method152 and is 
based on the reaction of proteins with an alkaline copper tartrate solution and Folin´s reagent 
The measurement was done according to manufacturer’s instruction. 5 µL of the standard 
(BSA) or sample was used, adding 25 μL copper tartrate solution, followed by the addition of 
200 μL of folin reagent. The Bio-Rad DC protein assay was measured at 750 nm with a 
microplate reader. 
4.3.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
The isolated proteins from each FPLC purification step were analyzed by SDS PAGE. 20 µL 
of the sample was mixed with 5 µL of 5x SDS loading buffer containing SDS and ß-
mercaptoethanol to denature precleared proteins at 90°C for 10 min. SDS is an anionic 
detergent that disrupts nearly all noncovalent interactions in native proteins and ß-
mercaptoethanol reduce disulphide bonds. The proteins were electrophoresed on a 
polyacrylamide gel. The gel consists of two layers: a stacking gel (pH 6.8) which consists of a 
lower percentage of 5% where the proteins are concentrated and ensures the simultaneous 
entry into the separating gel at the same height; and a separating gel (pH 8.8) with a higher 
percentage between 12-15% that separates the proteins according to their size. 
The stacking and the separating gels consisted of the following components: 
 Stacking gel Separating gel 
Acrylamide/Bis 5% (w/v) 12-15% (w/v) 
Tris-HCl (pH 8.8) 125 mM 375 mM 
SDS 0.1% (w/v) 0.1% (w/v) 
APS 0.1% (w/v) 0.1% (w/v) 
TEMED 0.1% (v/v) 0.1% (v/v) 
 
For the electrophoresis the Mini-sub cell GT, Bio-Rad was used. The electrophoresis was 
carried out at 120 V until the negatively charged SDS-proteins complexes migrate in the 
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direction of the anode at the bottom of the gel. The gel was used for Coomassie blue staining 
and western blotting. 
4.3.3. Coomassie blue staining 
For non-specific detection of proteins in SDS gels the Coomassie staining was performed 
with PageBlue Protein Staining Solution and an incubation time of 3-4 h or overnight. The 
gels were destained with destaining solution. To analyze and distinguish the mass of the 
proteins the image reader LAS 3000 was used. 
4.3.4. Western blot 
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane using the 
iBlot Blotting System and the procedure was done according to the manufacturer’s 
instructions. First the iBlot anode stack was placed to the bottom of the iBlot gel transfer 
device, the prerun gel was placed on the transfer membrane of the anode stack and a filter 
paper soaked with deionized water was placed on the prerun gel. The iBlot cathode stack 
was placed on the top of the presoaked filter paper with the copper electrode facing up and 
aligned to the right of the bottom stack followed by iBlot Disposable Sponge on the inner side 
of the lid, so the metal contact is to the top. The lid was closed and the blotting was 
performed for 7 min. At the end of the transfer, the nitrocellulose was removed and cut for an 
optimal size. To prevent nonspecific binding the already blotted nitrocellulose membrane was 
blocked with 1x Roti-Block for 1 h at RT. The excess of Roti-Block was removed by washing 
3x with 1x TBS/0.05% (v/v) Tween, the primary antibody was diluted with 1x Roti-Block and 
incubated for 1 h at RT or over night at 4°C. The primary antibody was removed by washing 
3x with 1x TBS/0.05% (v/v) Tween, subsequently the HRP-conjugated secondary antibody 
was diluted in 1x Roti-Block and incubated for 1 h at RT. Excess antibody was removed by 
washing 3x with 1x TBS/0.05% (v/v) Tween. To detect the specific proteins, ECL solution 
was used as substrate for this reaction, following the manufacturer’s protocol. For analyzing 
the proteins the image reader LAS 3000 was used. 
4.4. Recombinant protein expression and purification 
4.4.1. Expression and isolation of F1-CX3CL1 (CX3CL1 receptor antagonist) 
The expressed, isolated and purified CX3CL1 antagonist was previously published by 
Dorgham et. al.27, which is here also called F1-CX3CL1. Glycerol stock containing the pET-
26b(+)/F1_anta_His sequence in BL21 (DE3) pLysS E. coli was streaked on LB agar plates 
containing kanamycine/chloramphenicol double antibiotics and incubated overnight at 37°C. 
100 mL of preparatory culture medium (2.5 g yeast extract, 5 g peptone, 4 g NaCl, 500 mL 
deionized water) containing kanamycine/chloramphenicol was inoculated with the bacteria 
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from the agar plate and grown over night at 37°C, centrifuged at 10.000 rpm for 10 min and 
the supernatant was disposed. Expression medium containing kanamycine/chloramphenicol 
was inoculated with all bacterial cells from the preparatory culture medium and was grown at 
37°C until the optical density at 600 nM (OD600) was approximately 1. After adding 500 µM 
IPTG, growth was continued at 37°C over night followed by harvesting the bacterial cells at 
10.000 rpm for 10 min. The bacterial cells were dissolved in 100 mL 10 mM KH2PO4 pH 7 
and sonicated 2x for 1 min. 1 mM MgCl2 and 10 µL benzonase nuclease were added and 
sonicated 2x for 1 min. 5 mM EDTA, 1 tablet of protease inhibitor (complete Mini, EDTA-free 
tablet) was added and sonicated 2x for 1 min. 100 mL 10 mM of KH2PO4 pH 7 was added 
and centrifuged at 15.000 rpm for 10 min. The pellet was resuspended in 50 mL 25 mM 
KH2PO4 pH 7, 0.25% sodium deoxycholate, centrifuged at 15.000 rpm for 10 min. This step 
was repeated 2x. The pellet was again resuspended in 50 mL 25 mM KH2PO4 pH 7, 
centrifuged at 15.000 rpm for 10 min. This step was repeated 2x. The pellet was dissolved in 
2.5 mL 6 M guanidine-HCl, 50 mM Tris pH 8, 1 mM DTT and the pellet was dissolved under 
stirring conditions at 60°C for 1-2 h. The solution was cooled down and centrifuged at 
15.000 rpm for 30 min. The precipitate was centrifuged and the inclusion bodies were 
lyophilized over night. The CX3CL1 receptor antagonist was purified in a 2-step procedure. 
4.4.1.1. First purification step of F1-CX3CL1 using HisTrap HP 
The lyophilized pellet was resuspended in 4 mL 6 M guanidine-HCl and 20 mM sodium 
phosphate. First the column was washed with buffer A (6 M guanidine-HCl, 20 mM Tris 
pH 7.5), the protein was filtered over a 0.22 µm filter, loaded with buffer A on the column and 
washed with 5 column volumes. The bound protein was eluted with buffer B (6 M guanidine-
HCl, 20 mM Tris pH 7.5, 250 mM imidazol) applying a gradient elution (0 min: A:B 100:0; 
10 min: A:B 0:100). The concentration of the fractions under the peak were proofed and 
analyzed on a SDS-PAGE. The fractions of interest were pooled, subsequently diluted with 
100x redox buffer (100 mM Tris pH 8.5, 5 mM EDTA, 0.2 mM oxidized glutathione, 1 mM 
reduced glutathione). The protein was refolded over night at 4°C. The protein was dialyzed 
with 10 mM potassium phosphate, 5 mM EDTA for 2 h, followed by a second dialyzation with 
0.1% TFA in deionized water over night at 4°C. The F1-CX3CL1 protein was cleaved from the 
His Tag by means of enterokinase digestion using 0.35 U enterokinase per mg protein and 
used for further purification. 
4.4.1.2. Second purification step of F1-CX3CL1 using Resource S 
The lyophilized pellet was resuspended in 20 mM Tris pH 7 and digested with enterokinase 
(0.5 U/mg protein) over night. The column was washed with buffer A (20 mM MES pH 6), the 
protein was filtrated wit a 0.22 µm filter, loaded with buffer A on the column and washed with 
5 column volumes. The bound protein was eluted with buffer B (20 mM MES pH 6, 1 M NaCl) 
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applying a gradient elution (0 min: A:B 100:0; 10 min: A:B 0:100). The concentrations of the 
fractions under the peak were analyzed on a SDS-PAGE. The desired fractions were pooled 
and dialyzed with 0.1% TFA in deionized water over night at 4°C. The pure protein was 
lyophilized over night and stored at -20°C. 
4.4.2. Met-CCL5 expression and purification 
The CCL5 antagonist was expressed, isolated and purified as previously published by 
Proudfoot et. al.153. and is called here also Met-CCL5. Glycerol stock containing the pET-
26b(+)/Met-CCL5 sequence in Rosetta (DE3) pLysS E. coli was streaked on LB agar plates 
containing kanamycine/chloramphenicol double antibiotic and incubated overnight at 37°C. 
Expression medium containing kanamycine/ chloramphenicol was inoculated with the 
colonies of the agar plates and grown to an OD600 of 0.7 at 37°C. After adding 100 µM 
IPTG, growth was continued at 37°C for 3-4 h followed by centrifugation at 4.500 rpm for 
30 min. First the cells were wiped up in solution buffer (50 mM Tris, 1 mM Na-EDTA, 10 mM 
dithiothreitol, 25% sucrose, pH 8), following a sonication step. 0.4 mg lysozyme, 20 µg 
DNAse I and 2 µmol/mL MgCl2 was added to the suspension. Following the addition of lysis 
buffer (50 mM Tris, 1% Triton X-100, 1% deoxycholate, 100 mM sodium chloride, 10 mM 
dithiothreitol, pH 8), the suspension was incubated for 1 h at RT, followed by the addition of 
7 µmol/mL Na-EDTA. After the addition of 3.5 µmol/mL MgCl2, the suspension is incubated 
until the viscosity has decreased to the viscosity of water. 7 µmol/mL Na-EDTA was added 
followed by centrifugation at 11.000 g for 20 min at 4°C. The pellet was washed withwashing 
buffer I (50 mM Tris-HCl, 100 mM NaCl2, 1 mM Di-Na-EDTA, 1 mM dithiothreitol, 
0.5% Triton X-100) and centrifuged at 11.000 g for 30 min. The pellet was washed with 
washing buffer II (50 mM Tris-HCl, 100 mM NaCl2, 1 mM Na-EDTA, 1 mM dithiothreitol) and 
centrifuged at 11.000 rpm for 30 min. The protein was purified from inclusion bodies and the 
pellet was dissolved in 6 M guanidine-HCl, 50 mM Tris pH 8, 1 mM dithiothreitol at 60°C, 
followed by a centrifugation step at 11.000 g for 20 min and the supernatant was dialyzed to 
1% acetic acid. After centrifugation at 11.000 g for 20 min, the supernatant was lyophilized. 
The pellet is dissolved in 6 M guanidine-HCl, 5 mM Tris pH 8 and 1 mM dithiothreitol. 
Refolding of the protein was performed with a 1:10 dilution in renaturation buffer (50 mM Tris 
pH 8, 0.01 mM oxidized glutathione and 0.01 mM reduced glutathione) while stirring over 
night at 4°C. The suspension was centrifuged at 10.000 g for 30 min. The pH of the 
supernatant was adjusted to pH 5 using acetic acid whereas the conductivity was adjusted at 
20 mS with H2O. The Met-CCL5 protein was purified by a 2-step procedure. 
4.4.2.1. First purification of Met-CCL5 using SP Sepharose FF column 
The first purification step consisted of affinity purification using a SP Sepharose FF column. 
First the SP Sepharose FF column was washed with buffer A (50 mM sodium acetate 
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pH 4.5) and the protein is loaded by a loop with 1 mL/min buffer A. The bound protein was 
eluted with elution buffer (50 mM sodium acetate pH 4.5 and 2 M NaCl) applying gradient 
elution (0 min: A:B 100:0; 20 min: A:B 0:100). Protein rich fractions were pooled together 
followed by two different dialyzing steps, first with 1% acetic acid and second with 0.1% TFA. 
The protein was lyophilized, subsequently dissolved in 0.1% TFA for the further purification 
by HPLC. 
4.4.2.2. Second purification of Met-CCL5 using HPLC chromatography 
The second purification step was performed by means of reverse phase HPLC 
chromatography using a Vydac® column C8 250x10 mm, 5 µm with buffer A (0.1% TFA) and 
buffer B (0.1% TFA and 90% acetonitrile) applying gradient elution (0 min: A:B 100:0; 25 min: 
A:B 0:67) with a flow of  2 mL/min. After elution, the Met-CCL5 was dialyzed to 0.01% TFA 
and lyophilized for long-term storage. 
4.4.3. Protease-resistant CXCL12 (S4V and S2G4V) expression and 
purification 
The protease-resistant CXCL12 was expressed, isolated and purified as previously published 
by Segers et. al.53 and is named here also CXCL12 (S4V). Glycerol stock containing the 
modified pET-32a(+)/CXCL12 sequence in Rosetta (DE3) pLysS E. coli was streaked on LB 
agar plates containing ampicillin/kanamycin double antibiotics and incubated overnight at 
37°C. Pre-warmed 4 L of expression medium in a LAMBDA MINIFOR fermenter/bioreactor 
was inoculated with the colonies of the agar plates and grown to OD600 of 0.4 at 37°C. 
Growth was continued at 30°C until OD600 of 1.0. After adding 20 µM IPTG induction was 
continued at 30°C over night. The cells are harvested by centrifugation at 4.000 rpm for 
30 min. The supernatant was removed and the pellet resuspended in 1x PBS. Dissolved 
lysozyme was added to the suspension and incubated at RT for 15 min. BugBuster Protein 
Extraction Reagent was added to the cells and incubated for 10 min. After adding of 25 U of 
benzonase nuclease, the cells were incubated until the viscosity was like water and the 
lysate was subsequently centrifuged at 4.000 rpm for 15 min. The supernatant was removed 
and the remaining pellet extracted three times using extraction buffer containing Triton X-
100, 100 mM taurine, 50 mM sodium phosphate pH 7.5, 5 mM EDTA. The pellet was washed 
two times using 50 mM sodium phosphate pH 7.5. The pellet was dissolved in 6 M 
guanidine-HCl solution, 50 mM sodium phosphate pH 7.5 and cysteine was added to a final 
concentration of 6 mM. The solution was centrifuged at 4.000 rpm for 30 min, whereas the 
pellet was discarded. The solution was diluted 1:6 in 50 mM sodium phosphate pH 7.5 and 
cystine was added to a final concentration of 8 mM. The solution was allowed to stir over 
night for refolding at RT. The protease-resistant CXCL12 (S4V) and CXCL12 (S2G4V) were 
purified by a 3-step procedure. 
Methods 
51 
4.4.3.1. First purification of protease-resistant CXCL12 (S4V and S2G4V) using Ni-NTA 
column 
The first purification step consisted of affinity purification by the Histidine Tag present in the 
CXCL12 (S4V) and CXCL12 (S2G4V) protein with Ni-NTA column. The Ni-NTA resin was 
washed with buffer A (phosphate buffered saline pH 7.5 and 1 mM cysteine), the protein was 
loaded by a loop with 1 mL/min buffer A and bound protein was eluted using buffer B 
(phosphate buffered saline pH 7.5 and 1 mM cysteine, 250 mM imidazole) applying gradient 
elution (0 min: A:B 100:0; 10 min: A:B 0:100). 
4.4.3.2. Second purification of protease-resistant CXCL12 (S4V and S2G4V) using 
Heparin Sepharose 6 fast flow column 
The second purification step was performed using heparin sepharose 6 fast flow column, a 
buffer A (50 mM Tris pH 8, 1 mM cysteine) and the protein was loaded by a loop with 
1 mL/min buffer A. The protein is eluted with buffer B (50 mM Tris pH 8, 1 mM cysteine, 1 M 
NaCl) applying a gradient elution (0 min: A:B 100:0; 10 min: A:B 0:100). The eluted protein 
was dialyzed with 50 mM Tris pH 8 and 2 mM cysteine. The CXCL12 (S4V) and 
CXCL12 (S2G4V) protein was cleaved from the Thioredoxin (Trx) Tag by means of 
enterokinase digestion using 0.35 U enterokinase per mg protein. 
4.4.3.3. Third purification of protease-resistant CXCL12 (S4V and S2G4V) using Tricon 
Mono S 5/50GL 
The last purification step was performed using the Tricon Mono S 5/50GL, buffer A (50 mM 
MES buffer pH 6) and the protein was loaded by a loop with 1 mL/min buffer A. The protein 
was eluted with buffer B (50 mM MES buffer pH 6, 1 M NaCl). After elution, the 
CXCL12 (S4V) and CXCL12 (S2G4V) protein was dialyzed to 0.01% trifluoroacetic acid and 
lyophilized for long-term storage. 
4.5. Synthesis of biocompatible and degradable hydrogels 
Hydroxy-terminated, six arm, star shaped poly (ethylene oxide-stat-propylene oxide) (sP(EO-
stat-PO)) with a backbone consisting of 80% ethylene oxide and 20% propylene oxide 
(Mn = 12000 g/mol, Mw/Mn = 1.12) was obtained from Dow Chemicals for the further 
synthesis of biodegradable hydrogels. Prior to functionalization sP(EO-stat-PO) is purified by 
precipitation in THF/cold diethylether as solvent/non solvent system. N,N’-dicyclohexyl-
carbodiimide, 4 DMAP, 3,3’-dithiodipropionic acid, tris(2-carboxyethyl) phosphine, 
poly(ethyleneglycol) diacrylate (575 g/mol), hydrogen peroxide (30% w/w), dichloromethane, 
cysteamine and 5,5’-dithio-bis-(2-nitrobenzoic acid) were used as received. Tetrahydrofuran 
(THF) used was dried over LiAlH4.  
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4.5.1. Synthesis of Thiol Functionalized sP(EO-stat-PO) 
Thiol functionalized sP(EO-stat-PO) (SH-sP(EO-stat-PO)) has been prepared in a 2-step 
synthesis as previously described by Groll et. al.121. In the first step, sP(EO-stat-PO) has 
been crosslinked with disulfide crosslinker followed by reduction of the disulfide bonds to thiol 
groups in the second step. Typically, four alcohol groups have been transferred into thiol 
groups, leaving two unreacted -OH groups in the hydrogels 
4.5.1.1. Step 1: Cross linking of –OH groups 
For cross linking of four -OH groups of sPEG, a solution consisting of 3,3’-dithiopropionic 
acid (DTPA) (1.0 eq with respect to one -OH) (0.1051 g, 0.5 mmol) in dry THF (4 mL) was 
added drop wise to a solution consisting of the purified sPEG (Mn = 12000 g/mol, 3 g, 
0.25 mmol, 4 –OH = 1.0 mmol), DCC (1.1 eq with respect to one -COOH) (0.2269 g, 
1.1 mmol) and DMAP (1.1 eq with respect to one -COOH) (0.1343 g, 1.1 mmol) in CH2Cl2 
(6 mL) in an ice bath at 0°C over 10 min. The resulting mixture was allowed to stir at RT for 
12 h. The formed hydrogel is washed three times with CH2Cl2, twice with THF, ethanol and 
water followed by evaporation of remaining solvents on the rotary evaporator. Finally, the 
product is dried in a vacuum oven at 35°C for 12 h. 
4.5.1.2. Step 2: Reduction of disulfide bonds 
Step 2: TCEP was used for the reduction of disulfide bonds. TCEP (1.5 eq with respect to the 
disulfide units) (0.429 g, 1.5 mmol) was reacted with the cross linked polymer in 1x PBS 
buffer (pH 4) at RT for 2 h under inert gas atmosphere. Subsequently, the solution was 
dialyzed (MWCO = 3500 Da) for two days at RT against aqueous HCl solution (pH 3.5). 
Finally, the polymer solution is lyophilized and stored at 4°C for further use. The free thiol 
content of the polymer was determined using Ellman’s method. SEC (THF): 
Mn = 12900 g/mol, Mw/Mn = 1.1223. 
4.5.1.3. Hydrogel cross linked via Michael addition of thiols (slow degradable hydrogels 
[SDH]) 
SH-sP(EO-stat-PO) (0.0300 g, 2.5 x 10-3 mmol, 7.5 x 10-3 mmol with respect to SH groups 
(3 SH groups per molecule)) was dissolved in 1x PBS buffer pH 8.0 (30 µL) and mixed 
thoroughly. To this solution, PEG-diacrylate (0.0107 g, 1.86 x 10-3 mmol, 3.72 x 10-3 with 
respect to ACR groups (2 ACR groups per molecule)) and 3 µM of CXCL12 (S4V) were 
added. This equals a molar ratio 1:5 SH-polymer:ACR-PEG. All components were 
homogenized fast. 
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4.5.1.4. Hydrogel cross linked via oxidation of thiols (flow degradable hydrogels [FDH]) 
SH-sP(EO-stat-PO) (0.0300 g, 2.5 x 10-3 mmol, 7.5 x 10-3 mmol with respect to SH groups 
(3 SH per molecule)) is dissolved in 1x PBS buffer pH 7.4 (30 µL) and mixed thoroughly. To 
this solution 20 µL of 0.1 M H2O2 and 0.5 µM of Met-CCL5 were added. All components were 
homogenized fast. The gelation of the hydrogel starts in 5 min, so if the gels have to be 
transferred in well plates or mold it has to be done within this time. Cross linking then 
continues and will be 95% finished after 2 h and fully finished after 12 h. 
4.6. Fluorescence based Assay 
4.6.1. Flow Cytometry 
The laser based flow cytometry technique is a biophysical technology for analyzing cells by 
their size, granularity and protein expression. This technique employed cell counting, sorting, 
biomarker detection and protein engineering. In a buffer stream, one cell at a time passes by 
an argon laser, which excites fluorescently labeled cells. Measurements of the size (forward 
scatter) and granularity (sideward scatter) are independent from the fluorescence signal. In 
this study the flow cytometry technique was utilized for cell counting of transmigrated cells 
from the cell recruitment assay (4.7.4). In a buffer system the transmigrated cells (neutrophils 
and EOCs) were counted 1 min using a FACS Canto II flow cytometer and 
FLOW JO Software. 
4.6.2. Enzyme-linked immunosorbent assay (ELISA) 
ELISA is a method for determining the concentration of antigens in biological samples. The 
method used here is based on the principle of a sandwich immunoassay. The amount of 
mouse CXCL12, mouse CCL5 and human CCL5 from human sera was determined but also 
supernatants from the release assay were measured with this method using DuoSet ELISA 
Development Kits (mouse CXCL12/SDF-1, mouse CCL5/RANTES, human CCL5/RANTES) 
in accordance with the manufacturer’s instructions. A capture antibody specific for the 
antigen of interest is pre-coated onto a microtiter plate and incubated over night at RT. After 
aspiration and washing, the plate was blocked with 1% BSA in PBS for 1 h and 
aspiration/washing was repeated. The standards and samples were added for binding to the 
capture antibody and incubated for 2 h. After aspiration/washing, the detection antibody was 
added and incubated for 2 h. To remove the unbound detection antibody the 
aspiration/washing procedure was done followed by adding streptavidin-HRP and incubated 
for 20 min. The last step, was set by the substrate solution and the reaction yields blue then 
turns to yellow when the reaction was stopped with 2 M H2SO4. The optical density was 
determined using a microplate reader at 450 nm/570 nm. A standard curve was generated 
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for each set of sample assayed and the concentrations of the samples were calculated 
according to the standard curve. All samples were performed in duplicates or triplicates. 
4.6.3. Histochemistry and Immunhistochemistry 
4.6.3.1. Assessment of infarction size and collagen content 
The infarcted area and collagen content was determined in serial sections (5 µm) of the 
infarcted myocardium (10 sections per mouse) through quantifying Gomori’s 1-step trichrome 
stain-positive area using Diskus software and expressed as percentage of LV area and 
collagen are measured in six different fields from infarcted area per section and expressed 
as collagen content/mm². 
4.6.3.2. Quantitative immunohistochemistry and immunofluorescence 
The number of neutrophils, smooth muscle cells (SMCs) and vessels are determined in serial 
sections (3 per mouse, 200 µm apart) of the infarcted and treated myocardium. Sections are 
stained for neutrophils using chloracetatesterase, for SMCs using monoclonal mouse anti-
human α-actin (smooth muscle) clone 1A4 and for vessels using goat anti-mouse CD31 
monoclonal antibody (mAb) clone M-20. Areas with specific immunostaining are quantified 
using Diskus software by comparison to isotype controls and expressed as percentage of the 
infarcted area and cells are numbered in six different fields from infarcted area per section 
and expressed as cells/mm². 
4.7. Functional assay 
4.7.1. Isolation of angiogenic early-outgrowth cells (EOCs) 
The EOCs were isolated according to the established protocols154 from citrate/dextran 
anticoagulated peripheral blood buffy coats of healthy volunteers. Mononuclear cells (MNCs) 
were separated by density gradient centrifugation with Bicoll. The MNCs were washed 2x 
with PBS, resuspended in EC growth medium MV2 and plated on fibronectin-coated 
(10 µg/mL) 6-well plates (107 cells per well). At day 4, the medium was changed and at day 
5-7 the adherent cells were detached with accutase for 5 min at 37°C, counted and subjected 
to activity assay. Experiments with human material were approved by the local ethics board 
and all individuals gave informed consent. 
4.7.2. Isolation of neutrophil from peripheral blood 
The neutrophil isolation was done according to Bøyum et. al.155, using a isoosmotic density 
barrier (1.077 g/mL) containing metrizoate and a polysaccharide. This density barrier 
separates human peripheral blood mononuclear cells, which band at the interface from 
PMNs and erythrocytes and pellet the cells. The density and osmolarity of the barrier was 
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later increased156 to permit the simultaneous separation of the PMNs and erythrocytes. 
Whole blood was drawn from patients in the presence of EDTA (1.6 mg EDTA/mL blood) in 
an open system using a butterfly needle. For the isolation of neutrophils, 4.5 mL of 
Polymorphprep was layed in a 15 mL falcon tube, covered with the same amount of EDTA-
blood and centrifuged at 500 g for 30 min. After centrifugation the Polymorphprep is divided 
in different layers. The lowermost layer contains erythrocytes, subsequently the 
Polymorphprep, followed by the neutrophil layer, again a Polymorphprep layer, followed by 
the monocytes and the uppermost layer containing the serum. The top layers were aspirated 
and the neutrophils were transferred to a fresh 15 mL falcon tube. The neutrophils were 
washed in HBSS buffer containing 1% BSA and centrifuged at 300 g for 5 min. The 
supernatant was aspirated and the erythrocytes were lysed with lysis buffer for 10 min, again 
centrifuged and the supernatant was aspirated. The neutrophils were taken up again in 
HBSS buffer containing 1% BSA. Experiments with human material were approved by the 
local ethics board and all individuals gave informed consent. 
4.7.3. Static cell-adhesion assay 
Three different independent experiments were done for parallel-plate flow chamber adhesion 
to analyze the CX3CL1 receptor antagonist, Met-CCL5 and the protease-resistant CXCL12. 
Flow-resistant adhesion on ECs in response to recombinant chemokines was assessed in 
customized flow chambers as described in Postea et. al.117. 
4.7.3.1. Whole blood adhesion assay for analyzing the F1-CX3CL1 
To analyze the F1-CX3CL1, whole blood was drawn in the presence of 2.9 µM of 
recombinant Hirudin in an open system using a butterfly needle. The first 1-2 mL of drawn 
blood was discarded to prevent platelet activation. The leukocytes in the blood were labeled 
by the addition of rhodamine 6G (1 µM). In some experiments, a blocking anti-CX3CL1-
antibody, isotype control (5 µg/mL), the CX3CR1-antagonist F1-CX3CL1 or the heat-
inactivated F1-CX3CL1 (5 µg/mL) were added and incubated for 30 min at 37°C. HAoSMC 
were cultured in 35 mm dishes, activated with TNFα (10 ng/mL) for 4 h and assembled into 
flow chambers. Whole blood was perfused for 4 min at a wall shear stress of 1.5 dynes/cm2 
and subsequently perfused with Hank's buffer containing HEPES (10 mM), CaCl2 and MgCl2 
(1 mM each) and 0.5% human albumin to wash away erythrocytes allowing video 
microscopic quantification of adherent fluorescent cells. Adherent leukocytes were manually 
counted in at least 6 fields and expressed as cells/mm2. 
4.7.3.2. Neutrophil adhesion assay for analyzing the Met-CCL5 
After density barrier separation of venous blood (4.7.1), the isolated neutrophils were labeled 
by the addition of calcein (1 µM). Commercially available CXCL8 (200 ng/mL) and CCL5 
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(200 ng/mL) both used as positive controls, and Met-CCL5 (200 ng/mL) were added to 
500.000 neutrophils/reaction and incubated for 30 min at 37°C. HUVECs were cultured in 
35 mm dishes and were activated with TNFα (10 ng/mL) for 4 h and assembled into flow 
chambers. Neutrophils were perfused for 3 min at a wall shear stress of 1.5 dynes/cm2 and 
subsequently perfused with Hank's buffer containing HEPES (10 mM), CaCl2 and MgCl2 
(1 mM each) and 0.5% human albumin subsequently followed by video microscopic 
quantification of adherent fluorescent cells. Adherent neutrophils are manually counted in at 
least 6 fields and expressed as cells/mm2. 
4.7.3.3. Lymphocytic cell adhesion assay for analyzing the protease-resistant 
CXCL12 (S4V and S2G4V) 
Jurkat T lymphocytic cells were labeled by the addition of calcein (1 µM). The commercially 
available CXCL12 wild type (200 ng/mL) as a positive control, CXCL12 (S4V) (200 ng/mL) 
and CXCL12 (S2G4V) (200 ng/mL) are added to 500.000 Jurkat T lymphocytic cells/reaction 
and incubated for 30 min at 37°C. Human Umbilical Vein Endothelial Cells (HUVEC) were 
cultured in 35 mm dishes and were activated with TNFα (10 ng/mL) for 4 h and assembled 
into flow chambers. Jurkat T lymphocytic cells are perfused for 3 min at a wall shear stress of 
1.5 dynes/cm2 and subsequently perfused with Hank’s buffer containing HEPES (10 mM), 
CaCl2 and MgCl2 (1 mM each) and 0.5% human albumin subsequently followed by video 
microscopic quantification of adherent fluorescent cells. Adherent lymphocytes are manually 
counted in at least 6 fields and expressed as cells/mm2. 
4.7.4. Cell recruitment assay 
Activities of purified Met-CCL5 and the protease-resistant CXCL12 (S4V and S2G4V) were 
assayed by migration of neutrophils and EOC respectively and compared with the 
commercially available CXCL8 and CCL5, or CXCL12 wild types using Transwell 
chambers157. 500.000 cells were plated in the upper well of 6.5 mm transwell with 3.0 µm (for 
neutrophils) or 8.0 µm (for EOCs) pore polycarbonate membrane insert and chemokines 
(100 ng/mL) was added to the lower well. Cells are counted in the lower well after 1 h 
incubation for neutrophils and after 3 h incubation for EOCs. All experiments were performed 
in triplicate. 
4.7.5. Release assay 
4.7.5.1. Release of Met-CCL5 from fast degradable hydrogels (FDH) 
15 µL of hydrogel cross linked via oxidation of thiols containing 0.5 µM Met-CCL5 was 
incubated with 250 µL 1x PBS, 10 mM reduced glutathion and incubated over 24 h. After 0, 
2, 4, 8, 12 and 24 h 250 µL 1x PBS, 5 mM reduced glutathion was replaced and the 
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supernatant was analyzed using human CCL5/RANTES DuoSet ELISA kit (according to 
manufacturer’s instructions (4.6.2). 
4.7.5.2. Release of protease-resistant CXCL12 (S4V) from SDH 
15 µL of hydrogel cross linked via Michael addition of thiols containing 3 µM protease-
resistant CXCL12 (S4V) was incubated with 250 µL 1x PBS, 5 mM reduced glutathion and 
incubated over 4 weeks. After 0, 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30 days 250 µL of 
1x PBS, 5 mM reduced glutathion was replaced and the supernatant was analyzed using 
mouse CXCL12/SDF-1 DuoSet ELISA kit according to manufacturer’s instructions (4.6.2). 
4.7.6. Biocompatibility assay 
The biocompatibility of the protease-resistant CXCL12 (S4V), Met-CCL5 and biodegradable 
hydrogels were analyzed by two different methods, one was led by a proliferation assay and 
the other was a cell viability test performed. 
4.7.6.1. Proliferation assay 
Proliferation assay with HUVEC’s in the presence of protease-resistant CXCL12 (S4V), Met-
CCL5 and biodegradable hydrogels were performed. The BrdU Proliferation Assay is a non-
isotopic immunoassay for the quantification of bromodeoxyuridine (BrdU) incorporation into 
new synthesized DNA of actively proliferating HUVEC’s. The procedure is carried out 
according to manufacturer’s instructions. The samples are incubated and analyzed after 
4 and 72 h according to manufacturer’s instructions. 
4.7.6.2. Cell viability assay 
CellTiter-Blue cell viability assay with HUVEC’s in the presence of protease-resistant 
CXCL12 (S4V), Met-CCL5 and biodegradable hydrogels were performed. The CellTiter-Blue 
cell viability assay provides a homogeneous, fluorometric method for estimating the number 
of viable HUVEC’s present in multiwell plates. The CellTiter-Blue assay is based on the 
ability of living HUVEC’s to convert a redox dye (resazurin) into a fluorescent end product 
(resorufin). Viable HUVEC’s retain the ability to reduce resazurin into resorufin. Nonviable 
HUVEC’s rapidly lose their metabolic capacity, thereby losing their ability to reduce the 
indicator dye, and thus do not generate a fluorescent signal. The procedure is done 
according to manufacturer’s instructions and was analyzed after 0, 1, 2, 3, 4 and 24 h. 
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4.8. Animal models 
4.8.1. Mouse model of myocardial infarction (MI) and injection of 
biodegradable hydrogels containing chemokines 
Eight week old male C57BL/6 mice (n = 6-9 per group) were subjected to coronary occlusion 
as described earlier30, 158. Briefly, mice were intubated under general anesthesia (using 
ketamine and xylazine) and positive pressure ventilation was maintained using a rodent 
respirator. Hearts were exposed by left thoracotomy and MI is induced by suture occlusion of 
the left anterior descending artery (LAD) over a silicone tube. Biodegradable hydrogels SDH 
and FDH (15μL) were mixed with crosslinking agent and loaded with buffer or 0.5 μg Met-
CCL5 and/or 3 μg CXCL12 (S4V) and subsequently injected separately in a standardized 
manner, using a 36 gauge needle into 2 directly adjacent sites of the mouse myocardium at 
the border of the infarct area directly after inducing MI. The muscle layer and skin incision 
were closed with a silk suture, after polymerization was complete. The animals were treated 
with a single dose of buprenorphine (0.1 mg/mL) and kept under standard conditions one day 
or 4 weeks after MI until further investigation. Heart function of the mice was evaluated by 
echocardiography 1 day before, and 4 weeks after MI. All animal experiments and study 
protocols were approved by local authorities, complying with Romanian animal protection 
laws. 
4.9. Statistical analysis 
Data were represented as mean value ± standard errors. Data analysis was performed with 
Prism 4 software (Graph Pad) using one-way parametric ANOVA followed by Newman-Keuls 
post hoc testing or Kruskall-Wallis non-parametric testing with Dunns post hoc comparison, 
where appropriate. Differences with P < 0.05 were considered significant. 
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5. Results 
MI is a threatening consequence of atherosclerotic narrowing of coronary vessels. The most 
important goals are to understand the process of atherosclerosis, to identify possible 
therapeutic options for preventing the development of atherosclerosis and to develop 
possible therapeutic applications after MI. Chemokines play a very important role in the 
development of atherosclerosis and for the therapy after MI. This study examines different 
modified chemokines and/or chemokine antagonists, which play an essential role in the 
development of atherosclerosis and for the therapy after MI. The first part of this work 
describes the recombinant expression and purification of F1-CX3CL1, Met-CCL5, protease-
resistant CXCL12, and the synthesis of degradable hydrogels. The second part of this work 
describes a potential in vivo therapeutic approach with Met-CCL5 and the protease-resistant 
CXCL12 for the therapy after MI. The third part examines the role of F1-CX3CL1 antagonist 
on platelet-monocyte complex formation during atherosclerosis. 
CX3CL1 participates in diverse inflammatory processes including arterial atherosclerosis and 
inflammation and binds with the N-terminal part of the protein to its unique receptor CX3CR1. 
Both, platelets and monocytes express the CX3CR1 receptor117. To investigate the 
contribution of CX3CL1 in the PMC formation, a CX3CL1 antagonist, named F1-CX3CL1 was 
used. Six amino acids of the CX3CL1 were modified on the N-terminal part of the protein to 
obtain the F1-CX3CL1 antagonist27 (Table 1). The described F1-CX3CL1 antagonist was first 
published by Dorgham et. al.27. F1-CX3CL1 bound specifically to cells expressing CX3CR1, 
without being a signaling molecule and did not induce chemotaxis, calcium flux, or CX3CR1 
internalization as the naturally occurring CX3CL1 wild type27. 
The CCL5 chemokine is a proinflammatory cytokine that plays a critical role as neutrophil 
and macrophage activator in inflammation, atherosclerosis and after MI67. After MI, 
neutrophils are recruited within hours into the infarcted area and promote an inflammation 
reaction. To avoid the recruitment of neutrophils into the infarcted area and to decrease the 
inflammation reaction, a CCL5 antagonist, named Met-CCL5 was chosen. Met-CCL5 
contains an additional methionine residue on the N-terminal part of the protein to antagonize 
CCR5 and CCR1 receptors153 (Table 1). This methionylated protein is completely inactive in 
CCL5 bioassays of calcium mobilization and chemotaxis of promonocytic cell lines153.  
After MI, regeneration of the heart muscle is very important. Because, the appropriate blood 
supply is crucial for heart survival and function, angiogenesis is considered as an optimal 
therapeutic target. The CXCL12-CXCR4 ligand-receptor axis is implicating in angiogenesis of 
the heart35, 159, 160. The CXCL12 chemokine promotes tissue regeneration by mediating 
angiogenic EOCs recruitment into the ischemic area161, while CXCR4 stimulates proliferation, 
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cell survival and angiogenesis162, 163. The CXCL12-CXCR4 communication is essential for 
improving neo-myoangiogenesis and left ventricular remodelling164. After vascular injury, the 
CXCL12 expression is upregulated165, but this effect is limited by local proteases such as 
MMP-2 and DPPIV which cleaves the CXCL12 and becomes inactive53. Thus, proteolytic 
activity limits the effectiveness of CXCL12 in the inflammatory environment of infarcted 
myocardium53. The receptor binding site of the CXCL12 chemokine on the CXCR4 and 
CXCR7 receptor are located on the N-terminal site of this protein166. Because the cleavage 
sites of MMP-2 and DDPIV are also located on the N-terminus of the CXCL12 chemokine53, it 
was necessary to modify serine at position 4 to valine and to add an N-terminal serine 
obtaining the protease-resistant CXCL12 (S4V) (Figure 7A-B) (Table 1). The described 
modification was first published by Segers et. al.53. The receptor specificity and activity of the 
CXCL12 (S4V) chemokine described by Segers was retained for both CXCR4 and CXCR7, 
but with a lower activity towards CXCR4 receptor compared to native CXCL12167. The 
CXCL12 (S2G4V) is an antagonist (inactive control) only for the CXCR4 receptor with an 
additional exchange of proline to glycine at position 2 (Table 1).  
chemokine or antagonist N-terminal amino acid sequence 
CX3CL1 wild type -QHHGVTKC 
F1-CX3CL127 ILDNGVSKC 
CCL5 wild type -SPYSSDTT 
Met-CCL5153 MSPYSSDTT 
CXCL12 wild type -KPVSLSYR 
CXCL12 (S4V)53 SKPVVLSYR 
CXCL12 (S2G4V) SKGVVLSYR 
Table 1: N-terminal amino acid sequence of the modified chemokines and/or chemokine 
antagonists in comparison to the N-terminal amino acid sequence of the wild type chemokines. 
Figure 7: The first 8 amino acids of the naturally occurring CXCL12 chemokine. A. Wild type 
CXCL12 indicating the location of MMP-2 and DPPIV cleaving sites. B. CXCL12 (S4V) showing the 
modifications to provide resistance to MMP-2 and DPPIV, i.e. mutation of serine at position 4 to valine 
and addition of an extra N-terminal serine. Figure modified from Segers et. al.53. 
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For the in vivo investigation of Met-CCL5 and protease-resistant CXCL12 in mice after MI, 
synthetic hydrolysable hydrogels were implemented. Here the local role of Met-CCL5 and 
protease-resistant CXCL12 under controlled release using degradable hydrogels was 
investigated with the intention to recruit SC into the infarcted area for promoting a faster 
regeneration, and to prevent the infiltration of neutrophils into the inflamed myocardium for 
an improved healing of the heart after MI.  
In vitro the role of F1-CX3CL1 antagonist to platelet-monocyte complex formation during the 
progression of atherosclerosis was studied. The chemokine receptor CX3CR1 is an 
inflammatory mediator in vascular diseases. On platelets, its ligation with CX3CL1 induces 
platelet activation followed by leukocyte recruitment to activated endothelium117. For this 
reason, to evaluate the expression and the role of platelet-CX3CR1 during hyperlipidemia 
and during vascular injury, is important. 
5.1. Cloning, expression and isolation of F1-CX3CL1, Met-CCL5, 
protease-resistant CXCL12 (S4V) and CXCL12 (S2G4V) 
The constructs for F1-CX3CL1, Met-CCL5, protease-resistant CXCL12 (S4V) and 
CXCL12 (S2G4V) were created using the pET system and standard molecular biology 
techniques. The cloning of Met-CCL5 was done by Birgit Kramp in the working group of PD 
Dr. Rory Koenen (University Hospital of the LMU Munich, Institute for Cardiovascular 
Prevention (IPEK), Munich, Germany). The cloning of the protease-resistant CXCL12 (S4V) 
and CXCL12 (S2G4V) has been published earlier168. The F1-CX3CL1 and Met-CCL5 were 
cloned in the pET-26b(+) plasmid, while the protease-resistant CXCL12 (S4V) and CXCL12 
(S2G4V) were cloned in the pET-32a(+) plasmid. The cloning of F1-CX3CL1 into the 
pET26b(+) vector was done with the restriction enzymes Not I and Nde I (Figure 8A). The 
pET26b(+) vector for the expression of the F1-CX3CL1 protein contains the following: T7 
promoter and terminator, pBR322 and f1 origin, His Tag, lacI coding sequence, kanamycin 
coding sequence and multiple cloning sites. The cloning of Met-CCL5 into the pET26b(+) 
vector was done with the restriction enzymes BamH I and Nde I (Figure 8B). The pET26b(+) 
vector for the expression of the Met-CCL5 protein contains the following: T7 promoter and 
terminator, pBR322 and f1 origin, lacI coding sequence, kanamycin coding sequence and 
multiple cloning sites. For cloning the protease-resistant CXCL12 (S4V) and CXCL12 
(S2G4V) into the pET32a(+) vector, the cleavage enzymes Kpn I and Not I were used 
(Figure 8C-D). The expression vector pET32a(+) for protease-resistant CXCL12 (S4V) and 
CXCL12 (S2G4V) contains a T7 promoter and terminator , pBR322 and f1 origin, Trx Tag, 
lacI coding sequence, kanamycin coding sequence and multiple cloning sites. The 
expression of the target genes (F1-CX3CL1, Met-CCL5, protease-resistant CXCL12 (S4V) 
and CXCL12 (S2G4V)) was induced by the addition of IPTG, under the control of T7 
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transcription and translational signals and expressed in E. coli as “inclusion bodies”. The 
proteins were purified using different strategies.  
The recombinant F1-CX3CL1 was purified in a 2-step procedure: first, the isolation of the 
protein was done by FPLC, HisTrap HP column, followed by the refolding of the F1-CX3CL1, 
followed by a second isolation step using the Resource S column (Figure 9). The isolation of 
recombinant Met-CCL5 was also performed in a 2-step procedure: first, the refolding of the 
Met-CCL5 was performed, followed by cation exchange chromatography using FPLC and 
SP-Sepharose FF column and HPLC purification using a Vydac® reverse phase column 
(Figure 9) in a second step. The recombinant protease-resistant CXCL12 was purified in 
3 steps: first, refolding of the protease-resistant CXCL12 (S4V) and (S2G4V) followed by 
affinity purification with Ni-NTA, Heparin SepharoseTM and enterokinase digestion of the Trx 
Tag and Tricorn Mono STM 5/50GL by means of cation exchange chromatography (Figure 9). 
Two different CXCL12 chemokines, the so called CXCL12 (S4V), which is resistant to 
proteases MMP-2 and DPPIV and the inactive control CXCL12 (S2G4V), which functions as 
an antagonist for the CXCR4 receptor, were expressed and purified in the same manner. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Constructs for F1-CX3CL1, Met-CCL5, CXCL12 (S4V) and CXCL12 (S2G4V) fusion 
proteins and vectors. A. F1-CX3CL1 were cloned in the pET26b(+) vector under the T7 promoter 
and containing a His Tag. B. Met-CCL5 were cloned in the pET26b(+) vector under the T7 promoter. 
C. CXCL12 (S4V) and D. CXCL12 (S2G4V) were cloned in the pET232a(+) vector under the T7 
promoter and containing Trx Tag. 
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Figure 9: Scheme of the expression and isolation strategy of F1-CX3CL1, Met-CCL5 and 
protease-resistant CXCL12. 
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5.1.1. F1-CX3CL1 expression and isolation 
The F1-CX3CL1 protein was expressed in E. coli as “inclusion bodies” (Figure 9). To dissolve 
the “inclusion bodies” for the purification with FPLC, 6 M guanidine-HCl was used. 
Guanidine-HCl is one of the strongest denaturants used in physiochemical studies of protein 
folding. The F1-CX3CL1 protein contains a His Tag on its N-terminus (Figure 8). A His Tag is 
an amino acid motif in proteins that consists of at least six histidine residues. For the first 
isolation step of the F1-CX3CL1, the FPLC and the HisTrap HP column were used. HisTrap 
HP columns are prepacked with nickel sepharose and designed for simple, high-resolution 
purification of His Tagged proteins by immobilized metal ion affinity chromatography. The run 
was done at a flow rate of 1 mL/min and 1 mL fractions were collected (Figure 10A). The 
fractions under the peak were analyzed by SDS-PAGE (Figure 10B). The calculation of 
protein concentration for each fraction was measured by Lowry protein assay. A 
representative example for the first step of the isolation of F1-CX3CL1 is shown in Figure 10. 
The fractions of interest C5-C10 containing the F1-CX3CL1 protein were pooled for refolding. 
A refolding step was necessary because the F1-CX3CL1 protein was previously denatured 
with guanidine-HCl. The refolding was done over night at 4°C using 100 mM Tris pH 8.5, 
5 mM EDTA, 0.2 mM oxidized glutathione, 1 mM reduced glutathione. After refolding, the 
protein was dialysed in 10 mM potassium phosphate, 5 mM EDTA for 2 h. A second dialysis 
with 0.1% TFA in deionized water over night at 4°C was necessary. The enterokinase 
digestion was required to cleave off the His Tag from the F1-CX3CL1. To separate the F1-
CX3CL1 from the His Tag, the FPLC and the Resource S column were used. The 
Resource S is an ion exchange chromatography method which can separate molecules or 
groups of molecules that have only slight differences in charge, like the F1-CX3CL1 and the 
His Tag. Separation is based on the reversible interaction between a charged molecule and 
an oppositely charged chromatography medium. The run was performed at a flow rate of 
1 mL/min and 1 mL fractions were collected (Figure 11A). The fractions under the respective 
chromatogram peak were analyzed on SDS-PAGE (Figure 11B) and the protein 
concentrations for each fraction were measured by Lowry protein assay. The fractions under 
peak 1 D15-D14 and peak 2 D13-D11 were pooled together. Peak 2 seems to be the F1-
CX3CL1, because the isoelectric point (IEP) changes after enterokinase digestion from 8.79 
to 9.34 and Mw from 10828.35 to 8735.12. For this reason peak 2 was used for further 
examination. 
The purity and mass of F1-CX3CL1 chemokine was determined by means of MALDI-TOF 
(Figure 12A). The mass of the F1-CX3CL1 chemokine corresponds to the expected mass of 
8.73 kDa. The identity of the isolated F1-CX3CL1 was confirmed by Western blot analysis in 
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comparison to the commercially available recombinant CX3CL1 wild type using specific mAb 
(Figure 12B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: First isolation step of F1-CX3CL1. A. Representative FPLC trace using HisTrap HP 
column. The protein was eluted using buffer B (6 M guanidine-HCl, 20 mM Tris pH 7.5, 250 mM 
imidazol) and collected in 1 mL fractions. The y-axis represents the mAU (milli-absorbance-units) and 
the x-axis represents the eluent volume in mL. B. Coomassie staining for F1-CX3CL1 chemokine. 
SDS-PAGE was performed under reducing conditions. The fractions were analyzed on SDS-PAGE in 
comparison to a SeeBlue® Plus2 marker. Peak 1 (fraction C5-C10) were pooled together and used for 
further purification.  
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Figure 11: Second isolation step of F1-CX3CL1. A. Representative FPLC trace using Resource S 
(ion exchange chromatography) column. The protein was eluted using buffer B (20 mM MES pH 6, 
1 M NaCl) and collected in 1 mL fractions. The y-axis represents the mAU (milli-absorbance-units) and 
the x-axis represents the eluent volume in mL. B. Coomassie staining for F1-CX3CL1 chemokine. 
SDS-PAGE was performed under reducing conditions. The fractions under the peak were analyzed on 
SDS-PAGE in comparison to a SeeBlue® Plus2 marker. Peak 1 (fraction D15-D14) and peak 2 
(fraction D13-D11) were used for further examination. 
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Figure 12: Purity and mass determination of F1-CX3CL1 chemokine. A. The mass determination 
was done by means of MALDI-TOF. The mass of F1-CX3CL1 chemokine corresponds to 8.73 kDa. 
The y-axis represents the signal intensity in % and the x-axis represents the mass to charge ration 
(m/z). B. Western blot analysis of the isolated F1-CX3CL1 chemokine in comparison to the 
commercially available CX3CL1 wild type and a SeeBlue® Plus2 marker. 
5.1.2. Met-CCL5 expression and isolation 
The Met-CCL5 protein was expressed in E. coli as “inclusion bodies” (Figure 9). To dissolve 
the “inclusion bodies”, 6 M guanidine-HCl was used. Because the Met-CCL5 was denatured 
with guanidine-HCl, a refolding step was necessary to obtain the proper conformation of the 
protein. The refolding of the protein was done over night at 4°C using 50 mM Tris pH 8, 
0.01 mM oxidized glutathione, 0.1 mM reduced glutathione. After adjusting the pH to < 5, and 
the conductivity to < 20 mS, the first purification step using the FPLC and SP-Sepharose FF 
(Fast Flow) column followed. SP Sepharose FF is a strong cation exchanger, which is 
composed of cross-linked 6% agarose beads and shows high chemical stability. The run was 
done at a flow rate of 1 mL/min and 1 mL fractions were collected (Figure 13A). The fractions 
under the chromatogram peak were analyzed on dot blot (Figure 13B) and the protein 
concentrations for each fraction were measured by Lowry protein assay. The fractions of 
interest B14-B9 containing the Met-CCL5 were pooled for further purification. 
 B. A. 
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Figure 13: First isolation step of Met-CCL5. A. Representative FPLC trace using SP-Sepharose FF 
column. The protein was eluted using buffer B (50 mM sodium acetate pH 4.5 and 2 M NaCl) and 
collected in 1 mL fractions. The y-axis represents the mAU (milli-absorbance-units) and the x-axis 
represents the eluent volume in mL. B. Dot blot for Met-CCL5 chemokine. The fractions under the 
peak were analyzed. Fractions B14-B9 were pooled together and used for further purification. 
In the second step, Met-CCL5 protein was purified by means of reversed phase (RP) HPLC 
using the Vydac® column C8 250 x 10mm, 5 µm. The stationary phase is a thin film of non-
polar liquid phase that is chemically anchored to an inert material (silica particles). The silica 
particles on the surface are chemically linked to a non-polar layer. C8 column has a packing 
material composed of silica particles attached to C8 carbon units. The run was done using 
buffer A (0.1% TFA) and buffer B (0.1% TFA and 90% acetonitrile) applying gradient elution 
(0 min: A:B 100:0; 25 min: A:B 0:67) with a flow of 2 mL/min (Figure 14A). The fraction under 
the chromatogram peak 1, were analyzed on SDS-PAGE (Figure 14B) and the protein 
concentrations for each fraction were measured by Lowry protein assay. Peak 1 was used 
for further analysis. The Met-CCL5 was provided from Birgit Kramp and Dr. Marcella Langer 
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from the working group of PD Dr. Rory Koenen (University Hospital of the LMU Munich, 
Institute for Cardiovascular Prevention (IPEK), Munich, Germany).  
The purity of the Met-CCL5 chemokine was > 95% determined by HPLC (Figure 14A), 
Coomassie staining (Figure 14B) and mass determination by means of MALDI-TOF was 
confirmed (Figure 15A). The mass of chemokine corresponds to the expected mass of 
7.98 kDa. The identity of the isolated Met-CCL5 was confirmed by western blot analysis in 
comparison to the commercially available CCL5 wild type (Figure 15B). 
 
 
Figure 14: Second isolation step of Met-CCL5. A. Representative HPLC trace using Vydac® C8 
column. The protein was eluted using 0.1% TFA and 90% acetonitrile. The y-axis represents the mAU 
(milli-absorbance-units) and the x-axis represents the eluent volume in mL. B. Coomassie staining for 
Met-CCL5 chemokine. SDS-PAGE was performed under reducing conditions. The fraction under 
peak 1 was analyzed on SDS-PAGE in comparison to a SeeBlue® Plus2 marker. 
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Figure 15: A. Purity and mass determination of Met-CCL5 chemokine. The mass determination 
was done by means of MALDI-TOF. The mass of Met-CCL5 chemokine corresponds to 7.98 kDA. The 
y-axis represents the signal intensity in % and the x-axis represents the mass to charge ration (m/z). 
B. Western blot analysis of the isolated Met-CCL5 chemokine in comparison to the commercially 
available CCL5 wild type and a SeeBlue® Plus2 marker. 
5.1.3. Protease-resistant CXCL12 expression and isolation 
The protease-resistant CXCL12 (S4V) and CXCL12 (S2G4V) proteins were expressed in E. 
coli as “inclusion bodies” (Figure 9). The expression and isolation of the protease-resistant 
CXCL12 (S4V) and CXCL12 (S2G4V) have been published earlier168. The pure “inclusion 
bodies” were denatured in 6 M guanidine-HCl. To obtain the proper conformation, the fusion 
proteins were refolded overnight at 4°C by a 6-fold dilution in a 50 mM sodium phosphate pH 
7.5 buffer containing 6 mM cysteine and 8 mM cystine as redox additives. The protease-
resistant CXCL12 (S4V) and CXCL12 (S2G4V) proteins contain a Trx Tag on their N-
terminus (Figure 8C-D). The fist purification step was done using FPLC and the NiNTA 
column, which is an immobilized metal affinity chromatography. The Trx Tag is able to bind 
nickel ions on the NiNTA column. The run was performed at a flow rate of 0.5 mL/min and 
1 mL fractions were collected (Figure 16A). The fractions under the chromatogram peak 
were analyzed on SDS-PAGE (Figure 16B) and the protein concentrations for each fraction 
were measured using Lowry protein assay. Fractions B12-B7 under peak 3 contains the 
protease-resistant CXCL12 and were pooled together for further purification. The second 
purification step was performed by means of FPLC using the heparin sepharose column, 
which is an affinity chromatography. The heparin sepharose column purifies proteins with an 
affinity for heparin. The run was performed at a flow rate of 1 mL/min and 1 mL fractions 
were collected (Figure 17A). The fractions under the chromatogram peak were analyzed on 
SDS-PAGE (Figure 17B) and the protein concentrations for each fraction were measured 
B.A.  
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using Lowry protein assay. The fractions C12-D14 under the peak 1 were pooled together 
and used for the further purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: First isolation step of CXCL12 (S4V). A. Representative FPLC trace using NiNTA 
column. The protein was eluted using buffer B (20 mM phosphate pH 7.5, 1 mM cysteine, 500 mM 
imidazol) and collected in 1 mL fractions. The y-axis represents the mAU (milli-absorbance-units) and 
the x-axis represents the eluent volume in mL. B. Coomassie staining for CXCL12 (S4V) chemokine. 
SDS-PAGE was performed under reducing conditions. The fractions under the peak were analyzed on 
SDS-PAGE in comparison to a SeeBlue® Plus2 marker. Fractions B12-B7 under peak 3 were pooled 
together and used for further purification. 
The enterokinase digestion was required to digest the Trx Tag and then to separate the 
protease-resistant CXCL12 from the Trx Tag using FPLC and the strong cationic exchanger, 
Mono S column. The run was performed at a flow rate of 1 ml/min and 1 mL fractions were 
collected (Figure 18A). The fractions under the chromatogram peaks were evaluated on 
SDS-PAGE (Figure 18B) and the protein concentrations for each fraction were determined 
using Lowry protein assay. The fractions of interest B9-B7 containing the protease-resistant 
CXCL12 were pooled for further evaluation. The purity and mass of CXCL12 (S4V) and 
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CXCL12 (S2G4V) chemokines was > 95% and corresponds to 8.07 kDa and 8.03 kDa 
respectively (Figure 20A-B). The identity of the isolated chemokines was confirmed by 
western blot analysis in comparison to the commercially available CXCL12 wild type using 
specific mAb (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Second isolation step of CXCL12 (S4V). A. Representative FPLC trace using heparin 
sepharose column. The protein was eluted using buffer B (50 mM Tris pH 8, 1 mM cysteine, 1 M 
NaCl) and collected in 1 mL fractions. The y-axis represents the mAU (milli-absorbance-units) and the 
x-axis represents the eluent volume in mL. B. Coomassie staining for CXCL12 (S4V) chemokine. 
SDS-PAGE was performed under reducing conditions. The fractions under the peak were analyzed on 
SDS-PAGE in comparison to a SeeBlue® Plus2 marker. Fractions C13-D14 were pooled together and 
used for further purification. 
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Figure 18: Third isolation step of CXCL12 (S4V). A. Representative FPLC trace using cationic 
Mono S column. The protein was eluted using buffer B (50 mM MES pH 6, 1 M NaCl) and collected in 
1 mL fractions. The y-axis represents the mAU (milli-absorbance-units) and the x-axis represents the 
eluent volume in mL. B. Coomassie staining for CXCL12 (S4V) chemokine. SDS-PAGE was 
performed under reducing conditions. The fractions under the peaks were analyzed on SDS-PAGE in 
comparison to a SeeBlue® Plus2 marker. Fractions B9-B7 were pooled together and used for further 
purification. 
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Figure 19: Identity of the isolated CXCL12 (S4V and S2G4V) chemokines. Western blot analysis 
of the isolated chemokines in comparison to the commercially available CXCL12 wild type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Purity and mass determination of CXCL12 (S4V and S2G4V) chemokines by means 
of MALDI-TOF. A. The mass of CXCL12 (S4V) chemokine corresponds to 8.07 kDa. B. The mass of 
CXCL12 (S2G4V) chemokine corresponds to 8.03 kDa. The y-axis represents the signal intensity in % 
and the x-axis represents the mass to charge ration (m/z). 
A. 
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5.2. Synthesis of biocompatible and degradable hydrogels 
Hydrogels are networks of hydrophilic crosslinked polymeric particles with submicrometer 
size. The characteristics of hydrogels are biocompatibility, high-water content as well as 
tunable chemical and mechanical properties with the features of nanoparticles such as high-
surface area and overall sizes in the range of cellular compartments121. Hydrogels feature a 
high degree of flexibility similar to natural tissue. These properties make them intriguing 
candidates for entrapment of hydrophilic bioactive molecules such as proteins to provide a 
hydrophilic environment and protect them from degradation121. Two different biocompatible 
and degradable hydrogels were chosen as a scaffold to entrap the Met-CCL5 in a fast 
degradable hydrogel (FDH) for a very fast release over 24 h and the protease-resistant 
CXCL12 (S4V) in a slow degradable hydrogel (SDH) for a slow release over 4 weeks, to 
control the local release of the chemokines over time in the infracted myocardium of the 
mice. 
A star-shaped polymer sP(EO-stat-PO) and linear poly(glycol) (PG) were chosen as 
precursor for the hydrogels. Both polymers are hydrophilic and biocompatible, and the 
molecular weight is well below 30 kDa, which is set as a limit that allows renal clearance for 
linear polyethylene oxide (PEO)169. They were successfully functionalized with thiol groups 
through carbodiimide-mediated Steglich esterification between the free hydroxyl groups of 
the polymers and the disulfide containing dicarboxyacid121. The preparation of disulfide 
crosslinked particles from SH-sP(EO-stat-Po) polymers was performed by oxidation of thiol 
groups to disulfides and by Michael addition between thiol groups and acrylate (Figure 21). 
Disulfide formation proceeds through the deprotonated form of thiol groups. Thus, to 
maintain slightly basic reduction conditions, PBS buffer (pH 7.4) was used as a dispersed 
phase. The lyophilized chemokines were dissolved in PBS buffer. The oxidized hydrogels 
were mixed with PBS buffer containing Met-CCL5 for a fast delivery over 24 h in the tissue. 
The hydrogels obtained by Michael addition were mixed with the PBS buffer containing 
protease-resistant CXCL12 for a slow delivery over 4 weeks in the tissue. The described 
hydrogels were provided by Smriti Singh in the group of Prof. Dr. Jürgen Groll (University of 
Würzburg, Institute for Technology of Functional Materials in the Medicine, Würzburg, 
Germany). 
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Figure 21: Synthesis of biodegradable hydrogels. The thiolated polymer termed sP(EO-stat-PO) 
was crosslinked by two mechanisms: The first mechanism is an oxidation (by H2O2) of thiol groups to 
disulfides, which represents the fast degradable hydrogel (FDH) and was mixed with Met-CCL5 for a 
very fast delivery over 24 h. The second mechanism is a Michael addition between acrylate and thiol 
group, which represents the slow degradable hydrogel (SDH) and was mixed with protease-resistant 
CXCL12 (S4V) for a slow delivery over 4 weeks. 
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5.3. Intramyocardial release of engineered chemokines using 
biodegradable hydrogels prevents injury extension after 
myocardial infarction (MI) 
Before examination of the local therapy of MI with protease-resistant CXCL12 (S4V) in slow 
degradable hydrogels (SDH) and Met-CCL5 in fast degradable hydrogels (FDH), their 
functionality and biocompatibility was shown in vitro. Subsequently, the chemokines and 
hydrogels were injected in vivo, locally into the mouse myocardium as a potential therapeutic 
agent for the therapy after MI. 
5.3.1. Met-CCL5 antagonizes CCR1, CCR3 and CCR5 receptors and 
prevents neutrophil recruitment 
A variety of inflammatory diseases are characterized by tissue infiltration of neutrophils 
through its CCR1, CCR2, CCR3, CCR5, CXCR3 and CXCR4 receptors170. CCL5 activates 
the G-protein coupled receptor GPR75171 and interacts with CCR3172, 173, CCR5173, 174 and 
CCR1173, 175. Met-CCL5 antagonizes CCR5 activation and functions in response to its natural 
ligand in vitro74. The chemokines CXCL8 and CCL5 are strong chemoattractants of 
neutrophils in comparison to Met-CCL5 which antagonizes the neutrophil activation. The 
activity of recombinant Met-CCL5 was assessed using cell-recruitment assay with the 
designated target cell types. Isolated neutrophils stimulated with CXCL8 and/or CCL5 
showed considerable chemotaxis. Met-CCL5 specifically blocked the action of CCL5, but not 
of CXCL8. These results indicate that Met-CCL5 antagonizes the CCL5 receptor but not the 
CXCL8 receptor function (Figure 22A). The adhesion assay of stimulated neutrophils on 
HUVEC under flow conditions agreed with the above cell recruitment assay. The adhesion of 
neutrophils stimulated with CXCL8, CCL5 and in combination with CXCL8 and Met-CCL5 on 
HUVEC under flow conditions showed a high cell adhesion number. Met-CCL5 specifically 
blocked the action of CCL5, but not of CXCL8 (Figure 22B). The evaluation of cell cycle 
progression and the estimation of the number of viable cells were essential to exclude side 
effects before treating mice with the recombinant Met-CCL5. The proliferation was quantified 
using bromodeoxyuridine (BrdU) which was incorporated into newly synthesized DNA of 
actively proliferating HUVECs. The proliferation of HUVECs incubated with Met-CCL5 was 
analyzed in comparison to untreated cells. The data are expressed as the relative signal 
(RFU) and indicated the same proliferation of Met-CCL5-treated HUVECs in comparison to 
the negative controls (Figure 23A). For the estimation of cell viability the indicator dye 
resazurin was used, to measure the metabolic capacity of HUVECs, which is an indicator of 
cell viability. Viable HUVECs reduce resazurin into resorufin, which is a fluorescent dye. 
Nonviable HUVECs rapidly lose metabolic capacity, are not able to reduce the indicator dye, 
and are not able to generate a fluorescent signal. Met-CCL5-treated HUVECs indicated the 
same number of viable cells incubated over 12 h in comparison to untreated and viable cells 
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(Figure 23B). The treatment with Met-CCL5 did not impair the proliferation and viability of 
cultured HUVEC cells (Figure 23). 
 
Figure 22: Chemotaxis and adhesion assay with Met-CCL5-stimulated neutrophils. A. 
Chemotaxis assay of neutrophils towards Met-CCL5, CCL5 wild type and commercially available 
CXCL8 wild type. B. Adhesion assay under flow on activated HUVEC using Met-CCL5, CCL5 wild 
type and CXCL8-stimulated neutrophils. Depicted P-values are based on parametric evaluation, (n=9). 
 
Figure 23: Influence of Met-CCL5 on proliferation and cell viability of HUVECs. A. Proliferation 
assay and B. cell viability assay of BrdU labeled HUVEC (1000 cells/well) incubated with/without Met-
CCL5 (A, B) until 24 or 72 h, (n=2).  
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5.3.2. Protease-resistant CXCL12 retains receptor specificity and activity of 
native CXCL12 
The CXCL12 receptor binding site for CXCR4 and CXCR7 is located on the N-terminal site of 
the chemokine166. The cleavage sites of MMP-2 and DPPIV for CXCL12 are also located on 
the N-terminal site of the chemokine, which limit the effectiveness of CXCL1253. The CXCL12 
chemokine was modified on the N-terminal side to obtain a protease-resistant CXCL12 (S4V) 
and CXCL12 (S2G4V) chemokines (Figure 7) (Table 1). The chemotactic activity and 
receptor specifity were analysed for both protease-resistant CXCL12 (S4V) and CXCL12 
(S2G4V) chemokines. The activity of the recombinant CXCL12 (S4V) was assessed using 
cell-recruitment assay with the designated target cell types. The recombinant CXCL12 (S4V) 
induced the migration of angiogenic EOC to a slightly lower extent than CXCL12 wild type, 
whereas the activity of CXCL12 (S2G4V) was comparable with the negative control (Figure 
24A). Adhesion assay of CXCL12 (S4V)-stimulated Jurkat cells on HUVEC under flow 
conditions was comparable with the commercially available CXCL12 wild type. 
CXCL12 (S2G4V) showed significantly less adhesion compared to the CXCL12 (S4V) and 
CXCL12 wild type (Figure 24B). To exclude side effects of recombinant protease-resistant 
CXCL12 (S4V) before treating the mice, cell cycle proliferation and cell viability assay were 
performed. The proliferation assay for BrdU incorporation into newly synthesized DNA of 
actively proliferating cells (HUVECs) showed the same relative signals (RFU or proliferation) 
incubated with the recombinant protease-resistant CXCL12 (S4V) in comparison to the 
negative controls (Figure 25A). For the viability assay, HUVECs were treated with the 
CXCL12 (S4V) in comparison to non-treated cells and the results indicated no difference 
between the groups. The recombinant CXCL12 (S4V) showed neither effects on the 
proliferation and cell viability of cells (Figure 25B). 
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Figure 24: Chemotaxis and adhesion assay with CXCL12 (S4V and S2G4V)-stimulated angiogenic 
early outgrowth cells (EOCs). A. Chemotactic index of angiogenic EOC towards CXCL12 (S4V and 
S2G4V) and commercially available CXCL12 wild type. B. Adhesion assay using CXCL12 (S4V and 
S2G4V)-stimulated Jurkat cells on activated HUVEC under flow conditions in comparison to the 
commercially available CXCL12 wild type. Depicted P-values are based on parametric B. or non-
parametric A. ANOVA (n=6-9). 
Figure 25: Influence of CXCL12 (S4V) on proliferation and cell viability. A. Proliferation assay and 
B. cell viability assay of BrdU labeled HUVEC (1000 cells/well) incubated with/without CXCL12 (S4V) 
(A, B) until 24 or 72 h, (n=2). 
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5.3.3. Controlled release of chemokines using biocompatible and 
degradable hydrogels 
Hydrogels used for the application into the heart must simultaneously promote desirable 
functions for tissue regeneration, while not eliciting a severe and chronic inflammatory 
response. Hydrogels forming polymers are generally designed to be nontoxic to the cells of 
the surrounding tissue of the application site. The hydrogels should theoretically interact 
favorably with the heart tissue, on condition that they have not been contaminated during 
processing and that there are no cross-species immunological issues91. For testing of the 
compatibility of the hydrogels before injection into mice heart in vitro studies were performed. 
The proliferation of HUVECs in presence of the thiolated hydrogels compared to untreated 
cells was analyzed. Thiolated hydrogels-treated HUVECs show no effect on the proliferation 
(Figure 26A). Also, cell viability assay of hydrogel-treated HUVECs show similar results in 
comparison to untreated cells (Figure 26B) Currently, the majority of small and large 
molecule drugs are delivered into patients systemically without the use of scaffolds. 
Consequently, large doses are usually required for a desired local effect because of 
degradation of the drug and nonspecific uptake by other tissue. Hydrogel scaffolds are often 
utilized to stabilize and deliver bioactive molecules91. For an accurate delivery of the 
chemokines into the mouse hearts, the FDH and the SDH were used. In order to control the 
local release of the chemokines into the mice heart, delivery assay of both hydrogels (SDH 
and FDH) were performed. The SDH was conceived for formulation with the protease-
resistant CXCL12 (S4V) for a gradual release in order to recruit HCs from the circulating 
blood during a time period of 4 weeks after MI. In order to confirm the release rate, the 
CXCL12 (S4V)-SDH was incubated for 33 days in PBS to detect the local release over time. 
After 33 days the SDH was entirely degraded due to the hydrolytic cleavage of ester bonds in 
the backbone and release of chemokine was no longer detected (Figure 27A). The FDH is 
used for the formulation with Met-CCL5 for a quick release over 24 hours to inhibit neutrophil 
infiltration within the first hours after MI. This fast release of Met-CCL5 from FDH was 
confirmed by incubation in PBS and 5mmol/L glutathione, which led to complete degradation 
of the gel after 24 h due to disulfide bond cleavage. After 24 h the FDH is totally degraded 
and no chemokine could be detected (Figure 27B). 
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Figure 26: Influence of biopolymer on proliferation and cell viability. A. Proliferation assay and B. 
cell viability assay of BrdU labeled HUVEC (1000 cells/well) incubated with/without degradable 
polymer (A, B) until 24 or 72 h, (n=2). 
 
Figure 27: Release assay from hydrogels. A. Release of the protease-resistant CXCL12 (S4V) 
chemokine from the slow degradable hydrogel (SDH) over 33 d and B. of the Met-CCL5 chemokine 
from the fast degradable hydrogel (FDH) over 24 h. 
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5.3.4. Improvement of cardiac function in vivo after MI in mice by combined 
treatment with the protease-resistant CXCL12 and Met-CCL5 and 
biodegradable hydrogels 
MI is a common cause of heart failure, and recruitment of SC by CXCL12 could improve 
cardiac function176. In vivo, Met-CCL5 is able to reduce inflammation in models of induced 
inflammatory and autoimmune diseases74. Hydrogels ensure the local delivery of the 
chemokines over time in the body91. In order to investigate a possible beneficial role of a 
blocked short-term neutrophil influx after cardiac ischemia, combined with a longer-term 
recruitment of hematopoietic cells, the chemokine-loaded hydrogels were applied in an 
experimental model of MI. First, heart function of the mice was evaluated one day before and 
four weeks after MI induction using echocardiography. One day after analyzing the heart 
function the MI induction was performed followed by the local injection of Met-CCL5 and 
CXCL12 (S4V) formulated in two different hydrogels. The CXCL12 (S4V) was formulated in a 
SDH (CXCL12 (S4V)-SDH) for a slow delivery of the protease-resistant CXCL12 (S4V) for 
the recruitment of HC from the circulating blood, and the Met-CCL5 was formulated in the 
FDH (Met-CCL5-FDH) to prevent neutrophil-infiltration during the first 24 h, after MI. The 
mice were sacrificed 1 day after induction of MI to investigate the mobilization and 
recruitment of inflammatory cells, and 4 weeks after MI induction to examine the MI area and 
the neovascularization (Figure 28). In a study involving 44 mice surviving surgery, the effects 
of the injected chemokines on MI were examined in 4 groups (Table 2). 
 
Figure 28: Overview of mouse experiments. 
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 group 1 group 2 group 3 group 4 group 5 
treatment control FDH SDH Met-CCL5-FDH CXCL12 (S4V)-SDH 
Met-CCL5-FDH 
CXCL12 (S4V)-SDH 
Table 2: Overview of the groups with MI therapy. 
5.3.4.1. Functional changes of the hearts after MI were detected by echocardiography 
Heart function of the mice was evaluated 1 day before, and 4 weeks after MI using the Vevo 
700 software. The evaluation of the functional parameters of the heart revealed a significant 
improvement of cardiac function in the Met-CCL5-FDH + CXCL12 (S4V)-SDH group that 
received a combined treatment (Table 3 and Figure 29). The ejection fraction was increased 
in the group with Met-CCL5-FDH and CXCL12 (S4V)-SDH in comparison to the hydrogel and 
control group, but the combined treatment with Met-CCL5-FDH + CXCL12 (S4V)-SDH show 
the highest preservation of the heart function comparing to all other groups (Figure 29A, 
Table 3). Remarkably, the combined treatment with Met-CCL5-FDH + CXCL12 (S4V)-SDH 
was also able to improve cardiac output compared with the control group, hydrogel group 
and single chemokine-treated groups (Figure 29B, Table 3). No changes in heart weight 
were observed between the treated groups (Table 3). 
 Control FDH SDH Met-CCL5-
FDH 
CXCL12-SDH Met-CCL5-FDH
CXCL12-SDH
EF (%) 35.8 ± 1.85§§§ 31.6 ± 1.30 41.3 ± 2.31§§ 40.5 ± 1.83§§§ 50.1 ± 1.59***
CO (mL/min) 15.8 ± 0.42 13.8 ± 1.59 19.4 ± 1.92 16.5 ± 1.73 22.6 ± 2.43** 
Heart rate (BMP) 442 ± 11.4 426 ± 38.2 501 ± 36.7 502 ± 34.4 414 ± 34.9 
Heart weight (mg) 107 ± 6.58  119 ± 7.93 100 ± 8.77 104 ± 6.70 103 ± 4.86 
Table 3: Echocardiographic parameters. Ejection fraction (EF); Cardiac output (CO); Fast 
degradable hydrogel (FDH); Slow degradable hydrogel (SDH). **, ***; P<0.01, 0.001 vs. FDH SDH, 
respectively; n=6-9; §§, §§§; P<0.01, 0.001 vs Met-CCL5-FDH+CXCL12 (S4V)-SDH, respectively; 
n=6-9 mice; ANOVA 
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Figure 29: Cardiac function after experimental MI. Ejection fraction (EF) A. and cardiac output B. of 
FDH SDH, Met-CCL5-FDH, CXCL12 (S4V)-FDH and Met-CCL5-FDH+CXCL12 (S4V)-FDH -treated 
mice (n=6-9 per group), 4 weeks after MI. Depicted P-values are based on ANOVA. 
5.3.4.2. Treatment with protease-resistant CXCL12 and Met-CCL5 in biodegradable 
hydrogels after MI prevent neutrophil cell recruitment 
Recovered mouse myocardium was analyzed 1 day after MI and injection of chemokines in 
biodegradable hydrogels for mobilization and recruitment of inflammatory cells. The 
immediate infiltration of MI-induced neutrophils in the infarcted area (after 1 day) was 
reduced in both the Met-CCL5-FDH (272±35.8 mm–2) and the Met-CCL5-FDH+CXCL12 
(S4V)-SDH groups (299±33.6 mm–2), but not in the CXCL12 (S4V)-SDH group (876±235.9 
mm–2), compared with the control groups that received only hydrogel (810±51.3 mm–2) or 
PBS (760.7±72.2 mm–2) (Figure 30A-B). Thus, this confirmed the specificity of the 
administration of the CCR1 and CCR5 antagonist Met-CCL5 for the prevention of neutrophil 
recruitment. 
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Figure 30: Assessment of cardiac tissue damage after experimental MI. Neutrophil infiltration in 
the myocardium by esterase-staining A. and quantification B. of control (PBS), FDH SDH, Met-CCL5-
FDH, CXCL12 (S4V)-SDH and Met-CCL5-FDH+CXCL12 (S4V)-FDH -treated mice, 1 d after MI. 
Examples of stained neutrophils are marked with asterisks. Scale bars: 50 μm. Depicted P-values are 
based on parametric evaluation, n=6-9. 
5.3.4.3. Treatment with the protease-resistant CXCL12 and Met-CCL5 in biodegradable 
hydrogels after MI reducse infarct size and promotes neoangiogenesis 
Besides the evaluation of neutrophil content, the capability of the reduction of infarct size and 
neovascularization was examined. After 4 weeks, the infarcted area was notably reduced in 
the CXCL12 (S4V)-SDH (13.4±2.85 %) and in the combined Met-CCL5-FDH+CXCL12 
(S4V)-SDH group (12.8±4.18 %), compared to the groups that received hydrogel only 
(30.7±5.51 %) and Met-CCL5-FDH (25.7±4.73 %) (Figure 31A-B). Administration of the 
hydrogel itself did not affect infarct size, since the infarcted area of the control group was 
similar (30.3±3.72 %) (Figure 31A-B) 
Similarly, neovascularization after MI was also improved in both the CXCL12 (S4V) SDH 
(788±28.8 mm–2) and Met CCL5-FDH+CXCL12 (S4V)-SDH groups (1022±63.1 mm–2), to a 
higher extent as the Met-CCL5 FDH (466±29.4 mm–2), hydrogel group (328±32.5 mm–2) and 
control groups (407±62.4 mm–2), as quantified by CD31-staining (Figure 32A-B). This 
indicates a CXCL12 (S4V)-mediated increase of angiogenesis in infarcted myocardium, 
supporting our hypothesis. Interestingly, these findings also suggest that recruitment of 
hematopoietic cells through CXCR4 would serve to reduce infarct size rather than the 
blockade of initial neutrophil infiltration. 
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Figure 31: Assessment of cardiac tissue damage after experimental MI. Representative Gomori-
stained heart sections A. and histomorphometric quantifications B. of the hearts of FDH SDH, Met-
CCL5-FDH, CXCL12 (S4V)-SDH and Met-CCL5-FDH CXCL12 (S4V)-SDH treated mice, 4 weeks after 
MI. Depicted P-values are based on ANOVA (n = 6-9). 
 
Figure 32: Assessment of cardiac tissue damage after experimental MI. Neovascularization as 
quantified by representative CD31 staining A. and quantification B. of FDH SDH, Met-CCL5-FDH, 
CXCL12 (S4V)-FDH and Met-CCL5-FDH+CXCL12 (S4V)-FDH treated mice, 4 weeks after MI. 
Examples of capillaries are marked with asterisks. Scale bars: 50 μm. Depicted P-values are based on 
non-parametric B. ANOVA (n≥6). 
5.3.4.4. Detection of chemokines in mouse sera after MI and treatment with the protease-
resistant CXCL12 and Met-CCL5 in biodegradable hydrogels 
During treatment, the levels of CXCL12 (S4V) in mouse sera after 1 day and 4 weeks were 
not increased (Figure 33A-B), due to the very slow release rate from the hydrogel and the 
local application. Human Met-CCL5 levels were increased after one day of treatment with 
A. B. 
A. B. 
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Met-CCL5-containing FDH (Figure 33C), due to the quick release of human Met-CCL5 from 
these hydrogels. As expected, the human Met-CCL5 was no longer detected in the mouse 
sera after 4 weeks (Figure 33D). The concentrations of mouse CCL5 in sera were slightly 
increased after administration of any hydrogel variant (Figure 33E-F). 
 
 
Figure 33: Concentrations of chemokines in mouse sera. Detection of the amount of mouse 
CXCL12, human Met-CCL5 and mouse Met-CCL5 in mouse sera using ELISA. Depicted P-values are 
based on ANOVA (n = 6-9). 
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5.4. Role of platelet F1-CX3CL1 antagonist in platelet-monocyte 
complex (PMC) formation 
5.4.1. F1-CX3CR1 prevents PMC formation 
Incubation of THP-1 monocytic cells with TRAP-6-activated but not resting human platelets 
resulted in a significant PMC formation as shown by increased staining of the platelet marker 
CD61 in the monocyte-gated population (Figure 34). To test whether platelet-CX3CR1 plays 
a role in PMC formation, the platelets were preincubated with the CX3CR1-antagonist F1-
CX3CL127, this significantly decreased the PMC formation (Figure 34). The complete 
disruption of the PMC was achieved by their incubation with EDTA (10 mM for 15 min, 37°C), 
indicating the reversibility of their formation. 
 
 
 
 
 
 
 
Figure 34: Role of CX3CR1-CX3CL1 axis in PMC formation. PMC are dependent on the CX3CR1-
CX3CL1 interaction as their formation can be prevented by incubation of platelets with F1-CX3CL1 
antagonist (0.5 µg/mL). 
5.4.2. Platelet-CX3CR1 enhances CX3CL1-mediated adhesion of platelets 
and of PMC to SMC 
Upon arterial denudation, CX3CL1 expression is strongly upregulated on SMC177 and 
mediates interactions with CX3CR1-expressing cells109. In the following experiment, adhesion 
of TRAP-6-activated platelets to immobilized rhCX3CL1 was specifically increased by 
35.8%±6.13 (Figure 35A) (p< 0.05) as compared with adhesion to plastic and HSA and as 
shown by preincubation with a CX3CR1 neutralizing antibody. Together, these data indicate 
that CX3CR1 exposed on activated platelets is able to stably bind CX3CL1. In line, TNFα-
stimulated SMC, which have been shown to express CX3CL1 upon activation178 supported 
robust adhesion of blood leukocytes to smooth muscle cells, only when platelets were 
activated by the addition of TRAP-6 (Figure 35B). Pretreatment of the perfused SMC with a 
neutralizing CX3CL1 antibody blocked leukocyte adhesion, compared to an isotype control 
(Figure 35B). In addition, incubating the TRAP-6-activated whole blood with F1-CX3CL1 
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reduced stable leukocyte arrest to the same extent, indicating that the process was strongly 
mediated by the CX3CL1-CX3CR1 axis. All data studying the role of F1-CX3CL1 antagonist 
were published by Postea et. al.117. 
 
Figure 35: Recruitment of CX3CR1-expressing platelets on inflamed SMCs. A. Static adhesion of 
calcein-loaded human platelets to plastic (none), HSA (1%) and rhCX3CL1 (0.25 μg/well) in the 
absence or presence of a neutralizing CX3CL1 antibody (5 μg/mL). Data are representative of 
3 different donors. B. Perfusion of rhodamine-labeled anticoagulated whole blood untreated (grey bar) 
or pretreated with TRAP-6 (15 μM, black bars) over aortic SMC activated with TNFα (10 ng/ml, 4h). 
Stimulated SMC were pre-incubated with anti-CX3CL1 neutralizing mAb or isotype control (5 μg/mL). 
Alternatively, the blood was treated with F1-CX3CL1 or heat-inactivated F1-CX3CL1 (5 μg/mL) (n>3 
independent experiments. 
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6. Discussion 
6.1. Expression and isolation strategies 
Atherosclerosis ultimately leads to MI which is the major cause of death world wide179. 
Chemokines have a fundamental importance in the development of atherosclerosis and in 
the possible therapy of MI. Because chemokines have a fundamental importance, new 
therapeutic strategies are urgently needed to prevent the development of atherosclerosis and 
to cure the consequences of MI. Angiogenesis is a natural mechanism to restore reperfusion 
to the ischemic myocardium after MI180. This might be achieved by local proliferation of EC 
and by attraction of EOC through chemotaxis. To analyze the effects of F1-CX3CL1, Met-
CCL5 and protease-resistant CXCL12 on atherosclerosis and MI, it was necessary to 
express, isolate and purify these chemokines. To regulate the expression of the recombinant 
chemokines and / or antagonists the pET vector system was used, which is accomplished 
through the T7 promoter-driven system181-183. The pET system is a powerful system 
developed for the cloning and expression of recombinant chemokines or proteins in E. coli181-
183. The proteins were expressed in the cytoplasm of E. coli as “inclusion bodies”. As 
inclusion bodies are characterized by a relatively high specific density, they can be harvested 
after cell lysis by centrifugation at moderate rotor speed. To lyse the bacterial cells, it is 
important to prevent co-sedimentation of cell debris in order to obtain a maximum effect of 
lysis. An effective method the disruption of bacterial cells can be achieved by repetitive cell 
lysis, followed by high pressure dispersion, followed by repetitive high pressure dispersion of 
the “inclusion body” isolate184. A further notable way for extraction of “inclusion bodies” is the 
usage of chaotropic agents such as urea or guanidine-HCl. Caution needs to be taken 
though during this step, as the “inclusion bodies” may not completely disintegrate during this 
extraction procedure. Proteins expressed in “inclusion bodies” are generally in a misfolded 
condition and thus biologically inactive. Under normal cellular conditions, a subset of 
cytoplasmic proteins are able to fold spontaneously185 while aggregation-prone proteins 
require the existence of a number of molecular chaperones that interact reversibly with 
nascent polypeptide chains to prevent aggregation during the folding process186. Until now, 
no universal approach has been established for the efficient folding of aggregation-prone 
recombinant proteins187. Therefore a new optimal strategy has to be developed for each 
recombinant protein of interest. 
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6.1.1. F1-CX3CL1 expression and isolation 
Mizoue et. al.188 have reported that N-terminal modifications to CX3CL1 result in proteins with 
reduced agonistic properties. It was also shown that removal of the first seven residues of 
hCX3CL1 leads to an inactive analog with poor affinity for CX3CR1188. The study published by 
Inoue et. al.189 has reported that mCX3CL1 lacking the four N-terminal residues, behaves as 
an antagonist for mCX3CR1 in vitro and in vivo but there was no evidence that it binds also to 
hCX3CR1. In 2009, Dorgham et. al.27 described a phage-display strategy to select 
antagonistic CX3CL1 chemokine analogs, for which ligands are able to bind the CX3CR1 
receptor without triggering antagonist-induced signaling. The clone-ILDNGVS, also called F1 
showed the most potent antagonistic behaviour27. For this study, the same CX3CL1 
antagonist as Dorgham et. al.27 has been used. The recombinant F1-CX3CL1 protein was 
expressed in E. coli as insoluble “inclusion bodies” using the pET-26b(+) vector system 
(4.4.1). The recombinant protein possessed a His Tag in its N-terminal part. As discussed 
before it is necessary to find an optimal solubilizing and refolding agent to obtain an active 
conformation. An adequate solubilizing agent for F1-CX3CL1 was found to be guanidine-HCl 
with the addition of DTT that keeps the cysteines in the reduced state and cleaves disulfide 
bonds formed during preparation. For the first purification step the His Tag, which is located 
on the N-terminal part of the F1-CX3CL1, was applied for the binding on the His Trap HP to 
Ni2+ ions (Figure 10). To obtain the desired conformation of the protein oxidized and reduced 
glutathione were the best refolding agents for this process. Reduced glutathione disulfide 
bonds formed within cytoplasmic proteins to cysteines by serving as an electron donor. 
During this process, reduced glutathione is converted to its oxidized form glutathione 
disulfide190. The His Tag was removed from his F1-CX3CL1 by digestion with enterokinase 
and F1-CX3CL1 was purified using cation exchange chromatography (Resource S column). 
The isoelectric point of the F1-CX3CL1 differs from the His Tag and the undigested one. Due 
to the increase of the isoelectric point from 8.87 to 9.34 of the F1-CX3CL1 after digestion, the 
presumed cleaved F1-CX3CL1 chemokine was located under peak 2 (Figure 11) could be 
confirmed by mass spectrometry (Figure 12A) and western blotting (Figure 12B). 
6.1.2. Met-CCL5 expression and isolation 
The chemokine CCL5 plays a crucial role as neutrophil and macrophage activator in 
atherosclerosis and MI67. The treatment with anti-CCL5 mAb significantly reduced both 
infarct size and post-infarction heart failure in a mouse model of chronic cardiac ischemia67. 
The cardioprotective effects were associated with the reduction of leukocyte recruitment in 
the infarcted hearts. Marino et. al.142 showed that the injection of an antagonist against 
CCL5, reduced leukocyte infiltration in a mouse model of myocarditis. Blocking the 
chemokine CCL5 suggests a possible therapeutic application aiming at reducing 
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inflammation during the reperfusion period of the heart. Proudfoot et al153. have published 
about a CCL5 receptor antagonist Met-CCL5 that contains an additional methionine at the N-
terminus of the protein that reduces leukocyte infiltration191. For this study the same Met-
CCL5 as described by Proudfoot et. al.153 has been used. The recombinant Met-CCL5 was 
also expressed in “inclusion bodies” of the E. coli bacterial strain using the pET-26b(+) vector 
(4.4.2). As discussed before, the best solubilizing agent for Met-CCL5 was guanidine-HCl 
and DTT. For the first purification step of the Met-CCL5 a strong cation exchanger (SP 
Sepharose FF) was utilized, which is suitable for a small-scale of protein purification (Figure 
13A). A proper technique for the second purification step of Met-CCL5 was reverse phase 
chromatography using Vydac® C8 column (Figure 14). A relatively short retention time was 
necessary for the purification of Met-CCL5, by this reason the C8 column was the best in 
comparison to C18 which shows a higher retention and C4 which shows less retention 
towards non-polar compounds. The identity of the purified Met-CCL5 chemokine was 
confirmed by mass spectrometry (Figure 15A) and western blotting (Figure 15B). 
6.1.3. CXCL12 (S4V and S2G4V) expression and isolation 
The protease-resistant CXCL12 (S4V), which was already published by Segers et al53. to be 
resistant to MMP-2 and DPPIV/CD26 cleavage, was expressed and purified. First, the native 
CXCL12 chemokine was modified on the N-terminal site at position 4 from serine to valine 
and an additional serine in front of the sequence obtaining the same modifications as 
previously published53. To verify, if an additional modification would lead to the inactivation of 
this chemokine, a proline at position 2 was modified to glycine generating the following 
CXCL12 (S2G4V) chemokine. The recombinant CXCL12 (S4V and S2G4V) proteins were 
expressed in E. coli as insoluble “inclusion bodies” employing the Trx Tag, and using the 
pET-32a(+) vector system (4.4.3). When the Trx Tag is expressed from pET-32a(+) vector in 
E. coli, it can accumulate approximately to 40% of the total cellular protein while remaining 
fully soluble192. The very good soluble expression suggests that Trx Tag is translated very 
efficiently, especially when the Trx Tag is positioned at the aminoterminus of the fusion 
where protein translation initiates193. The very compact folding of the Trx Tag which is >90% 
of its primary sequence is involved in strong elements of secondary structure. This explain 
his high thermal stability (Tm = 85°C), the robust folding characteristics and its success as a 
fusion partner protein194. It was proposed that Trx Tag may serve a covalent joined chaperon 
protein by keeping folding intermediates of linked heterologous proteins in solution long 
enough for them to adopt their correct final conformation194. Guanidine-HCl was used as 
optimal solubilizing agent for the CXCL12 (S4V and S2G4V)-Trx in inclusion bodies. The 
CXCL12 (S4V and S2G4V) chemokines contain disulfide bonds and the addition of reduced 
and oxidized forms of low molecular weight thiol reagents like cysteine provides the 
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appropriate redox potential and allow formation and reshuffling of disulfides195. To obtain the 
desired conformation of the protein, cystine redox agent were found to be the best refolding 
agent for this process in comparison to glutathione that was also investigated during 
optimizing this method. For the first purification step, the Trx which is located on the N-
terminal end of the CXCL12 (S4V and S2G4V) chemokines were applied for the binding on 
the Ni-NTA column (Figure 16). For further purification, affinity chromatograpy using Heparin 
Sepharose, which allows the separation of biomolecules with affinity to heparin (Figure 17) 
was performed for CXCL12 (S4V and S2G4V). Heparin is a natural ligand for CXCL12. 
During the purification the correct folded CXCL12 (S4V and S2G4V) binds stronger to 
heparin while the wrongly folded CXCL12 (S4V and S2G4V) binds not as strongly to the 
column. After the Heparin Sepharose purification, a very pure protein with the correct folding 
was obtained. Subsequently, the Trx Tag was removed from CXCL12 (S4V and S2G4V) by 
means of enterokinase digestion. Cleaved Trx Tag were finally separated by means of cation 
exchange chromatography using the Mono S. The isoelectric point of the CXCL12 (S4V and 
S2G4V) differs from the Trx Tag and the undigested chemokine. Because of an increase of 
the isoelectric point from 7.68 to 9.90 of the CXCL12 (S4V and S2G4V) after digestion, the 
assumption was that the desired CXCL12 (S4V and S2G4V) chemokines are located under 
peak 2 (Figure 18). The mass and identity of CXCL12 (S4V and S2G4V) was confirmed by 
means of mass spectrometry and western blotting the (Figure 19, Figure 20). 
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6.2. Intramyocardial release of engineered chemokines using 
biodegradable hydrogels prevents injury extension after MI 
In this study, a novel strategy of combining the Met-CCL5 and protease-resistant CXCL12 
treatment was proposed, for the simultaneous activation of two important mechanisms for 
preservation of heart function: inhibition of neutrophil infiltration and enhanced 
neovascularization by increasing recruitment of HCs. Met-CCL5 antagonizes CCR1 and 
CCR5 activation and function in response to its natural ligand CCL5, and is able to reduce 
inflammation in models of induced inflammatory and autoimmune diseases, but also after 
MI71. Recombinant Met-CCL5 chemokine was formulated in a synthetic, biodegradable 
hydrogel for a fast release and was shown to reduce inflammation and the migration of 
neutrophils during the first hours after MI. On the other hand, it is well known that CXCL12 
plays a very important role in driving chemotaxis of SC and progenitor cells to the infarcted 
myocardium and promoting neovascularization and tissue regeneration53. Due to the fast 
degradation, CXCL12 quickly disappears after very short action. Therefore in this study, the 
mutant CXCL12 was used, which is resistant to MMP-2 and DPPIV/CD26 cleavage 
formulated in a synthetic, biodegradable hydrogel for a controlled long term release. 
Combined treatment with CXCL12 (S4V) in a slowly degrading gel improved the heart 
function, decreased infarction area and increased capillary density 4 weeks after MI 
compared with control group (Figure 36). 
Currently, the majority of small and large molecular drugs are delivered into patients 
systemically (e.g. oral or intravenous release) without the use of a scaffold. Consequently, 
large doses are usually required for a desired local effect because of non-specific uptake by 
other tissue, which can lead to serious side effects. Thus, biodegradable hydrogels are 
utilized here to stabilize and deliver bioactive molecules in the desired tissue for a better 
dose monitoring and an exact release122 allowing a local and specific release of Met-CCL5 
and protease-resistant CXCL12 into the heart tissue over 24 h or 4 weeks, respectively. 
Natural CXCL12 was broadly used in models of MI. However, the injection of CXCL12 after 
MI has shown limited results40. One reason for the inefficiency of natural CXCL12 might be 
the rapid cleavage by MMP-253. Until now, the physiological role of this cleavage is unknown, 
yet CXCL12 inactivation by MMPs stops mobilization of HCs from the BM53. Up-regulation of 
MMP-2 after MI is well known and plays an important role in the extracellular matrix turnover 
and remodeling. Therefore, to sustain the CXCL12 function in vivo it is essential to block its 
degradation. The protease-resistant CXCL12 chemokine is resistant to MMP-2 and DPPIV 
cleavage53, with preserved ability to recruit SC in vitro and in vivo, confirmed on migration of 
angiogenic EOC, on cell adhesion of CXCL12 (S4V)-stimulated Jurkat cells on HUVEC 
under flow conditions and in experimental model of MI. For the herein described mouse in 
vivo study, the protease-resistant CXCL12 variant was implemented to investigate the 
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improvement of cardiac function after MI. When incorporated into a slowly degradable 
hydrogel, CXCL12 is released gradually over weeks, assuring a local high amount of 
chemokine and a continuous stimulation of SC recruitment. Accordingly, neo-angiogenesis 
after MI was increased after treatment with CXCL12 (S4V)-containing hydrogels, 
demonstrating the efficiency of the treatment (Figure 36). 
 
Figure 36: Schematic representation of the therapeutic approach using protease-resistant 
CXCL12 in SDHs and Met-CCL5 in FDHs in experimental models of MI. Modified from Ghadge et. 
al.21. 
On the other hand, to reduce inflammation induced by MI, recombinant Met-CCL5 was used 
to inhibit neutrophil infiltration. It is well established that CXCL8 and CCL5 are strong 
agonists for neutrophil recruitment. Met-CCL5 is able to antagonize the actions of CCL5 not 
only in vitro, but also in vivo71. Since the infiltration of neutrophils occurs only for a short time 
period190, the Met-CCL5 was combined with a very quickly biodegradable hydrogel, which 
assures the release of this antagonist only for several hours. This is essential to avoid the 
blocking of later functions of CCL5, e.g. over CCR5, such as recruitment of reparatory 
monocytes or T regulatory cells196, which is necessary for a proper healing and scar 
formation (Figure 36). 
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The combined treatment with both recombinant chemokines formulated in a time-dependent 
degradable hydrogel, show significantly preserved heart function and improved remodeling of 
the ventricle. The cardioprotective effects of the Met-CCL5 and protease-resistant CXCL12 
are mediated through reduced infiltration of neutrophils in the infarcted myocardium and 
increased recruitment of HCs, respectively. Indeed, it was found a decreased neutrophil 
infiltration after treatment with Met-CCL5-FDH, and after combined treatment with Met-CCL5-
FDH and protease-resistant CXCL12 (S4V)-SDH. These results are comparable with those 
found in CCR1-deficient mice, or after anti-CCL5 mAb treatment, which showed that the 
initial inhibition of CCL5 exerts cardioprotective effects during early MI through its anti-
inflammatory properties71, reducing both infarct size and post-infarction heart failure in 
mouse model of chronic cardiac ischemia67 (Figure 36). 
Moreover, increased angiogenesis was noticed after CXCL12 (S4V)-SDH alone and 
combined CXCL12 (S4V)-SDH and Met-CCL5-FDH treatment, suggesting that the preserved 
ability of protease-resistant CXCL12 mediated HC recruitment through its CXCR4 receptor. 
As expected, Met-CCL5 alone was not able to promote angiogenesis. However, although a 
decrease in infarction size was observed in all treated groups, it appears that only combined 
treatment with CXCL12 (S4V) and Met-CCL5 is able to additionally improve the heart 
function and to assure the optimal healing and remodeling of the ventricle after MI. 
In summary, my thesis provides evidence that the combined therapy of the protease-
resistant CXCL12-SDH and Met-CCL5-FDH preserves cardiac function, promotes 
angiogenesis and facilitates wound healing by recruitment of hematopoietic stem cells from 
the circulating blood and attenuating neutrophil-induced myocardial inflammation. This novel 
strategy might constitute an additional option to optimize cardiac repair and remodeling after 
myocardial injury and might complement cell-based therapies. 
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6.3. Role of platelet F1-CX3CL1 antagonist to PMC formation 
In the present part of this study, the contribution of platelet-derived F1-CX3CR1 on monocyte 
recruitment to endothelium was investigated. The presence of functional platelet-derived 
CX3CR1 was demonstrated before, but only in the context of adhesion to ECs197-199. As it is 
known from literature, CX3CL1 is able to induce chemotaxis, adhesion and cell signaling 
through CX3CR1200. It is well-established that platelets do not act as single players in the 
inflammatory process. For example, interaction of monocytes with platelets increases the 
adhesive properties of monocytes towards inflamed or atherosclerotic endothelium200, 201 and 
platelets interact with adherent leukocytes via the adhesion receptor GP1B and the leukocyte 
integrin αMβ2 (CD11b/CD18)202. An important finding in this study is that activated but not 
resting human platelets led to a significant platelet-THP-1 complex formation as measured by 
increased staining of the platelet marker CD61 in the monocyte-gated population. Platelet-
CX3CR1 thus appears to play a notable role in PMC assembly, as pre-incubation of platelets 
with the CX3CR1-antagonist F1-CX3CL1 significantly decreased PMC formation (Figure 34). 
In in vitro static adhesion assay, a pronounced role of platelet-derived CX3CR1 in the 
adhesion to immobilized CX3CL1 was observed, which is consistent with a recent study 
showing CX3CR1-dependent binding of platelets to CX3CL1-coated microbeads199. 
Furthermore, under shear flow in whole blood, a robust adhesion of leukocytes on activated 
SMC, which express CX3CL1 after stimulation178, 203, was recorded only after activation of the 
blood platelets with TRAP-6, hinting towards an involvement of platelet-leukocyte interactions 
in this process. By blocking CX3CL1 or CX3CR1 it was shown that the leukocyte adhesion 
strongly depended on the CX3CL1–CX3CR1 axis.  
In conclusion, this part of the study clearly shows that human platelets carry the functional 
chemokine receptor CX3CR1 which can be enhanced on the surface upon activation by 
inflammatory stimuli, similarly as seen for platelet activation by classical agonists. 
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7. Summary 
Chemotactic cytokines and their receptors play an important role in CVDs. The progress of 
atherosclerosis may cause MI. MI induces an inflammatory immune response, which causes 
a progressive expansion of the infarcted area and dilation of the ventricles with replacement 
of the adjacent myocardium by connective tissue, the so-called "remodeling" of the heart 
muscle. The regeneration of the blood vessel network system by recruitment of HCs for 
recovering the supply of the infarcted area with oxygen, nutrients, and the prevention of 
apoptosis of myocytes can be beneficial for heart function. In order to gain further knowledge 
in the development of atherosclerosis the role of platelet-CX3CR1 receptor and his CX3CL1 
ligand was studied during the formation of PMC. 
The first part of this study includes the recombinant expression of the Met-CCL5, protease-
resistant CXCL12 (S4V) and F1-CX3CL1 in E. coli. The chemokines were expressed with 
different techniques as inclusion bodies in the cytoplasm and were purified by sequential 
steps with chromatographic methods using FPLC. The second part of this study includes the 
design of a novel therapeutic strategy with Met-CCL5, a chemokine receptor antagonist to 
suppress initial neutrophil infiltration, and a protease-resistant CXCL12 (S4V) variant, which 
is inert to MMP-2 and exopeptidase cleavage, but retains its chemotactic bioactivity for 
recruitment of circulating HCs, promoting neovascularization after MI. To control the proper 
timing and local release of Met-CCL5 and CXCL12 (S4V), two different biodegradable 
hydrogels were implemented, a FDH for delivering Met-CCL5 over 24 h and a SDH for a 
gradual release of CXCL12 (S4V) over 4 weeks. In a mouse model, intramyocardial injection 
of these agents reduced infarct size, blocked neutrophil recruitment into the affected tissue, 
stimulated capillary formation, and improved cardiac function after MI. Last part of this study 
showed whether platelet-CX3CR1 plays a role in PMC formation. The platelets were 
preincubated with the CX3CR1-antagonist F1-CX3CL1 and the PMC formation was 
evaluated. 
This study describes the expression of different chemokines which play an important role in 
CVDs. Furthermore, time-controlled release of Met-CCL5-FDH and CXCL12 (S4V)-SDH 
could demonstrate blocking of neutrophil recruitment to the inflamed myocardium and 
recruiting HC from circulating blood, thereby improving cardiac function after MI. As result, 
this study describes a novel and a promising therapeutic strategy to sustain the endogenous 
reparatory mechanisms, and may represent a potentially clinical relevant alternative to cell-
based therapies. Additionally, the formation of PMC and the detection of platelet-bound 
CX3CL1 on SMCs suggest a significant involvement of the CX3CR1–CX3CL1 axis in platelet 
accumulation and monocyte recruitment at sites of arterial injury in atherosclerosis. The F1-
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CX3CL1 antagonist inhibits the formation of the interaction of the CX3CR1–CX3CL1 axis and 
the formation of PMC is reduced. 
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8. Zusammenfassung 
Chemotaktische Cytokine und ihre Rezeptoren spielen eine wichtige Rolle bei der 
Entwicklung von kardiovaskulären Erkrankungen und ihren Folgen. Das Fortschreiten von 
Atherosklerose kann zum Herzinfarkt führen. Der Myokardinfarkt induziert eine entzündliche 
Immunantwort, die zu einer progressiven Expansion des Infarktbereichs und Dilatation der 
Herzkammern mit Erneuerung des benachbarten Myokardbindegewebes führt, welche das 
sogenannte "Remodelling" des Herzmuskels verursacht. Für die Verbesserung der 
Herzfunktion, ist die Regeneration des Blutgefäß-Netzwerk-Systems durch Rekrutierung von 
hämatopoetischen Stammzellen notwendig, welche die Versorgung des infarktierten 
Bereiches mit Sauerstoff und Nährstoffen begünstigt, und die Apoptose von Myozyten 
verhindert. Um neue Erkenntnisse auf dem Gebiet der Atheroskleroseentwicklung zu 
gewinnen wurde die Rolle von Blutplättchen-CX3CR1 Rezeptor und dessen CX3CL1 
Liganden untersucht. Dabei wurde die Rolle der CX3CR1- CX3CL1 Achse bei der Bildung 
von Blutplättchen-Monozyten-Komplexen (PMC) mit Hilfe des F1-CX3CL1 Antagonisten 
überprüft. 
Der erste Teil dieser Arbeit umfasst die rekombinante Expression von Met-CCL5, protease-
resistentem CXCL12 (S4V) und F1-CX3CL1 in E. coli. Die Chemokine wurden mit 
unterschiedlichen Methoden als Einschlusskörper im Zytoplasma exprimiert und durch 
sequentielle Schritte mit chromatographischen Methoden unter Verwendung von FPLC 
aufgereinigt. Der darauffolgende Teil dieser Arbeit umfasst die Entwicklung einer neuartigen 
therapeutischen Strategie mit Met-CCL5, einem Chemokin-Rezeptor-Antagonist zur 
Unterdrückung der ersten Neutrophilinfiltration, und einer proteaseresistenten CXCL12 (S4V) 
Variante, die von Matrixmetalloproteinase-2 und Exopeptidase nicht gespalten werden kann, 
aber seine chemotaktische Bioaktivität für die Rekrutierung von zirkulierenden 
hämatopoetischen Stammzellen behält, welche die Neovaskularisierung nach Myokardinfarkt 
fördert. Um die genaue lokale Freisetzung von Met-CCL5 und CXCL12 (S4V) zu 
gewährleisten, wurden zwei verschiedene biologisch abbaubare Hydrogele implementiert, 
ein schnell abbaubares Hydrogel (FDH) zur Abgabe von Met-CCL5 über 24 h und ein 
langsam abbaubares Hydrogel (SDH) für eine langsame Freisetzung von CXCL12 (S4V) 
über 4 Wochen. Im Mausmodell konnte gezeigt werden, dass die intramyokardiale Injektion 
dieser Komponenten zu einer Verringerung der Infarktgröße, zu einer Blockierung der 
Neutrophil-Rekrutierung in das betroffene Gewebe, zu einer Stimulation von 
Kapillargefäßbildung und zu einer insgesamt verbesserten Herzfunktion nach Myokardinfarkt 
geführt haben. Der letzte Teil dieser Arbeit beinhaltet die Untersuchung des thrombozytären-
CX3CR1 Rezeptors und CX3CL1 Liganden bei der Bildung von PMC. Dabei wurden 
Plättchen mit dem F1-CX3CR1-Antagonisten vorinkubiert und die PMC-Bildung bewertet. 
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Diese Arbeit beschreibt die Expression verschiedener Chemokine die eine wichtige Rolle bei 
der Entwicklung von kardiovaskulären Erkrankungen und ihren Folgen darstellen. Des 
Weiteren konnte gezeigt werden, dass eine zeitlich kontrollierte Freisetzung von Met-CCL5-
FDH und CXCL12 (S4V)-SDH, die Rekrutierung von Neutrophilen im entzündeten 
Myokardium hemmt, als auch die Rekrutierung von hämatopoetischen Stammzellen aus dem 
zirkulierenden Blut fördert, welche die Herzfunktion nach Myokardinfarkt verbessern. Als ein 
Ergebnis dieser Arbeit konnte eine neue und vielversprechende therapeutische Strategie zur 
Aufrechterhaltung des endogenen reparatorischen Mechanismus aufgezeigt werden, welche 
eine potentiell klinisch relevante Alternative zur Zelltherapie darstellen kann. 
Weiterhin wurde die Rolle von thrombozytär-gebundenem CX3CL1 auf glatte Muskelzellen 
(SMC) bei der Bildung von PMC untersucht. Hierbei konnte gezeigt werden, dass die 
CX3CR1-CX3CL1 Achse bei der Akkumulation von Blutplättchen und der Rekrutierung von 
Monozyten während der Gefäßverletzung und bei der Bildung von Atherosklerose eine 
wichtige Rolle spielt, indem der F1-CX3CL1 Antagonist die Wechselwirkung der CX3CR1-
CX3CL1 Achse hemmt und die Bildung von PMC reduziert. 
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